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ABSTRACT 
 
High blood pressure (HBP) is a primary risk factor for cardiovascular disease 
(CVD). Identification of modifiable dietary risk factors for HBP is crucial. The 
objective of this dissertation is to estimate the effects of long-term protein, dairy, 
and yogurt intakes on risk of HBP and subsequent CVD risk among those with 
HBP. 
 
Data from four prospective studies of middle-aged adults were used: the 
Framingham Offspring Study (FOS) (n=1,361), Nurses’ Health Study (NHS) 
(n=66,987), NHS II (n=84,368), and Health Professionals Follow-Up Study (HPFS) 
(n=30,512). Diet was assessed via 3-day diet records in FOS and semi-quantitative 
food frequency questionnaires in NHS, NHS II, and HPFS. HBP was assessed by 
mercury sphygmomanometer or anti-hypertensive medication use in FOS and 
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self-report in NHS, NHS II, and HPFS. Self-reported incident CVD was validated 
by physician review in the NHS and HPFS. Cox proportional hazard models 
were used to calculate hazard ratios, 95% confidence intervals (CI) associated 
with cumulative average dairy intakes while controlling for potential 
confounding by age, sex, height, activity, smoking, energy, diet quality scores, 
fruits and vegetables (FV), fiber, and fat intake. 
 
Higher total protein intake led to a 40% (95% CI: 0.45-0.78) HBP risk reduction in 
FOS. When combined with higher FV or fiber consumption, higher protein 
intake resulted in a HBP risk reduction of 39% and 51%, respectively. Higher 
total dairy (3-<6 s/day) led to 13% (95% CI: 0.83-0.92; p-trend<0.0001), 26% (95% 
CI: 0.69-0.78; p-trend<0.0001), and 9% (95% CI: 0.84-0.98; p-trend<0.0001) reduced 
HBP risks across NHS, NHS II, and HPFS, respectively. In pooled analyses across 
these cohorts, higher total dairy (3-<6 s/day) or yogurt (≥5 s/week) intakes in 
combination with higher diet quality scores resulted in 23% (95% CI: 0.73-0.80) 
and 31% (95% CI: 0.65-0.74) HBP risk reductions, respectively. Among 
hypertensives, regular yogurt consumers (≥2 s/week) had statistically significant 
17% and 18% lower risks of CVD in NHS and HPFS, respectively; HPFS men 
consuming 2-<6 s/d of total dairy also had an 11% lower CVD risk.  
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These results suggest that higher usual intakes of total protein, dairy and yogurt 
have beneficial effects on HBP risk and subsequent CVD in middle-aged adults.  
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CHAPTER 1: INTRODUCTION 
 
 
1.1 HIGH BLOOD PRESSURE PREVALENCE AND IMPLICATIONS 
  
 
High blood pressure (HBP) is a major risk factor for cardiovascular and renal 
diseases and continues to be a growing public health concern worldwide. Data 
from the National Health and Nutrition Examination Survey (NHANES) 2005-
2008 showed that the overall prevalence of HBP among American adults 18 years 
of age and older was 30.9%.1 The 2015 Heart Disease and Stroke Statistics from 
the American Heart Association (AHA) estimates that about a third of Americans 
(80 million) have HBP, with 77% of them on antihypertensive medication but 
only 54% of those on antihypertensive medication having their HBP controlled.2 
HBP was estimated to contribute to nearly half of all cardiovascular disease-
associated deaths in the United States (US) in 2007-08.3 The prevalence of HBP is 
concerning because of its direct, independent relationship with chronic disease 
risk. In 2007, HBP was cited as the primary or contributing cause of death for 
over 330,000 Americans3 and is responsible for more than 7 million annual deaths 
worldwide.1 Moreover, HBP-related cost of healthcare and loss of productivity in 
2010 was estimated to be $76.6 billion in the US.1  
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The 2014 AHA update estimated that 41% of adult Americans will have a 
diagnosis of HBP by the year 2030.4 The 2010 AHA update reported that HBP 
prevalence is similar among men and women over 20 years old (34.4% and 
32.6%, respectively) with an additional 37.4% of American adults have 
prehypertension.5 HBP risk increases with age, being male, smoking, having high 
cholesterol, diabetes, a sedentary lifestyle, and being African American (43% 
having HBP).5 Being one of the major risk factors for cardiovascular disease 
(CVD),4 HBP prevention is imperative.  
 
According to the AHA, high blood pressure, or hypertension (HTN), is defined 
as a medical condition with which the systolic blood pressure (SBP), or the force 
that occurs when blood pumps out of the heart and into the arteries, is greater 
than or equal to 140 mm Hg; or when the diastolic blood pressure (DBP), or the 
force that is created as the heart rests between heart beats, is greater than or 
equal to 90 mm Hg.4 Prehypertension is having SBP levels between 120-139 mm 
Hg and DBP levels between 80-89 mm Hg based on two properly measured 
seated BP readings and is considered as an indicator for HTN.6 Maintaining 
healthy blood pressure (BP) levels is important in order to allow the oxygen-rich 
blood to reach aerobic tissues of the body. Over time, the higher the BP (or the 
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more forcefully the heart pumps out blood), the more the tissues that comprise 
the arterial walls are stretched beyond its healthy limits and becomes damaged. 
These damaged blood vessels are more prone to rupture, which can cause 
hemorrhagic strokes and aneurysms. Vascular scars can catch debris such as 
cholesterol and plaques, which makes it more difficult for the blood to reach the 
other parts of the body. This would then lead to an increased workload in the 
circulatory system, which puts a heavier strain on the heart. Plaque buildup, or 
atherosclerosis, could ultimate block the blood flow, which causes heart attacks 
and strokes (two major types of CVD). HBP is the most likely cause of a 
hemorrhagic stroke (when a blood vessel within the brain bursts).2 Other types of 
CVD include: heart failure, heart valve conditions, and arrhythmia. Heart failure, 
or congestive heart failure (CHF), occurs when the heart works too hard in order 
to pump blood to other areas of the body. Arrhythmias refer to the abnormal 
heart rhythms. This affects how well the heart pumps blood throughout the 
body. Heart valve problems include: stenosis – when the heart valves do not 
open sufficiently to allow normal blood flow; regurgitation – when the heart 
valves do not properly close and blood is allowed to leak through; and mitral 
valve prolapse - when the valve leaflets bulge or return back into the upper 
chamber, which causes them not to close properly7. 
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1.2 PREVALENCE AND IMPLICATIONS OF CARDIOVASCULAR DISEASE 
CVD is the leading global cause of death with 17.3 million attributable deaths 
annually.2 It is projected to grow to more than 23.6 million by 2030. In the US, 
787,000 Americans (1 out of 3) died from heart disease, stroke, or other CVD 
outcomes in 2011.2 Furthermore, total costs attributed to CVD totaled more than 
$320 billion.2 The correlation between HBP is CVD is striking: 69% of people 
worldwide who have their first heart attack, 77% who have their first stroke, and 
74% who have their first CHF incident are hypertensive.2 CVD risk increases as 
BP levels rise. Results from the Multiple Risk Factor Intervention Trial (MRFIT) 
of over 360,000 middle aged men across the country, showed that both systolic 
blood pressure (SBP) and diastolic blood pressure (DBP), taken independently 
from each other and other major risk factors, were significantly related to CVD 
risk.8 Similar observations were observed for middle-aged Caucasian and African 
American women in the Charleston Heart Study.9 Although these studies were 
done in the 1980s and 1990s, the trend continuous well into the 2000s.10-12 
According to the World Health organization, two-thirds of the cerebrovascular 
disease burden as well as half of the ischemic heart disease burden are 
attributable to pre-HBP or HBP levels.13 CVD and HBP incidence statistics are 
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projected to grow in the near future, warranting identification of modifiable risk 
factors to mitigate this public health burden.  
 
1.3 DIETARY PROTEIN AND BLOOD PRESSURE 
BP is affected by many complex factors. Diet plays a key modifiable role thus 
making it important to identify specific foods and nutrients that can beneficially 
affect BP and also be easily incorporated into population-based strategies for 
HBP prevention. Evidence from recent reviews14,15 and meta-analyses16,17 suggest 
that dietary protein consumption may benefit BP. These aforementioned meta-
analyses of short-term clinical trials concluded that compared with 
carbohydrates, higher dietary protein intake led to modest reductions in BP. In 
the Rebholtz meta-analysis, both animal and plant proteins were found to have 
similar short-term BP-lowering effects.17 Observational studies, which have been 
largely cross-sectional, have shown weak beneficial effects of plant proteins in 
particular on BP.15 There are few observational studies (and no clinical trials) that 
have addressed the long-term effects of animal and plant proteins on BP, and 
results are conflicting.18-20 The Western Electric Study (WES), an 8 year 
longitudinal study that followed 1,714 middle-aged working men in Chicago, 
and the Seguimiento Universidad de Navarra (SUN), an 11 month prospective 
  6
study that followed 5,880 Spanish men and women 20 years of age and older, 
found only vegetable protein consumption to be inversely correlated with BP.18,20 
When total protein was assessed among 4,100 young adults 18-30 years of age in 
the Coronary Artery Risk Development in Young Adults (CARDIA) study, total 
protein was inversely associated with both SBP and DBP, with stronger 
associations for DBP.19 The inconsistencies of the above prospective cohort 
studies warrant the need for more longitudinal studies examining the 
independent effects of dietary protein on BP. 
 
Only one trial has attempted to elucidate the independent effect of a high protein 
diet on BP. In a randomized crossover design with three dietary interventions: 
high protein, high carbohydrate, and high monounsaturated fats, the 
investigators of the OmniHeart trial concluded that both the monounsaturated 
fat diet and the higher protein diet led to lower BP as well as improvement in the 
overall lipid profile. More importantly, it was the higher-protein diet rather than 
a lower-carbohydrate diet that had the greatest BP-lowering effect in adults.21 
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1.4 DAIRY AND BLOOD PRESSURE 
Various studies suggest that dietary protein may have a beneficial effect on blood 
pressure although a recent review emphasizes the need for additional studies to 
delineate the role of specific protein sources (e.g., dairy).14 Dietary patterns such 
as the Dietary Approaches to Stop Hypertension (DASH), is one of the five 
preventive strategies that The Joint National Committee (JNC) on Prevention, 
Detection, Evaluation, and Treatment of HBP recommends.6 Weight loss, 
reduced sodium intake, moderate physical activity, and moderation of alcohol 
intake being the other four preventive strategies.6 The DASH diet is characterized 
by higher intakes of fruits and vegetables (FV) and low-fat dairy and has been 
shown to have BP-lowering effects in clinical trial settings.22 In fact, a later study 
examining the effect of a high FV diet compared to a DASH diet (high FV and 
low-fat dairy), showed that across all the subgroups in the trial (Caucasians, 
African Americans, hypertensive, and non-hypertensives), the DASH diet led to 
a greater BP decrease than just the FV diet alone.23 This landmark trial led to the 
possible independent, antihypertensive effect of dairy, a rich source of complete 
protein. 
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The 2010 Dietary Guidelines Advisory Committee (DGAC) reviewed the 
evidence for the association between dairy intake and BP. They concluded that 
overall, there is a moderate body of evidence pointing to an inverse relationship 
between the intake of milk and milk products and BP, particularly SBP; the 
evidence for a reduction in DBP is weaker.24 However, the DGAC summary 
suggests that the evidence is not completely consistent and that differences in 
results across studies may result from actual differences in effects of different 
types of dairy products or from residual confounding associated with other 
dietary factors, weight loss and demographic factors.24  
 
Dairy intake has been inversely associated with BP and risk of HTN in several 
prospective studies. Data from the CARDIA study25, the Women’s Health 
Study26, and the Rotterdam study27 indicated that a high intake of total dairy was 
associated with a lower HTN risk. Although some studies have observed a 
positive association between dairy and blood pressure, there are a few such as 
one in elderly women28,29, the Hoorn Study19, and the general Dutch population30 
that show no association between dairy intake and BP. 
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BP-effects of dairy has also been studied within the context of an eating pattern. 
Most notably, the DASH eating pattern, which was derived from a multicenter 
randomized controlled feeding trial that enrolled 459 prehypertensive and stage 
1 hypertensive (SBP: 140-159 mm Hg or DBP: 90-99 mm Hg) adults with a mean 
age of 44 years (youngest being 22 years old) for eight weeks.31 The DASH 
pattern (vs. the control diet with low intakes of fruits, vegetables and dairy) 
lowered SBP and DBP by 5.5 and 3.0 mm Hg, respectively. The high FV diet 
reduced BP by approximately half as much as the DASH pattern. Not only was 
the DASH diet effective in lowering BP in all of the subjects in the study, 
reductions were greatest among those with established HTN and African 
Americans.22 There were very limited number of studies that looked at 
differential effects of diet on African Americans at the time and one of the 
strengths of the DASH trial was that many subgroups were represented: younger 
individuals, older subjects, blacks, whites, Asians, Native Americans, 
prehypertensives, and stage 1 hypertensives. The DASH diet contained greater 
amounts of potassium, calcium, fiber, and magnesium, which were all 
hypothesized to have BP-lowering effects.31,32 At the same time, the it also 
contained lower amounts of red and processed meats, sodium, and sugar-
sweetened beverages, which were all believed to have BP-raising effects.32 
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Although it was only a short-term trial, it has been replicated a number times 
including in the PREMIER study.33 The PREMIER Clinical Trial enrolled 810 
individuals with prehypertension or stage 1 HTN. After the 6-month follow up, 
the intervention group that included DASH had a mean SBP level that was 4.3 
mm Hg lower than that in the control group (given advice only) while the 
intervention arm without DASH was 3.7 mm Hg lower than in the control 
group.33 The follow-up at 18 months found that subjects in the group that 
included DASH had a 23% lower risk of HTN compared with the “advice only” 
group while those in the established lifestyle intervention had a 17% lower HTN 
risk.34 
 
In summary, while some observational and clinical trial evidence to date 
suggests a beneficial effect of dairy in BP control, considerable inconsistency is 
present across study designs and results. Further long-term epidemiological data 
are needed to address these issues.  
 
1.5 YOGURT AND BLOOD PRESSURE  
Most studies of dairy intake and BP have combined all types of dairy into one 
exposure. The nutrient profiles of the different dairy subtypes vary. For example, 
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vitamin D, which in low levels can activate the renin-angiotensin-aldosterone 
system and lead to increases in BP directly by vasoconstriction35, is only fortified 
in milk but not in cheese or yogurt products. Cheese products have a higher 
sodium content than yogurt and milk products.36 Albeit controversial, sodium 
intake has been hypothesized to have harmful effects on BP but no such 
association has been observed on cheese-derived sodium.37 Recent evidence 
suggesting a protective role of branched-chain amino acids (BCAA) on CVD and 
its ability to form hypotensive lactotripeptides38 also vary with different dairy 
source. Table 1.1 below compares BP-related nutrients between the three major 
sources of dairy: milk, cheese, and yogurt. Yogurt contains the highest amounts 
of BCAA, potassium, magnesium, and calcium while having the lowest amount 
of sodium.36 
Table 1.1: Nutrient profiles of one serving of yogurt, milk, and hard cheese 
 
Nutrients 1 c. plain 
yogurt 
1 c. whole 
milk 
1.5 oz. hard 
cheese 
Calories (kcal) 149 146 173 
Total fat (g) 7.96 7.98 14.38 
Total protein (g) 8.5 7.9 10.2 
Leucine (mg) 858 647 842 
Isoleucine (mg) 463 403 523 
Valine (mg) 703 468 609 
Vitamin D (IU) 5.0 5.0 10 
Total carbohydrates (g) 11.4 12.8 0.57 
Calcium (mg) 296 276 115 
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Magnesium (mg) 29.4 24.4 11 
Potassium (mg) 380 349 32 
Sodium (mg) 113 97.6 274 
 
Fermented dairy products have been around for centuries. Yogurt is one of the 
major fermented dairy products worldwide and according to the United States 
Department of Agriculture (USDA), a food product can only be called “yogurt” if 
it was produced via fermentation with a bacterial strain containing Lactobacillus 
bulgaricus and Streptococcus thermophilus.39 For the past 20 years, fermented dairy 
products such as yogurt have gained much attention for their health benefits.40,41  
 
Preliminary evidence indicates that fermented dairy products may play a 
hypotensive role in BP control.40 It was reported that the consumption of 
fermented milk, which contained 2.5-3.5 mg/kg/day of two casein-derived 
tripeptides: valine-proline-proline (VPP) and isoleucine-proline-proline (IPP), 
resulted in a reduction of SBP by 177 mm Hg in Spontaneously Hypertensive 
Rats (SHR).42 One of the largest human double-blind, placebo-controlled 
randomized trials that involved 94 hypertensive subjects, in which the 
experimental group received 150 mL of milk that was fermented by Lactobacillus 
helveticus twice a day for ten weeks, resulted in a SBP decrease of 4.1 mm Hg and 
their DBP was lowered by 1.8 mm Hg.43 Although only for a short duration, 
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fermented dairy products have shown beneficial effects on BP. This warrants 
long-term, well-controlled human studies to evaluate fermented dairy benefits 
on CVD risk and its attributed risk factors including HTN.  
 
Few observational studies and no clinical trials have examined the benefits of 
yogurt consumption on BP.44 The Women’s Health Study of 28,886 middle-aged 
US women found that decreased HBP risk was independently associated with 
higher intakes of low-fat dairy products, calcium, and vitamin D after a 10-year 
follow-up.26 There was no association between high-fat dairy and risk of HBP. Of 
the four categories of low-fat dairy products including skim milk, yogurt, cottage 
cheese, and sherbet, only skim milk was inversely associated with HBP risk 
Another study in a French cohort observed a slight decrease in DBP with a 
higher intake of any dairy product except for cheese but there was no association 
with SBP.45 With this inconsistency in findings, it is imperative to question the 
extent in which different dairy products affect BP. 
 
Yogurt intake was shown to be inversely associated with weight gain in 
combined analysis of data from the Nurses’ Health Study (NHS), NHS II, and 
Health Professionals Follow-Up Studies (HPFS).46 Cross-sectional studies 
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indicate that more than 85% of hypertensive individuals are overweight or 
obese.47 These effects on body weight maybe responsible for other yogurt-related 
metabolic effects. Extensive clinical trial data show a substantial and BP-lowering 
effect of weight loss and an overall strong relationship between obesity and 
HTN. These reductions in BP occur in overweight and obese individuals 
regardless of reaching a normal BMI (body mass index of <25 kg/m2).48 Neter et al 
performed a meta-analysis of 25 randomized, controlled trials, and found that a 
weight loss of 1 kg was associated with 1 mm Hg reduction in SBP and DBP in 
prehypertensive subjects.49 The largest of the trials included in the meta-analysis, 
Trials of Hypertension Prevention (TOHP), demonstrated a larger weight loss 
effect combining a behavioral weight loss intervention along with the dietary 
intervention in prehypertensive adults. This combination led to mean weight loss 
of 2 kg in a 6-month follow-up. The weight loss was accompanied by a mean 
decrease of SBP and DBP of 3.7 and 2.7 mm Hg respectively50 along with a 42% 
decreased risk of incident HBP51. The TOHP trial results show strong clinical 
evidence that reductions in body weight and body fat is strongly correlated on 
BP reductions. Yogurt intake has also been associated with a better metabolic 
profile. In the Framingham Offspring Study, consumption of yogurt has been 
linked with lower levels of triglycerides, glucose, and lower presence of insulin 
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resistance, even after controlling for diet quality.52 BMI adjusted led to some but 
not a complete attenuation of most of these effects. 
 
While the specific mechanisms by which dairy products may benefit blood 
pressure are not known, several have been hypothesized. The original DASH 
trial cited the mineral content of dairy (i.e., its calcium, potassium and 
magnesium content) as having potentially beneficial effects on blood pressure. 
While calcium is involved in blood pressure regulation, it appears that its effects 
are relatively modest and may only aid those with low baseline calcium 
levels.53,54 Out of the three BP-related minerals in dairy, the effect of potassium 
seems to be the strongest, with higher levels of intake being shown to relate to 
lower BP levels in a number of individual studies55,56 and several meta-
analyses.57,58  
 
Studies of magnesium and blood pressure have been inconclusive,59 although 
several studies have linked magnesium to being a natural calcium channel 
blocker via steric inhibition with sodium on vascular smooth muscle cell binding 
sites. This induces endothelial-dependent vasodilation and lower BP levels.60-62 
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Yogurt is a concentrated source of calcium, potassium, and magnesium,63 lending 
to its appeal for further investigation of yogurt-specific mechanisms on BP. 
 
1.6 DAIRY AND CARDIOVASCULAR DISEASE 
There is an ample amount of evidence to recommend that a generally healthier 
lifestyle can prevent a substantial proportion of CVD.64 The public have long 
been advised by the medical and scientific community to reduce saturated 
animal fats, which includes dairy fat, in the diet to improve health and reduce 
the risk of CVD. But the evidence supporting this notion is lacking. A 2010 meta-
analysis of 21 prospective observational studies with over 300,000 participants of 
whom around 11,000 developed coronary artery disease (CAD) or stroke during 
5-23 years of follow-up showed that there is no evidence that dietary saturated 
fat is linked with an increased risk of CAD or CVD.65 Dairy products, especially 
whole milk, cheese, and butter can be high in saturated fat. It is estimated that 
dairy products (excluding butter) contribute to 24% of the saturated fat intake of 
the typical American diet.66 Similar percentages were observed in European 
countries (25-30%).67 
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In several studies, particularly in Europe, dairy consumption has been inversely 
associated with risk of CVD68. In the Honolulu Heart Program69, investigators 
observed that middle-aged men who did not drink milk, had a two-fold increase 
in rates of stroke than men who consumed 2 cups of milk per day. A recent meta-
analysis concluded that every 200 mL increase in milk consumption per day led 
to a 6% reduction in risk of CVD70.  In that study, the protective effects were 
stronger for risk of stroke than for coronary heart disease (CHD). These findings 
may suggest that the inverse association between dairy consumption and 
cardiovascular risk is linked with its effects on blood pressure.  
Even fewer studies examined the yogurt-specific effect on CVD risk. Some have 
found that yogurt intake reduced low density lipoprotein cholesterol (LDL-
C):total cholesterol levels71-73 and benefitted arterial intima-media thickness28, 
suggesting that yogurt consumption may protect against development of CVD. 
A meta-analysis of short term intention studies of the effect of a probiotic milk 
product on plasma cholesterol showed a 4% decrease in total cholesterol and a 
5% decrease in LDL-cholesterol in European cohorts.74 The effects of yogurt on 
HBP risk is less clear but the intermediate effects of yogurt intake may reduce 
overall cardiovascular risk by benefitting cholesterol levels and vascular 
integrity. 
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1.7 OVERVIEW OF STUDIES 
1.7.1 Framingham Offspring Study 
The Framingham Offspring Study (FOS) is a second-generation cohort consisting 
of the offspring from the Framingham Heart Study (FHS). The FHS started in 
1949 with the examination of 5,209 subjects (1,644 spouse pairs), aged 30-62, to 
evaluate risk factors and determine certain characteristics of CHD in the town of 
Framingham, Massachusetts.75 At that time, very little was known about the 
etiology of CVD but CVD-related deaths continue to increase steadily and has 
become a burden in American public health. It is a longitudinal study, which is 
still ongoing today, and in 1971, gave rise to the FOS. 
 
The FOS had two major aims: to determine whether there have been secular 
changes in the levels of CVD risk factors between the FHS and FOS and to 
examine the presence of genetic and familial effects in determining levels of these 
risk factors.76 5,135 subjects were enrolled in the FOS, with 5,124 attending the 
first exam. Diet was assessed via 3-day diet records starting on exam 3 (1983-
1987) and also on exam 5 (1991-1995)77. For these analyses, the baseline exam is 
the first exam when diet was collected. Although most the subject had exam 3 
diet data, some only had exam 5 and thus for those who only had exam 5 diet 
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data, exam 5 serves as their baseline exam. For those who had both exam 3 and 
exam 5 dietary data, the mean was calculated and exam 3 remains their baseline 
exam. Along with BP triplicate measurements via the standard mercury 
sphygmomanometer, anthropometric, blood chemistries, urinalysis, medical 
histories, and lifestyle habits at each exam occurring every four years. Follow-up 
was through the end of the exam 7 cycle (up to 2001). The timeline for FOS in 
these analyses is illustrated in figure 1.1. 
 
1.7.2 Nurses’ Health Study  
The Nurses’ Health Study (NHS) was established in 1976 with the primary 
purpose of investigating the potential long-term effects of oral contraceptive use. 
At that time, it was a potent drug that was being prescribed to many women and 
little was known of its health effects. The study has been broadened over time to 
include the effects of many health related and lifestyle practices including diet 
and physical acticvity.78  
 
Registered nurses were selected with the assumption that with their nursing 
education, they would be able to respond accurately to brief, biennial 
questionnaires. Along with their education, they would most likely be motivated 
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and interested in the overall goal of this prospective study. The original nurses 
were between the age of 30-55 years, married, and lived in 11 populous states: 
California, Texas, Florida, Ohio, Michigan, Maryland, New Jersey, Pennsylvania, 
New York, Connecticut, and Massachusetts. 
 
From the initial 170,000 mailed responses, around 122,000 responded (71.7% 
response rate). A follow-up questionnaire was sent every two years thereafter. 
These biennial questionnaires asked the nurses about diseases and other health-
related behaviors such as: alcohol use, smoking, menopausal status, and 
hormone use. A dietary component was added to the biennial questionnaires in 
1980 to recognize the importance of nutrition in the development of chronic 
disease. For each food, a commonly used household unit or portion was 
specified. The nurses were asked how often, on average over the previous year, 
they had consumed each food item. Subsequent dietary questionnaires were 
collected in 1984, 1986, 1990, and four years thereafter. As expected, a high 
response rate was observed at each biennial questionnaire cycle (~90%) starting 
in 1980. Figure 1.1 below shows the study timeline for NHS that was used in 
these analysis. Eight sets of food frequency questionnaires (FFQ) were used, with 
follow-up continuing through 2008. 
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Quality of life questions were added in 1992 and every four years thereafter. In 
order to have a more accurate and objective measure of certain dietary 
biomarkers, genetic markers, and hormone levels, 33,000 blood samples were 
collected in 1989-90, with 18,700 of these participants having a follow-up 
collection in 2000-01. 
 
1.7.3 Nurses’ Health Study II 
The Nurses’ Health Study II (NHS II) was established in 1989 to study the effects 
of oral contraceptives along with diet and lifestyle risk factors in a younger 
population (ages 25-42). This younger generation of women nurses included 
those who began use of oral contraceptives during adolescence and were thus 
maximally exposed during their early reproductive life. Such early use of oral 
contraceptives were hypothesized to have an adverse effect on cancer risk. The 
upper age group in NHS II represented the younger age group in the original 
NHS in order to examine health effects over time. Nursing boards in the 
following states were able to provide information on birth date and age on the 
target population of nurses: California, Texas, Missouri, Kentucky, Iowa, 
Indiana, Michigan, Ohio, Pennsylvania, New York, Connecticut, Massachusetts, 
North Carolina, and South Carolina. After a 24% baseline overall response rate 
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(123,000 of 517,000), exclusions of incomplete forms and ineligible women led to 
a total of 116,686 remaining in the NHS II. 
 
Every two years starting in 1989, members of the NHS II cohort received a 
follow-up questionnaire with questions regarding disease diagnoses and 
health/lifestyle behaviors including alcohol use, smoking, menopausal status, 
and hormone use. The first FFQ was collected in 1991 and subsequent diet 
questionnaires were administered every four years. A two-page quality-of-life 
supplement was included in the first mailing of the 1993 and 1997 
questionnaires. 
 
Blood and urine samples for dietary and genetic markers from approximately 
30,000 nurses were collected in the late 1990′s. Response rates were similar to 
NHS (approximately 90%) for each two year questionnaire cycle. Figure 2 below 
shows the study timeline for NHS II. Follow-up began in 1991 and continued 
through 2011 for these analyses 
 
1.7.4 Health Professionals Follow-Up Study 
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The Health Professionals Follow-Up Study (HPFS) began in 1986 when 51,529 
American male health professionals, ages 40-75 years, provided information on 
their medical history, lifestyle, and dietary intake. The HPFS was designed to 
evaluate effects of nutrition factors on men’s health and incidence of chronic 
diseases such as CVD and cancer. It was designed to complement the all-female 
NHS cohort, which examines similar factors on chronic disease outcomes. Of the 
participants recruited, 29,683 were dentists, 4,185 were pharmacists, 3,745 were 
optometrists, 2,220 were osteopath physicians, 1,600 were podiatrists, and 10,098 
were veterinarians. Similar to the NHS, male health professionals were targeted 
under the assumption that being a medical provider, they would be motivated 
and committed to participate in a long-term study and would be highly 
interested in the findings from such study on various health outcomes. 
 
Every two years, HPFS cohort members received questionnaires similar to NHS 
participants inquiring disease diagnoses and various health-related topics which 
included: smoking behaviors, physical activity, and medications taken. FFQ’s 
were first administered in four-year intervals starting in 1986. Figure 2 below 
illustrates the timeline of HPFS that was used for these analyses. Six sets of FFQs 
were used, with follow-up continuing through 2010. 
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Figure 1.1: Study Timelines for the FOS, NHS, NHS II, and HPFS 
Cohorts 
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1.8 GOALS OF THE DISSERTATION 
HBP is a growing public health burden that is strongly associated with CVD, the 
number cause of death in America and worldwide. As BP levels increase, the risk 
of CVD increases significantly. With an aging population and with BP strongly 
correlated with older age, the need to identify modifiable risk factors and 
behaviors to alleviate BP increases is crucial. There is a moderate amount of 
mostly cross-sectional and short-term experimental evidence that implicates 
dietary protein to have BP-lowering effects alone or in a context of healthy eating 
pattern such as the DASH diet but long-term studies are less clear. Specific 
protein sources such as dairy, has been shown to have a beneficial effect on BP as 
well. With inconsistent observational studies and only several long-term 
prospective studies, the antihypertensive effects of protein and dairy need to be 
examined further. With only several in-vitro and in-vivo studies and a few cross-
sectional evidence that suggest a beneficial effect of fermented dairy, especially 
yogurt, on BP levels, a longitudinal study is warranted to elucidate yogurt’s 
long-term BP effects. 
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1.9 OBJECTIVES OF THE DISSERTATION 
The objectives of this dissertation are to use dietary and BP data from over 11 
years of follow-up in the Framingham Offspring Study to quantify the long-term 
effects of total protein intake on mean BP levels and incident HBP risk. Next, 
three prospective cohorts: Nurses’ Health Study I, II, and the Health 
Professionals Follow-Up Study of over 180,000 participants, will be used to 
estimate the longitudinal effects of total dairy and yogurt, on incident HBP risk 
and subsequent risk of CVD among those with HBP. 
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CHAPTER 2: HIGHER PROTEIN DIETS PREDICT LOWER HIGH BLOOD 
PRESSURE RISK IN FRAMINGHAM OFFSPRING STUDY ADULTS 
 
2.1 ABSTRACT 
Background: Short-term clinical trials suggest that dietary protein has blood 
pressure-lowering effects but long-term effects of total, animal and plant proteins 
are less clear. 
Objective: To evaluate effects of total, animal, and plant proteins on mean 
systolic (SBP) and diastolic blood pressure (DBP) and incident high blood 
pressure (HBP) risk among middle-aged adults in the Framingham Offspring 
Study. 
Methods: Men and women (ages 30-54) without prevalent HBP, cardiovascular 
disease or diabetes with three-day dietary records from exams 3 or 5 (n=1,361) 
were included and followed for a mean of 11.3 years for development of HBP. 
Protein intakes adjusted for body size were derived using the residual method. 
Analysis of covariance and Cox proportional hazard’s models were used to 
adjust for age, sex, education, height, activity, smoking, fat calories, diet quality, 
and body mass index.  
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Results: Higher adjusted protein intakes were associated with lower mean SBP 
and DBP. Both animal and plant proteins lowered BPs and led to statistically 
significant reductions in HBP risk (hazard ratios (HR) of 0.68 and 0.51, 
respectively). Subjects in the highest tertile of total protein intake had a 40% 
lower long-term risk (95% confidence interval (CI): 0.45-0.78) of developing HBP. 
Beneficial effects of protein were apparent for both men and women and for 
normal weight and overweight individuals. Higher protein diets also 
characterized by higher fiber intakes led to a 51% reduction (95% CI: 0.37-0.66) in 
HBP risk.  
Conclusion: Adults consuming more dietary protein from both plant and animal 
sources had lower long-term risks of HBP. 
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2.2 BACKGROUND 
High blood pressure (HBP) is a major cause of cardiovascular disease and renal 
failure.79 Evidence from recent reviews14,15 and meta-analyses16,17 suggest that 
dietary protein consumption may benefit BP. Both of these meta-analyses of 
short-term clinical trials concluded that compared with carbohydrates higher 
dietary protein led to modest BP reductions. In the Rebholtz meta-analysis, both 
animal and plant proteins were found to have similar short-term effects on 
BP.16,17 Observational studies, which have been largely cross-sectional, have 
shown weak beneficial effects of plant proteins in particular on BP.14 There are 
few observational studies (and no clinical trials) that have addressed the long-
term effects of animal and plant proteins on BP, and results are conflicting.18-20  
 
The Dietary Approaches to Stop Hypertension (DASH) studies have documented 
the importance of diet patterns to BP.57 The greatest reductions in BP in the 
DASH trials have been seen with higher intakes of FV (fruits and vegetables) 
plus higher intakes of low-fat dairy products (an important source of dietary 
protein). In general, the effects of FV alone are modest.80 Higher dietary fiber 
intakes have also been associated with a BP- lowering effect, particularly among 
hypertensive individuals.81 Combined effects of dietary protein and fiber intakes 
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on BP are less clear although at least one review suggests that they may be 
additive.82  
 
The goal of the current study was to evaluate the longitudinal effects of the 
amount and type of dietary protein on mean BP and the risk of incident HBP 
among middle-aged adults in the Framingham Offspring Study (FOS). The 
interactive effects of dietary protein with FV and dietary fiber were also 
examined.  
 
2.3 METHODS 
2.3.1 Study Population 
 The Framingham Offspring Study (FOS) began in 1971 with enrollment of 5,124 
offspring (and spouses) from the original Framingham Heart Study cohort. 
Subjects were evaluated at roughly four-year intervals following the baseline 
visit and BP was measured at each exam. Diet was assessed using three-day diet 
records at the third (starting in 1984) and fifth examination visits.83  
 
Subjects (n=3,284) were included who had complete dietary data at examination 
3, 5, or both. For those with complete data at both visits, mean dietary protein 
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intake was estimated. For those with dietary data only at exam 3 or 5, protein 
intake from that exam was used. Exam 3 served as the baseline visit for eligible 
subjects with dietary data at that visit; exam 5 served as baseline for those with 
missing dietary data at exam 3.  
 
Additional exclusions included 1,284 who were outside of the age range (30-54 
years) at the time of dietary assessment; 294 with extreme values for total energy 
(<1200 or >4000 kilocalories/day for men; <1000 or >3500 kilocalories/day for 
women), alcohol (>20% of calories) or foods (e.g., >35 eggs/wk) , a BMI<18.5, 
missing data on potential confounders, or lacking all follow-up data; and 345 
subjects with prevalent type 2 diabetes, CVD, or hypertension (HTN) at baseline, 
leaving 1,361 subjects available for proportional hazard’s modeling. For 
calculation of mean BP at the first follow-up exam after baseline, an additional 26 
subjects were excluded who were missing that data. 
 
2.3.2 Dietary Measurement 
Approximately 16,000 days of diet records were collected during exams 3 and 5. 
A trained nutritionist instructed families in the completion of diet records (on 
two weekdays and one weekend day) and the use of two-dimensional food 
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models for estimating portion sizes. Diet records were entered into the Nutrition 
Data System (NDS), developed at the University of Minnesota.84 The NDS 
program calculated each subject’s daily intake of protein (grams) in addition to 
other macro- and micro-nutrients, including dietary fiber. The NDS provided 
estimated daily intakes for total, animal, and plant protein. FV intake per day 
(quantified in cup equivalents) was calculated by linking food codes output from 
the NDS system with USDA Pyramid food codes derived from the Continuing 
Survey of Food Intake of Individuals (CSFII).85 FV and dietary fiber were 
combined with dietary protein in selected analyses.  
 
2.3.3 Blood Pressure Outcomes 
BP was measured by a Framingham physician using a standard mercury 
sphygmomanometer. Two measurements were taken after subjects sat quietly for 
5 minutes. Mean baseline SBP and DBP values were estimated during the same 
examination cycle in which baseline dietary assessment was completed. Follow-
up SBP and DBP were measured at four year intervals at the routine examination 
visits. Incident HBP was defined as any of the following: (1) mean SBP ≥ 140 mm 
Hg or DBP ≥ 90 mmHg at two consecutive exams, or (2) mean SBP ≥ 160 mm Hg 
or DBP ≥95 mm Hg on a single exam, or (3) use of anti-hypertensive medication 
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for BP-lowering purposes. Follow-up for incident HBP started at the time of the 
last dietary protein assessment and continued until the first of the following: 
incident HBP, loss to follow-up, death, or end of follow-up (through the end of 
exam 7).  
2.3.4 Potential Confounders 
The following were considered as potential confounding factors: age, sex, 
education level (high school or less vs. beyond high school), physical activity, 
cigarette smoking, Healthy Eating Index (HEI) score, baseline BP, height, 
baseline BMI, and dietary fat intake (% of calories from fat and saturated fat). A 
physical activity index, a modification of the original method by Kannel86, was 
calculated as the number of self-reported hours per day spent doing moderate or 
vigorous activities multiplied by a numeric weight derived from the oxygen 
consumption required (liters/min) for that activity. Cigarette smoking was 
assessed at every exam visit. Subjects were considered current smokers if they 
smoked at any time during the baseline exam period. Mean cigarettes smoked 
per day during the same period were estimated. Body weight was measured at 
baseline using a calibrated spring balance scale and height were measured at 
each exam with a standard stadiometer. To reduce the effect of measurement 
error, average adult height from all available measures between ages 30 and 54 
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years of age was used to calculate baseline BMI [weight (in kilograms) divided 
by average height (in meters squared)]. To measure overall diet quality, Healthy 
Eating Index (HEI) scores were derived from the 2005 MyPyramid Food 
Guidance System which incorporates key recommendations in the 2005 Dietary 
Guidelines for Americans.87 Other specific dietary factors such as the, total 
energy, dietary sodium, monounsaturated fatty acids, alcohol intake, FV, and 
fiber were assessed as potential confounders and dropped from the final models 
as they led to less than a 5% change in the effect estimates. 
 
2.4 STATISTICAL ANALYSIS 
To derive estimates of protein intake (total, animal, plant) that were adjusted for 
body size, mean intakes were computed using the residual method, regressing 
each subject’s protein intake on body weight. This method was modeled from 
Willett's energy-adjustment method88 with resulting protein residuals being 
uncorrelated with (and therefore not confounded by) body weight. For the initial 
analyses, each protein variable was classified into tertiles using the weight-
adjusted residual variables. To assess the effects of protein combined with 
intakes of FV and fiber, weight-adjusted protein residuals were dichotomized 
(<median vs. ≥median), as were intakes of total FV and fiber, using sex-specific 
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medians (for FV: 2.92 cup-equivalents/day for men and 2.65 cup-equivalents/day 
for women; for fiber: 16.83 grams/day for men and 13.38 grams/day for women). 
Diet combinations were created by classifying each subject into one of four 
dietary intake categories (for example: (a) low intakes of both protein and FV, (b) 
low protein and high FV intakes, (c) high protein and low FV intakes, and (d) 
high intakes of both). 
 
Analysis of covariance (ANCOVA) modeling was used to compare adjusted 
mean SBP and DBP levels after four years of follow-up across tertiles of protein 
consumption as well as protein combined with FV and fiber intakes. In this 
prospective analysis, it was necessary to consider subjects who developed HBP 
during the follow-up period (since HTN treatment would impact follow-up BP 
levels). For those who developed HBP but were not on drug treatment, no 
adjustment to the follow-up SBP or DBP measures was needed. However, for 
new cases of treated HBP, mean baseline BP levels were substituted for follow-
up BP.  
 
Cox proportional hazard’s models were used to estimate the hazard ratio (HR) 
and 95% confidence interval (CI) for long-term risk of developing HBP 
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associated with dietary protein intake independently and combined with FV and 
fiber intakes. Final multivariable models included the following potential 
confounders: age, sex, education level, height, physical activity, smoking status, 
HEI score, and percent of energy from fat. Since BMI could be a causal 
intermediate in these analyses, the final models were run with and without 
follow-up BMI. In addition, stratified analyses were completed by protein type 
(animal vs. plant), baseline BMI (<25 vs. ≥ 25 kg/m2), and sex. All analyses were 
performed using Statistical Analysis Systems software, version 9.1 (SAS 
Institute).  
 
2.5 RESULTS 
Baseline characteristics of FOS subjects in each tertile of total protein intake are 
shown in table 2.1. Those with higher protein intakes were taller, more educated, 
leaner, and were more likely to be male (p<0.001, for all). Those with lower 
protein intakes consumed fewer calories, FV, and fiber (p<0.001, for all). Baseline 
blood pressure was slightly lower among individuals with the highest tertile 
baseline protein intakes (p=0.02 for SBP and p=0.06 for DBP). 
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Table 2.1. Baseline characteristics by tertile of total protein intake in the 
Framingham Offspring Study 
 
 Tertiles of estimated protein intake1  
Baseline Characteristics 1 (low) 2 3 (high) p value 
  n 444 445 446  
  Age, (y) 44.4 (6.2) 43.2 (6.4) 43.4 (6.5) 0.01 
  Height, cm 167.3 (8.9) 168.1 (8.6) 171.3 (9.3) <0.001 
  BMI, kg/m2 26.3 (4.7) 24.8 (3.6) 25.0 (3.5) <0.001 
  Male, % 27.7 37.8 60.0 <0.001 
  Current smoker, % 28.4 24.5 24.7 0.21 
  Attained high school education, %  58.2 70.1 70.8 <0.001 
  Physical activity index 12.2 (7.3) 12.3 (8.2) 12.8 (8.1) 0.42 
  SBP, mm Hg 117.7 (13.0) 115.7 (11.6) 114.6 (11.9) 0.02 
  DBP, mm Hg 76.3 (8.4) 75.2 (8.5) 75.1 (8.0) 0.06 
  Energy, kcals/d 1555 (364) 1876 (414) 2393 (535) <0.001 
  Total protein1, g/d 58.0 (8.5) 77.7 (4.8) 102.6 (13.8) <0.001 
  Animal protein1, g/d 39.3 (8.5) 54.8 (7.6) 75.1 (13.5) <0.001 
  Plant protein1, g/d 17.7 (5.0) 21.7 (6.7) 26.2 (8.9) <0.001 
  Calories from carbohydrates, %  47.6 (8.3) 45.1 (7.6) 43.4 (7.7) <0.001 
  Calories from fat, %   35.4 (6.3) 36.2 (6.4) 36.4 (6.5) 0.049 
  Calories from saturated fat, %  12.2 (2.9) 12.3 (2.9) 12.6 (3.0) 0.06 
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  Fruits/vegetables, cup eq/d  2.6 (1.2) 3.0 (1.3) 3.5 (1.7) <0.001 
  Fiber, g/d 13.1 (4.5) 15.5 (5.4) 18.9 (7.3) <0.001 
  Whole grains, oz eq/d 0.5 (0.6) 0.6 (0.8) 0.7 (0.8) <0.001 
Values are mean (SD) for continuous variables and % for categorical variables.  
p denotes the significance of the linear trend across tertiles of protein intake. 
1Protein intakes expressed as weight-adjusted residuals (g/d) 
 
Table 2.2 shows that protein consumption (total, animal, plant) was inversely 
associated with both SBP and DBP after four years of follow-up. Overweight 
subjects (BMI ≥ 25 kg/m2) had generally higher BP levels than leaner individuals 
(BMI < 25 kg/m2) but protein intake was linked with lower BPs for both groups. 
Among the overweight, both animal and plant proteins led to lower DBP levels 
while leaner subjects consuming more animal and plant proteins had lower SBP 
levels.  
 
Table 2.2. Multivariable-adjusted blood pressure levels by tertiles of total, 
animal, and plant protein intake among adults 
Baseline intake All1 Baseline BMI < 252 Baseline BMI ≥ 252 
  Total protein3 n SBP DBP n SBP DBP n SBP DBP 
    T1  444 120.5 
(0.6) 
77.1 
(0.4) 
195 116.5 
(0.9) 
73.7 
(0.6) 
249 124.4 
(0.9) 
80.4 
(0.5) 
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Values are mean (SE). 
BMI, body mass index; DBP, diastolic blood pressure; SBP, systolic blood pressure; T, tertile. 
    T2 445 119.1 
(0.6) 
76.5 
(0.4) 
251 115.8 
(0.8) 
74.4 
(0.5) 
194 122.7 
(0.9) 
79.0 
(0.6) 
    T3  446 117.7 
(0.6) 
75.6 
(0.4) 
237 113.1 
(0.8) 
72.9 
(0.6) 
209 122.6 
(0.9) 
78.3 
(0.6) 
    p for trend  0.001 0.02  0.006 0.29  0.17 0.02 
  Animal protein3          
    T1  445 120.0 
(0.6) 
77.0 
(0.4) 
207 116.2 
(0.9) 
73.8 
(0.6) 
238 124.1 
(0.9) 
80.2 
(0.6) 
    T2 442 119.8 
(0.6) 
76.7 
(0.4) 
238 115.7 
(0.8) 
74.2 
(0.6) 
204 124.2 
(0.9) 
79.5 
(0.6) 
    T3  448 117.6 
(0.6) 
75.6 
(0.4) 
238 113.5 
(0.8) 
73.1 
(0.6) 
210 121.7 
(0.9) 
78.2 
(0.6) 
    p for trend  0.02 0.049  0.03 0.41  0.08 0.02 
  Plant protein3          
    T1  445 120.7 
(0.6) 
77.5 
(0.4) 
192 116.4 
(1.0) 
74.4 
(0.6) 
253 125.1 
(0.8) 
80.7 
(0.5) 
    T2 446 118.4 
(0.6) 
76.5 
(0.4) 
247 115.4 
(0.8) 
73.7 
(0.5) 
199 121.3 
(0.9) 
79.3 
(0.6) 
    T3  444 118.3 
(0.6) 
75.3 
(0.4) 
244 113.8 
(0.9) 
73.0 
(0.6) 
200 123.1 
(1.0) 
77.6 
(0.6) 
  p for trend  0.03 0.001  0.04 0.11  0.06 0.0002 
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1Adjusted for age, sex, education, height, activity, smoking status, % energy from fat, BMI status 
(normal, overweight or obese).  
2Adjusted for age, sex, education, height, activity, smoking status, % energy from fat.  
3Protein intakes expressed as weight-adjusted residuals in g/d. 
 
The effects of dietary protein combined with total FV or fiber consumption on 
adjusted mean BP levels are shown in Table 2.3. We explored first independent 
effects of the sex-specific tertiles of FV and fiber intake on mean BP levels (data 
not shown) and found that those in the highest tertile of FV intake had a mean 
SBP that was 2.1 mm Hg lower (p=0.02) and a DBP that was 0.8 mm Hg lower 
(p=0.16) than those with the lowest intakes. The highest dietary fiber intakes were 
associated with stronger BP-lowering effects (p=0.001 for SBP; p=0.002 for DBP). 
In Table 2.3, subjects consuming more protein combined with either higher FV or 
fiber intakes had lowest mean SBP and DBP levels. For example, adults with 
higher protein and fiber intakes had SBP levels that were 4.0 mm Hg lower (and 
DBP levels that were 2.3 mm Hg lower) than those with lower intakes of both 
(p<0.001 for both SBP and DBP). In general, the effects of dietary fiber on BP 
seemed were stronger than those for FV. Finally, more protein consumption led 
to beneficial effects on BP for both men and women while the benefits of dietary 
fiber seemed stronger for women than for men.  
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Table 2.3. Multivariable-adjusted blood pressure levels according to combined 
intakes of total protein with FV or fiber  
 
 Mean blood pressures after 4 years of follow-up 
Baseline diet pattern1 N SBP2 P value DBP2 P value 
All 
  Protein + FV  
    Low protein, low FV (reference) 387 120.3 (0.7) - 76.8 (0.4) - 
    Low protein, high FV 279 120.4 (0.8) 0.88 77.4 (0.5) 0.35 
    High protein, low FV 280 118.6 (0.8) 0.10 76.2 (0.5) 0.31 
    High protein, high FV 389 117.4 (0.7) 0.002 75.5 (0.4) 0.02 
  Protein + fiber  
    Low protein, low fiber (reference) 413 121.1 (0.6) - 77.3 (0.4) - 
    Low protein, high fiber 253 119.0 (0.8) 0.04 76.7 (0.5) 0.32 
    High protein, low fiber 256 119.2 (0.8) 0.07 77.0 (0.5) 0.63 
    High protein, high fiber 413 117.1 (0.6) <0.001 75.0 (0.4) <0.001 
Men 
  Protein + FV  
    Low protein, low FV (reference) 113 124.2 (1.1) - 80.5 (0.8) - 
    Low protein, high FV 80 122.7 (1.4) 0.40 80.2 (0.9) 0.75 
    High protein, low FV 165 120.0 (1.0) 0.13 79.5 (0.6) 0.31 
    High protein, high FV 200 120.2 (0.9) 0.006 78.3 (0.6) 0.02 
  Protein + fiber  
    Low protein, low fiber (reference) 128 123.2 (1.1) - 80.4 (0.7) - 
    Low protein, high fiber 65 124.5 (1.5) 0.49 80.2 (1.0) 0.88 
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    High protein, low fiber 150 121.7 (1.0) 0.30 79.7 (0.7) 0.46 
    High protein, high fiber 215 120.5 (0.8) 0.055 78.2 (0.6) 0.02 
Women 
  Protein + FV  
    Low protein, low FV (reference) 274 117.8 (0.8) - 74.4 (0.5) - 
    Low protein, high FV 199 118.5 (1.0) 0.55 75.4 (0.6) 0.21 
    High protein, low FV 115 116.1 (1.2) 0.24 73.6 (0.8) 0.39 
    High protein, high FV 189 115.2 (1.0) 0.04 73.4 (0.6) 0.22 
  Protein + fiber  
    Low protein, low fiber (reference) 285 119.5 (0.8) - 75.2 (0.5) - 
    Low protein, high fiber 188 115.9 (1.0) 0.004 74.2 (0.6) 0.24 
    High protein, low fiber 106 117.8 (1.3) 0.25 75.3 (0.8) 0.94 
    High protein, high fiber 198 114.4 (0.9) <0.001 72.6 (0.6) 0.001 
Values are mean (SE). 
BMI, body mass index; DBP, diastolic blood pressure; FV, fruits and vegetables; SBP, systolic 
blood pressure. 
1Cutpoint for dichotomous baseline intakes was set at the median (< median vs. ≥median) for 
protein intake (as weight-adjusted residuals, g/d), FV (cup equivalents/d), and fiber (g/d).  
2Adjusted for age, sex (only for all subjects model), education, height, activity, smoking status, % 
energy from fat, baseline BMI.  
  
There were 346 cases of incident HBP that occurred during the follow-up period 
(mean time = 11.3 years). Figure 2.1 illustrates the hazard ratios for incident HBP 
associated with total, animal, and plant protein intakes. After adjusting for age, 
sex, education, height, physical activity, smoking, HEI score, and percent of 
calories from fat, subjects in the highest tertile of total protein intake had a 40% 
lower risk of incident HBP (HR: 0.60, 95% CI: 0.45-0.78) compared with those in 
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the lowest tertile. Both animal (HR: 0.68, 95% CI: 0.52-0.89) and plant (HR: 0.51, 
95% CI: 0.38-0.68) protein consumption led to statistically significant reductions 
in HBP risk. To determine whether BMI might explain any of the effects of 
protein on HBP risk, baseline BMI was added to Model 2; statistically significant 
reductions in HBP risk remained for high plant protein intakes but were 
somewhat attenuated for total and animal proteins. 
 
Figure 2.1 Adjusted hazard ratios for incident HBP by tertile of total, animal, 
and plant protein intake 
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In Figure 2.2, adjusted HRs for incident HBP associated with protein combined 
with either FV or fiber are shown. Overall, subjects who consumed more protein 
combined and more FVs intakes had a statistically significant 39% reduction in 
risk of HBP compared with those in the referent group (Model 1). Those who 
consumed more protein with a higher fiber diet, had a 51% lower risk (95% CI: 
0.37-0.66) of incident HBP than those with lower intakes of both. These effects 
were slightly weakened by the addition of BMI to Model 2.  
 
Figure 2.2 Adjusted hazard ratios for incident HBP by category of total protein 
combined with FV or fiber 
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High vs. low protein: <median vs. ≥median). High vs. low FV (and fiber): <sex-specific vs. ≥sex-
specific median. Model 1 is adjusted for age, sex, education level, height, physical activity, 
smoking status, HEI score, and percent of calories from fat. Model 2 is additionally adjusted for 
BMI. 
 
2.6 DISCUSSION 
In this study, adults who consumed more protein, whether from animal or plant 
sources, had statistically significantly lower SBP and DBP levels after four years 
of follow-up. In general, these beneficial effects were evident for both overweight 
(≥ 25 kg/m2) and normal weight (< 25 kg/m2) individuals. Consuming more 
dietary protein was also associated with lower long-term risks of incident HBP 
and, when the diet was also characterized by higher intakes of fiber, higher 
protein intakes led to 40-60% reductions in risk of HBP.  
 
The current analyses add to a very limited number of longer-term prospective 
studies of protein intake and BP in adults.14 Our results contrast with those of 
both the Western Electric Study (WES) and the Seguimiento Universidad de 
Navarra (SUN) study that found only vegetable protein consumption to be 
inversely correlated with BP.18,20 In the Coronary Artery Risk Development in 
Young Adults (CARDIA) study, total protein intake among 4,100 young adults, 
ages 18-30 years, was inversely associated with both SBP and DBP, but the effects 
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were strongest for DBP.19 In Framingham with a somewhat older study 
population, the protein effects were generally similar for SBP and DBP. 
Short-term clinical trials of protein biomarkers also suggest beneficial effects on 
BP.14,89,90 These clinical trials have typically compared higher-protein diets with 
higher-carbohydrate diets, making it difficult to separate beneficial effects of 
higher protein intakes from those of a lower-carbohydrate diet. The OmniHeart 
Trial compared three “healthy dietary” interventions among adults with 
prehypertension or stage 1 HTN: a diet similar to DASH with 58% of calories 
from carbohydrates (vs. 48% in the two other arms), a diet higher in unsaturated 
fats, particularly monounsaturated fats (21% vs. 13% from monounsaturated 
fats), and a diet higher in protein (25% of calories from protein vs. 15%).21 Partial 
substitution of carbohydrates with either protein or unsaturated fats led to 
greater BP reductions than the higher carbohydrate diet alone. The current long-
term data from the FOS offer important evident to suggest that both animal and 
plant proteins have BP-lowering effects in non-hypertensive adults.  
 
Dietary proteins may affect BP through a number of pathways and those 
pathways may differ according to the amino acid composition of the food 
source.15 Arginine, an amino acid found in many plant and animal sources 
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including eggs, acts as a vasodilator through nitric oxide pathways, contributing 
to lower BP.91 Also, the increased plasma amino acid levels from a higher protein 
diet may affect proximal sodium reabsorption or lead to alterations in cell 
permeability, thereby enhancing BP-related renal dynamics.92 Dairy products are 
common sources of animal protein in the American diet. Some studies including 
at least one meta-analysis93 suggest that biologically-active peptides from milk 
protein, including two casein-derived tripeptides (isoleucine-proline-proline and 
valine-proline-proline) may directly impact BP by inhibiting the angiotensin-
converting enzyme (ACE) pathway.94  
 
It has been suggested in a number of studies, including those of the landmark 
DASH diet trials, that FV intakes are linked with a lower risk of HTN.57,95 
Mechanisms could involve antioxidant defense capacity and the ability to 
combat oxidative stress.96 FV contain phytochemicals including flavonols, 
phytosterols and polyphenols that are thought to have BP-lowering effects.97 
They are also important sources of other nutrients such as magnesium and 
potassium with known BP-lowering effects.95 Despite these purported 
mechanisms, the overall effects of FV on BP are generally modest.80  
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This study found a strong beneficial effect of dietary fiber on BP when combined 
with a higher protein diet. Several meta-analyses of randomized controlled trials 
provide strong support for BP-lowering effects of fiber, particularly among 
hypertensive subjects.81,98 While exact underlying mechanisms are unclear, it has 
been hypothesized that dietary fiber enhances insulin sensitivity and improves 
vascular endothelial function which may, in turn, benefit BP.99,100  
 
It is also possible that the observed benefits of FV or dietary fiber on BP could be 
a consequence of intermediate effects on BMI, as was seen in a recent study.101 
Our analyses suggest that while there is modest attenuation of the results by the 
inclusion of BMI in the models, independent beneficial effects of these diet 
patterns characterized by higher intakes of protein and higher intakes of FV or 
fiber remain. 
 
Epidemiologic studies of diet-disease relations share a number of limitations. Of 
necessity, dietary data for adults are obtained by self-report and are thus subject 
to both random error and potentially biased reporting. In addition, of the 5,124 
subjects enrolled in the FOS, only 3,284 (64%) provided dietary data. Further, we 
had no protein biomarker information in this study to validate reported intakes. 
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The FOS has a number of important strengths as well. The available diet record 
data were collected in a standardized fashion and, of those included in these 
analyses, most subjects (62%) contributed six days of diet records. Our study is 
one of very few long-term studies that have separated the effects of animal and 
plant proteins in their effects on BP. Further, the study has extensive and 
systematically-collected information on potential confounders, enhancing both 
the precision and validity of the results. 
 
2.7 CONCLUSION 
The longitudinal data from this study suggest that higher intakes of dietary 
protein from both animal and plant sources may be linked with significantly 
lower risks for developing HBP during the middle adult years. The observed 
beneficial effects on BP in these data were partially attenuated by controlling for 
intermediate effects of protein on body fat. These results provide no evidence to 
suggest that individuals concerned about the development of HBP should avoid 
dietary protein. Rather, protein intake may play a role in the long-term 
prevention of HBP. 
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CHAPTER 3: HIGHER LONG-TERM INTAKES OF TOTAL DAIRY AND 
YOGURT ARE LINKED WITH A LOWER RISK OF INCIDENT HIGH 
BLOOD PRESSURE IN MIDDLE-AGED ADULTS 
 
3.1 ABSTRACT 
Background: Observational studies suggest a beneficial effect of increased dairy 
intake on risk of high blood pressure (HBP) but the independent effects from 
specific types of dairy, such as yogurt, cheese, and milk are lacking. 
Objective: To estimate the independent effects of total dairy, yogurt, cheese, and 
milk, on risk of incident HBP among middle-aged nurses in the Nurses’ Health 
Study (NHS), NHS II, and male health professionals in the Health Professionals 
Follow-Up Study (HPFS). A secondary objective was to evaluate the modifying 
effects of a healthy diet or BMI on the independent effects of the dairy exposures.  
Methods: Data from three prospective studies of middle-aged adults were used: 
the NHS (n=66,987), NHS II (n=84,368), and HPFS (n=30,512) without prevalent 
HBP, cardiovascular disease, cancer, or diabetes with reported dietary intakes 
from validated, semi-quantitated food frequency questionnaires were included. 
NHS, NHS II, and HPFS participants were followed for a maximum of 30, 20, 
and 26 years respectively for development of HBP, which was ascertained via 
  51
self-report in updated biennial questionnaires. Time dependent Cox proportional 
hazard’s models were used to calculate hazard ratios (HR) and 95% confidence 
intervals (CI) and to control for potential confounding by age, race, HBP family 
history, calories, activity, intakes of fruits and vegetables (FV), and total protein. 
The addition of updated BMI was added in a separate model to evaluate the 
potential intermediate effects of body composition on risk of HBP. Fixed effects 
meta-analysis was used to combine the results from each cohort and to evaluate 
between-study heterogeneity. 
Results: Participants who had a usual yogurt intake of 5 or more servings/week 
(s/wk) in the NHS, NHS II, and HPFS cohorts respectively saw a 20% (95% CI: 
0.74-0.87), 17% (95% CI: 0.77-0.90), and a 6% (95% CI: 0.83-1.07) HBP risk 
reduction compared to the referent group of <1 serving/month. The addition of 
BMI attenuated the effects to 14% and 11% in the NHS and NHS II cohorts 
respectively, but the effects remained statistically significant. The effect of yogurt 
was modified by an overall healthy diet. Those with a high usual yogurt intake 
of ≥ 5 s/wk combined with a high DASH diet score (tertile 3), had a statistically 
significant 31% lower risk of among the three cohorts. Pooled analyses among 
the three cohorts showed that participants with a high milk (2-<6 s/d) or high 
cheese (1-4 s/d) intake experienced a 13% (95% CI: 0.85-0.89) and an 8% (95% CI: 
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0.88-0.96) reduced risk of HBP. Total dairy intake was inversely associated with 
risk of HBP in each of the three cohorts (p for linear trend<0.0001 for all). Those 
with the highest usual total dairy intake (3-<6 s/d) saw a 13% (95% CI: 0.83-0.92), 
26% (95% CI: 0.69-0.78), and a 9% (95% CI: 0.84-0.98) lower risk of HBP in the 
NHS, NHS II, and HPFS respectively. BMI slightly attenuated the effects but each 
remained statistically significant. When combined with a high DASH diet score, 
those with high dairy intakes (3-<6 s/d) among the three cohorts saw a 23% 
reduced HBP risk compared to those with low dairy intakes (<1.5 s/d) and a low 
DASH score.  
Conclusion: Higher usual intakes of total dairy and yogurt are associated with a 
lower risk of HBP across the NHS, NHS II, and HPFS cohorts, with yogurt 
having a greater effect than total dairy. Our study adds solid evidence that high 
long-term dairy intakes, especially yogurt, is linked with lower incidence of HBP. 
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3.2 BACKGROUND 
 
In NHANES 2009-2012, it was estimated that 32.6% (or 80 million) American 
adults 20 years or older had high blood pressure (HBP).102 Annual HBP-
attributable deaths were estimated to be 65,123 in 2013,2 a 39.3% increase from 
2001.103 The direct and indirect cost of HBP is $46.4 billion with a projected cost of 
$274 billion by 2030.104 With the increasing cost of HBP-associated healthcare, 
and HBP being regarded as the most important attributable risk factor for 
mortality105, modifiable behaviors factors that may affect blood pressure (BP) are 
needed to be determined in order to alleviate the public health burden of HBP. 
 
Understanding the effects of dietary patterns and implementing them remains 
the primary prevention tool for HBP. The Dietary Approaches to Stop 
Hypertension (DASH) trial was the first feeding trial that provided innovative, 
solid evidence of how certain food groups consumed together in an eating 
pattern can influence BP.22 The randomized feeding trial tested the DASH diet, 
which had lower amounts of total and saturated fat, and cholesterol while 
providing high intakes of fiber and protein along with antihypertensive minerals 
such as calcium, potassium, and magnesium, at intakes around the 75th 
percentile of the usual American consumption, along with the typical American 
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diet as the control group, and a diet with increased intakes of 8-9 servings/d of 
fruits and vegetables (FV) only (without enrichment of dairy). The benefits were 
greatest for both SBP and DBP in the DASH diet group, which additionally 
contained 2 to 3 servings of low-fat dairy per day, compared to the diet enriched 
with 8-9 servings of fruits and vegetables (FV) only.22 The most recent Dietary 
Guidelines for Americans (DGA) released by the United States Department of 
Agriculture (USDA) and Department of Health and Human Services (DHHS) in 
2015 echoed a similar sentiment that eating an overall healthy diet of whole 
grains, FV, lean meats, poultry, seafood, legumes, nuts, and low-fat or fat-free 
dairy products can help combat preventable diet-related diseases106. All of the 
components promoted by the 2015 DGA are already constituents of the DASH 
diet. Several longitudinal studies in middle-aged Americans in the NHS107 and 
the Insulin Resistance Atherosclerosis Study108 have linked adherence to the 
DASH diet to lower risks of chronic diseases such as HBP, CVD, and type 2 
diabetes (T2DM). Although the DGA are not specifically targeting BP, its 
evidence-based guidelines mirroring the DASH diet sends a powerful and 
influential message to the American public that having an overall balanced diet 
is consistently associated with positive health outcomes and lower risk of several 
chronic diseases. 
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Several longitudinal studies including those in middle-aged Americans in the 
National Heart, Lung, and Blood Institute Family Heart Study109 and the 
Women’s Health Study26 observed that increased overall dairy intake is linked 
with lower mean BP and HBP risk. In 2010, the Dietary Guidelines for Americans 
committee concluded that there was moderate evidence from mostly 
observational studies (eight cross-sectional and three prospective cohort studies) 
and several randomized experimental trials of a beneficial effect of dairy 
consumption to lower BP, and dairy intake was associated with lower risk of 
CVD and T2DM110. A recent meta-analysis and systematic review of five 
observational studies from US and European cohorts by Ralston et al. concluded 
that total dairy and low-fat dairy intakes were inversely associated with risk of 
HBP.37 Although the evidence for the beneficial effects of dairy intake on HBP 
seems consistent based on cross-sectional and longitudinal studies, some have 
shown mixed findings. Alonso et al showed a beneficial effect of low-fat dairy in 
the Atherosclerosis Risk in Communities (ARIC) study on BP but no effect of 
total dairy on BP in African Americans over an 8 year follow up.111 This finding is 
in contrast to findings from the original DASH trial where a greater BP-lowering 
effect was observed among African Americans than Caucasian participants. One 
reason for this disparity is likely attributed to the randomized feeding study 
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design of the DASH trial, where all foods were provided and dietary intake was 
followed more closely, measured with greater accuracy than with simple dietary 
recall methods used in observational cohort studies like ARIC.  
 
Some clinical trials have also shown inconsistent results of dairy’s effect on BP. 
Van Meijl et al conducted a 16 week, randomized crossover feeding trial, in 
which weight was kept constant, in overweight and obese subjects in which they 
saw a decrease in SBP with the addition of low-fat dairy (500 mL of low-fat milk 
and 150 g. of low-fat yogurt at each day of the intervention with both milk and 
yogurt containing 1.5% fat) but no effect on DBP.112 In contrast, a 6-month clinical 
trial evaluating the effects of increased total dairy intake on body composition 
and metabolic health while keeping weight stable saw no effects of 3-5 s/d of 
dairy supplementation on BP.113 Although it has been shown that dairy has BP-
lowering effects independent of body weight22, it is difficult to tease apart a BP 
effect from weight change, since most clinical interventions have unintended 
effects on weight114. Since most of the dairy interventions related to BP have 
incorporated small changes to eating patterns, these small changes can have 
sizeable impact on macronutrient intakes and on body weight. The primary focus 
is how specific changes in dairy consumption impact blood pressure and even 
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though body composition is an important determinant of BP, the intervention 
has to be applied in a broader scale in both weight-stable and weight-loss 
settings. More carefully conducted longitudinal and experimental studies that 
carefully account for the amount and types of dairy being consumed is the best 
way to specify what the effect of each dairy product is on BP. This is key as 
different populations respond to dairy interventions in different capacities.115  
 
In terms of antihypertensive effects of dairy, especially fermented dairy such as 
yogurt, the casein protein has been studied most extensively116. It has been 
observed in animal models41,117 and in vitro118,119 that the caseins in milk facilitate 
calcium and phosphate absorption in the small intestine.116 Calcium and 
phosphate are the main substrates needed for the production of small 
biopeptides which are made from either milk protein digestion in the enterocyte 
or by fermentation of milk by lactobaccili bacteria typically added to yogurt.116 
These biopeptides have the potential to be a non-pharmacologic means to lower 
BP. Observational studies that specifically evaluate yogurt consumption in 
relation to BP are scarce but beginning to emerge. Beydoun et al showed that 
yogurt intake was associated with lower SBP using the NHANES 1999-2004 
data.44 Yogurt was recently shown to be associated with a lower incidence of 
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metabolic syndrome in an elderly Mediterranean population in the PREDIMED 
study120 and a lower risk of hypertension (HTN) in the Framingham Offspring 
Study (FOS) Cohort.121 These observational studies do not have ample statistical 
power in order to capture effects of usual daily intakes of yogurt. 
 
Long-term observational studies on the effect of dairy, and especially yogurt, on 
BP are lacking. Only one long-term longitudinal study specifically quantified 
yogurt’s BP-lowering effect. Wang et al conducted their analysis using data from 
the FOS, a cohort of 2,636 participants followed for over 10 years.121 This study 
was limited in its statistical power to only estimate the potential beneficial effect 
of 1 serving of yogurt per week121 – an intake level that falls below the USDA 
recommended 2-3 servings/day of total dairy from various subtypes considered 
together (milk, cheese, yogurt).122 Yogurt is usually combined with other dairy 
foods as a “total dairy” exposure in epidemiologic analyses, and its specific 
effects may therefore be underestimated. Yet, there has been a substantial 
increase in yogurt consumption in the past decade. Only 4.3% of American 
adults consumed yogurt on a given day in 1999, compared to 9.3% in 2011.123 
Thus, investigations into yogurt-specific health effects are warranted. Yogurt is 
highly concentrated with casein and whey proteins, as well as calcium, 
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magnesium, and potassium63, all of which have been observed to have BP-
lowering effects in animal studies as well as observational and experimental 
studies in humans115. Well-conducted long-term studies are needed in order to 
assess the potential benefits of daily yogurt consumption on cardiometabolic risk 
factors such as HBP in order to refine dietary guidance for the population. The 
aim of this study is to estimate the long-term effects of total dairy and yogurt 
intake on incident HBP among middle-aged women and men in the Nurses’ 
Health I, II, and Health Professionals Follow-Up cohorts. These three cohorts are 
comprised of over 300,000 participants and were followed up for 20-30 years, 
which enables us to observe enough variation in yogurt intake to be able to 
estimate yogurt-specific effects on risk of HBP. 
 
3.3 METHODS 
 
3.3.1 Study Population 
 
Data from three prospective cohort studies will be used for these analyses: the 
Nurses’ Health Study (NHS), Nurses’ Health Study II (NHS II), and the Health 
Professionals Follow-Up (HPFS) Study. The NHS was composed of 121,741 
female registered nurses, ages 30-55 years at enrollment in 1976 when the first 
medical history and lifestyle questionnaires were mailed. Follow-up 
  60
questionnaires were sent every two years thereafter up through 2010. The NHS II 
was initiated in 1989 with enrollment of 116,430 female registered nurses, ages 
25-42 years, who similarly provided medical history and lifestyle information 
and completed a follow-up health-related questionnaire every two years up 
through 2011. The HPFS began in 1986 with 51,529 American men ages 40-75 
years, who worked in a variety of medical fields and completed biennial medical 
and lifestyle questionnaires through 2010. Baseline dietary assessments using a 
standardized food frequency questionnaire (FFQ) were completed in 1980, 1991, 
and 1986 for subjects in the NHS, NHS II, and HPFS, respectively.124 The goal of 
these three large cohorts was to examine diet and lifestyle factors that affected 
overall health and risk of chronic diseases.  
 
For the current analyses, we excluded men and women at the time of the baseline 
dietary assessments who had diagnoses of HBP, angina, stroke, myocardial 
infarction (MI), coronary artery bypass grafting (CABG), diabetes (including type 
1, type 2, or gestational diabetes), or cancer. Additional exclusion criteria 
included the following: participants who left >70 of the 131 food items blank on 
the baseline food frequency questionnaire (FFQ) or who reported unusual total 
energy intakes (<500 or >3,500 kcals/d for women and <800 or >4,200 kcals/d for 
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men), had missing follow-up HBP information, missing dairy intake, and high 
total dairy (≥6 s/d), cheese (>4 s/d), and milk (≥6 s/d) intakes. After exclusions, 
data from 69,351 NHS, 84,368 NHS II, and 30,512 HPFS participants were left for 
analysis. The study protocol was approved by the institutional review boards of 
the Boston University School of Medicine and Brigham and Women’s Hospital. 
 
3.3.2 Assessment of Dairy and Yogurt Consumption  
 
In the 1980 NHS questionnaire, a 61-item FFQ was administered to NHS 
participants to collect dietary information on usual intake of foods and beverages 
in the previous year. To assess updated dietary intake during the extended 
follow-up, an expanded 131-item FFQ was mailed in 1984, 1986, 1990, 1994, 1998, 
2002 and 2006 in the NHS. The expanded FFQ was used for NHS II in 1991, 1995, 
1999, 2003, and 2007; similarly for HPFS in 1986, 1990, 1994, 1998, 2002, and 2006. 
 
All of the FFQs asked participants how often, on average, they consumed each 
food or beverage item in a standard portion size within the past year. There were 
nine possible responses that ranged from “never, or less than once per month” to 
“6+ per day.” Each FFQ response was converted to a continuous value 
representing average daily servings consumed. For example, if someone chose 
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“2-3 per day,” the midpoint value (2.5 servings/day) was used to represent their 
intake. Table 3.1 below shows the conversion of each possible FFQ response to its 
corresponding intake value. 
Table 3.1 Conversion of FFQ intake categories into continuous frequency intakes  
 
(servings/day)  
 
FFQ Category Daily Intake Value assigned1  
Never 0.00 
1-3/month 0.07 
1/week 0.14 
2-4/week 0.43 
5-6/week 0.79 
1/day 1.00 
2-3/day 2.50 
4-5/day 4.50 
6+/day 6.00 
 
1These values reflect the actual intake as servings/day (s/d). For categories with a range of intake, 
the midpoint of the range was used and converted to servings/day. 
 
 
Nutrient intake was calculated by multiplying the frequency of consumption of 
each food item by the nutrient composition in the standard position size of that 
food from the USDA’s food composition database.125 The reproducibility and 
validity of these FFQs have been shown elsewhere.124,126-128 The correlation 
coefficients for individual dairy foods in the NHS are: 0.69 for skim milk, 0.56 for 
whole milk, 0.97 for yogurt, 0.73 for ice cream, 0.70 for cottage cheese, and 0.57 
for hard cheese.126 
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For these analyses, serving sizes are reported in terms of USDA’s MyPyramid 
serving sizes85. For a few of the dairy foods on the FFQ, serving sizes did not 
match the standard MyPyramid serving sizes. These were converted in order to 
reflect standard dairy food servings as defined by USDA’s MyPyramid85. For 
example, the MyPyramid serving size for ice cream, sherbet, and frozen yogurt is 
1 ½ cups85. Therefore, ice cream, sherbet, and frozen yogurt intakes reported on 
the FFQ were divided by 3 in order to represent a fraction of the MyPyramid 
serving of dairy. Using the MyPyramid definition of a dairy product (foods that 
are made from milk and retain their calcium content,)85 cream cheese, butter, and 
cream were excluded as part of the total dairy variable85. Total dairy intake in 
these analyses includes: all milk (skim, low-fat, reduced-fat, and whole), ice 
cream, sherbet/frozen yogurt, cheese (cottage/ricotta, hard, sliced), and yogurt. 
Total yogurt intake will be used as the exposure in these analyses. Therefore, all 
varieties of yogurt were summed together to create the total yogurt exposure for 
these analyses. 
 
3.3.3 High Blood Pressure Outcome Ascertainment 
 
At every biennial questionnaire, participants in each cohort were asked if they 
were diagnosed with HBP by a physician. This method of self-report has been 
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previously validated in the NHS cohort: a subsample of 161 women who did not 
report HBP had their BP checked by a physician; all measured systolic blood 
pressure (SBP) and diastolic blood pressure (DBP) levels were below 140 and 90 
mm Hg, respectively. Furthermore, self-reported HBP diagnoses were validated 
for 51 out of 62 NHS participants who agreed to have their medical records 
checked.129 Validity was similarly observed in the NHS II: relevant medical 
records were obtained from a subset of randomly selected NHS II participants 
who self-reported a new diagnosis of HBP on the 2005 questionnaire, along with 
randomly selected nurses who denied this diagnosis in 2005 and in every 
previous year. The sensitivity of self-reported HBP was 94% in NHS II and the 
specificity of a nurse reporting no diagnosis of HBP was 85%130. In HPFS, a 
random sample of 100 participants reporting a diagnosis of HBP on the 1988 
questionnaire was followed-up, where 39 agreed to have their medical records 
accessed. The records confirmed that all of them had HBP or were receiving 
antihypertensive treatment131. 
 
Subjects with prevalent HBP at the time of the baseline dietary assessments were 
excluded from these analyses. A participant was considered to have prevalent 
HBP if he or she reported this diagnosis at the baseline questionnaire: 1980 
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(NHS), 1991 (NHS II), or 1986 (HPFS). Participants were considered to be 
incident HBP cases if they reported a new physician-diagnosed HBP diagnosis 
on the routine follow-up questionnaires. 
 
3.3.4 Covariate assessment 
 
Updated information on chronic disease risk factors such as body weight (in kg), 
age (years), physical activity, and family history of HTN were asked in the 
biennial follow-up questionnaires and race was asked in the baseline 
questionnaire. Height was converted to meters and used to calculate BMI 
(weight/height2). Participants reported their average weekly time spent in several 
recreational activities including: walking or hiking, jogging, running, bicycling, 
and heavy outdoor work. Participants also reported their usual walking pace and 
the number of flights of stairs climbed daily. Total metabolic equivalent (MET) 
hours of activity per week (MET-hr/week)132,133 were calculated in order to 
incorporate activity duration, intensity, and frequency. The reproducibility and 
validity of these questionnaire have been described previously.134 In a subgroup 
of NHS II participants (N=151), the correlation over a 1-year period between 
activity reported via questionnaire vs past-week recalls was 0.79. For vigorous 
activities, the correlation was 0.62.134 
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Since yogurt has been associated with an overall healthy diet52, A DASH diet 
score was constructed in order to observe potential effect modification of an 
overall healthy diet on the yogurt-specific effect on HBP. The calculation of the 
DASH diet score has been previously described107. In brief, 8 foods and nutrients 
that characterize the DASH diet comprised the DASH diet score: high intakes of 
low-fat dairy products, fruits, vegetables, nuts and legumes, and whole grains 
and low intakes of red and processed meats, sugar-sweetened beverages and 
sodium135. A DASH diet score was calculated using data from each FFQ by 
classifying the participants into quintiles of intake for each of the 8 
aforementioned components. For whole grains, low-fat dairy, fruits, vegetables, 
and nuts and legumes, those in the highest quintile received a score of 5 and 
those in the lowest quintile of intake received a score of 1. For sodium, sugar-
sweetened beverages, and red and processed meats, those in the lowest quintile 
of intake received a score of 5 and those in the highest quintile of intake received 
a score of 1. The DASH score was calculated by summing the quintile rankings of 
the 8 components, yielding a range from 8-40, with 40 being the score that most 
closely resembled a DASH diet.  
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3.4 STATISTICAL ANALYSES 
 
Cumulative averages of dietary intakes were used in these analyses and their 
calculation has been described previously elsewhere.136 In these analyses, dietary 
intakes from each diet questionnaire were given equal weight in the calculation 
of the cumulative average. For example, the cumulative average intake of yogurt 
in 1999 is the simple average of yogurt intake from 1991, 1995, and 1999. Figure 1 
below illustrates the calculation of cumulative average yogurt intake in the NHS 
II at each dietary questionnaire year.  
Figure 3.1 Study diagram for NHS II 
             1989  1991  1993  1995  1997  1999  2001  2003  2005  2007   2009  2011 
 
Cumulative average yogurt at 2003=mean(yogurt91+yogurt95+yogurt99+yogurt03) 
 
Cumulative averages were calculated from baseline up to the censoring events of 
death, end of study, or lost to follow-up. When a participant reported HBP, diet 
at the previous exam was carried forward in order to best represent long-term 
dietary intake and to minimize within-person variation137. In addition, the 
updating of cumulative average dietary intake was stopped when participants 
developed MI, CABG, stroke, T2DM, or cancer as these diagnoses may prompt a 
       Diet             Diet           Diet              Diet             Diet       
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change in diet, which may confound the relationship between dairy and 
HBP.137,138 Total dairy and yogurt intakes at previous questionnaires were carried 
forward for those with missing follow-up dairy and yogurt intakes. While those 
with missing dietary data at all exam years were excluded from these analyses. 
 
Total dairy was separated into high-fat and low-fat to assess whether dairy fat 
had differential effects on risk of HBP. High-fat dairy included whole milk, high-
fat cheese, and ice cream. Low-fat dairy was comprised of reduced fat and skim 
milk, yogurt, low-fat cheese, sherbet, and cottage cheese. Total, high-fat, and 
low-fat dairy, as well as yogurt, milk, and cheese were categorized in order to 
estimate the independent effect of each dairy exposure. Cutpoints were chosen to 
optimize analytic power and to represent intakes that are easily interpretable and 
applicable to both daily recommendations and the FFQ categories. For example, 
yogurt intake was categorized as: <1 serving/month (s/mo) (ref), 1 s/mo-<1 
serving/week (s/wk), 1-<2 s/wk, 2-<5 s/wk, and ≥5 s/wk. Total dairy was 
categorized into the following categories: <0.5 s/d (ref), 0.5-<1.5 s/d, 1.5-<3 s/d, 3-
<6 s/d. 
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To determine whether the effects of yogurt were modified by a healthy diet 
pattern, we removed dairy and yogurt in the DASH diet score and used two new 
DASH scores (one without dairy and one without yogurt) to make combined 
categories with dairy and yogurt intake. This enabled us to see the independent 
and combined effect of a high dairy/yogurt intake and an overall healthy diet as 
measured by the DASH score. Both derived DASH scores included: fruits, 
vegetables, nuts and legumes, and whole grains and low intakes of red and 
processed meats, sugar-sweetened beverages and sodium. The only difference is 
that the DASH score without yogurt has all the other low-fat dairy components 
in the score while the DASH score without dairy does not have dairy included in 
the score.  
 
Sensitivity analyses were used in order to further collapse yogurt intake into 
three categories: <1/month (low), 1/month-<5/week (moderate), ≥5/week (high). 
These three yogurt categories were then combined with tertiles of the DASH diet 
score (without yogurt) in order to see possible additive effects of a high yogurt 
intake and varying levels of the DASH diet score. Similar combined categories 
were created via sensitivity analyses for total dairy with tertiles of the DASH diet 
score (without dairy). 
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BMI can also act as a potential effect modifier or a causal intermediate in the 
association between total dairy or yogurt on HBP. Therefore, yogurt and dairy 
intakes were combined with three BMI categories (<25, 25-<30, ≥30 kg/m2) in 
order to see the differential effects of dairy and yogurt among the normal weight, 
overweight and obese.  
 
Each participant’s person years of follow-up began from the date of return of the 
baseline FFQ to the first occurrence of any of the following events: HBP 
diagnosis, death, loss to follow-up, or end of follow-up (30 June 2010 for NHS, 30 
June 2009 for NHS II, and 31 January 2010 for HPFS). Time-dependent Cox 
proportional hazard regression models were used to estimate the hazard ratio 
(HR) and the 95% confidence interval (CI) for all dairy exposure variables in 
relation to incident HBP risk. Multivariable models to estimate the independent 
effect of yogurt on HBP included: age, race, family history of HBP, physical 
activity, total energy, total protein intake, intakes of fruit and vegetable, cheese, 
and milk. Updated BMI was added in a separate model to determine potential 
mediating effects of body composition on HBP risk.  
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To test for linear trend, the median value was assigned to each exposure category 
and this value was modeled as a continuous variable. All of the analyses were 
conducted separately in each cohort. A fixed-effects model was used to combine 
all three cohorts by a meta-analysis approach, having ruled out substantial 
enough heterogeneity of effects that would have required the use of a random 
effects model. All statistical tests were two-sided using alpha levels of 0.05 for all 
statistical tests and the construction of confidence intervals. SAS version 9.4 (SAS 
Institute Inc, Cary, NC, USA) was used to perform all statistical analyses. 
 
3.5 RESULTS 
 
There were 81,908 total cases of incident HBP, including 41,584 cases during a 
maximum of 30 years of follow-up in the NHS, 26,134 cases during a maximum 
of 20 years in the NHS II, and 14,190 cases during a maximum of 24 years in the 
HPFS.  
 
 
Table 3.2 Age-standardized demographic characteristics of the NHS, NHS II, 
and HPFS study cohort at baseline by yogurt intake categories 
 
A. NHS (N=69,351) Yogurt Intake Categories (1 C s/d)1 
 <1/mo 
(N = 22,456) 
1/mo-<1/wk 
(N = 14,700) 
1-<2/wk 
(N = 20,134) 
2-<5/wk 
(N = 10,721) 
≥5/wk 
(N = 1,340) 
Age (years) 2 46.7 (7.2) 45.2 (7.2) 44.6 (7.0) 44.5 (6.9) 45.2 (7.1) 
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Activity (MET-hrs/wk) 11.5 (15.5) 12.8 (19.2) 14.4 (18.9) 16.3 (21.3) 19.0 (27.1) 
BMI (kg/m2) 23.9 (4.1) 24.0 (4.0) 23.9 (3.9) 23.7 (3.9) 23.5 (3.9) 
  <25 kg/m2, % 69.2 69.7 71.5 73.5 74.8 
  25-<30 kg/m2, % 22.3 21.7 21.0 19.7 19.6 
  ≥30kg/m2, % 8.5 8.5 7.6 6.8 5.7 
Race (white, %) 97.8 97.4 98.0 97.9 97.7 
Current smoker, % 37.9 27.3 23.9 22.5 22.7 
Family history HBP (%) 39.2 44.0 46.0 45.8 37.5 
BP-lowering medication, % 5.7 5.5 5.8 5.8 5.6 
Current post-menopausal 
hormone use, % 
5.9 6.0 5.7 6.2 5.6 
B. NHS II (N=84,368)                                            Yogurt Intake Categories (1 C s/d)1 
 
<1/mo  
(N = 23,429) 
1/mo-<1/wk  
(N = 18,196) 
1-<2/wk 
(N = 23,540) 
2-<5/wk 
(N = 16,598) 
≥5/wk 
(N = 2,605) 
Age (years)2 36.0 (4.7) 35.9 (4.7) 35.9 (4.7) 36.0 (4.7) 36.1 (4.6) 
Activity (MET-hrs/wk) 18.0 (24.8) 19.3 (25.4) 21.5 (26.9) 25.1 (31.3) 30.4 (36.1) 
BMI (kg/m2) 24.7 (5.4) 24.4 (5.0) 23.9 (4.5) 23.9 (4.6) 24.1 (5.0) 
  <25 kg/m2, % 64.2 66.9 70.9 71.3 69.3 
  25-<30 kg/m2, % 21.2 20.8 19.8 19.3 18.9 
  ≥30kg/m2, % 14.6 12.3 9.4 9.4 11.9 
Race (white, %) 95.3 96.2 97.3 97.8 97.5 
Current smoker, % 16.6 11.7 10.3 9.3 9.5 
Family history HBP, % 52.9 51.6 50.8 51.5 53.3 
BP-lowering medication, % 2.5 2.2 1.59 1.8 2.1 
Current post-menopausal 
hormone use, % 
2.6 2.24 2.3 2.2 3.0 
Oral contraceptive use, % 11.1 11.1 11.3 11.0 10.4 
C. HPFS (N=30,512)                                              Yogurt Intake Categories (1 C s/d)1 
 
<1/mo  
(N = 15,856) 
1/mo-<1/wk  
(N = 6,201) 
1-<2/wk  
(N = 4,901) 
2-<5/wk  
(N = 2,910) 
≥5/wk  
(N = 644) 
Age  (years) 2 52.6 (9.3) 50.7 (8.9) 50.0 (8.7) 51.2 (9.2) 51.5 (9.6) 
Activity  (MET-hrs/wk) 19.8 (27.1) 22.9 (33.0) 25.7 (33.7) 26.0 (29.2) 32.5 (41.6) 
BMI  (kg/m2)* 25.3 (3.0) 25.2 (3.0) 25.0 (3.0) 24.9 (3.1) 24.4 (2.8) 
  <25 kg/m2, % 50.0 50.7 54.7 55.5 63.5 
  25-<30 kg/m2, % 43.6 43.3 40.2 38.5 33.2 
  ≥30kg/m2, % 6.5 6.0 5.1 6.0 3.3 
Race (white, %) 95.3 95.4 96.2 95.2 95.6 
Current smoker, % 11.6 6.4 4.6 3.6 2.6 
Family history HBP, % 34.0 34.2 35.9 36.2 37.4 
BP-lowering medication, % 2.00 2.33 1.88 2.21 2.29 
1Values are means (SD) or percentages and are standardized to the age distribution of the study 
population. 
2Value is not age adjusted 
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The age-adjusted baseline demographic characteristics by 1 cup servings/d (1 C 
s/d) of yogurt in all three cohorts are shown in Table 3.2. Mean age at baseline for 
NHS, NHS II, and HPFS were: 44.7, 35.8, and 50.8 years respectively. Those in the 
highest yogurt intake category were more active, least likely to be overweight or 
obese and smokers. In both NHS II and HPFS, those with the highest yogurt 
intake (≥5/week) had the highest percentage of those having a family history of 
HBP while the opposite was observed in the NHS. We also observed that the 
percentage of participants on BP-lowering medication was similar in all yogurt 
categories among all cohorts 
 
 
Table 3.3. Age-standardized diet and food intakes of the NHS, NHS II, and 
HPFS study cohorts at baseline by yogurt intake categories 
 
 
A. NHS (N=69,351) Yogurt Intake Categories (1 C s/d)1 
 <1/mo 
(N = 22,456) 
1/mo-<1/wk 
(N = 14,700) 
1-<2/wk 
(N = 20,134) 
2-<5/wk 
(N = 10,721) 
≥5/wk 
(N = 1,340) 
      
Alcohol (g/d) 6.7 (11.5) 6.1 (10.0) 6.1 (9.5) 5.9 (9.0) 5.8 (9.3) 
DASH diet score 22.0 (4.5) 23.5 (4.5) 24.5 (4.4) 25.7 (4.4) 26.5 (4.4) 
FOODS      
Whole grains (g/d) 11.5 (12.1) 14.0 (13.1) 15.1 (13.1) 16.4 (13.8) 17.1 (13.9) 
Total fiber (g/d) 15.6 (3.9) 16.3 (4.0) 16.8 (4.2) 17.4 (4.4) 17.6 (4.4) 
Fruits & vegetables (s/d) 3.5 (1.9) 3.9 (2.0) 4.1 (2.0) 4.6 (2.2) 5.0 (2.4) 
SSB (12 oz. or 1 can s/d) 0.53 (0.93) 0.41 (0.75) 0.37 (0.71) 0.34 (0.72) 0.34 (0.77) 
Red & processed meats (s/d) 1.2 (0.99) 1.2 (0.96) 1.1 (0.94) 1.0 (0.91) 1.0 (0.95) 
B. NHS II (N=84,368) Yogurt Intake Categories (1 C s/d)1 
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<1/mo  
(N = 23,429) 
1/mo-<1/wk  
(N = 18,196) 
1-<2/wk 
(N = 23,540) 
2-<5/wk 
(N = 16,598) 
≥5/wk 
(N = 2,605) 
Alcohol (g/d) 2.8 (6.3) 3.1 (6.0) 3.3 (6.0) 3.4 (5.7) 3.3 (5.9) 
DASH score 21.9 (4.7) 23.8 (4.7) 25.0 (4.8) 26.5 (4.8) 27.8 (4.9) 
FOODS      
Whole grains (g/d) 17.1 (15.1) 20.4 (15.3) 21.7 (15.7) 23.3 (15.9) 23.6 (17.1) 
Total fiber (g/d) 17.0 (5.3) 18.1 (5.3) 18.7 (5.3) 19.5 (5.6) 20.1 (7.0) 
Fruits & Vegetables (s/d) 4.3 (2.59) 4.8 (2.6) 5.3 (2.8) 6.0 (3.1) 6.7 (3.6) 
SSB (12 oz. s/d) 0.63 (1.0) 0.47 (0.83) 0.41 (0.74) 0.35 (0.67) 0.31 (0.69) 
Red & Processed meats (s/d) 1.2 (0.73) 1.2 (0.68) 1.1 (0.66) 1.1 (0.67) 1.0 (0.69) 
C. HPFS (N=30,512)                   Yogurt Intake Categories (1 C s/d)1 
 
<1/mo  
(N = 15,856) 
1/mo-<1/wk  
(N = 6,201) 
1-<2/wk  
(N = 4,901) 
2-<5/wk  
(N = 2,910) 
≥5/wk  
(N = 644) 
Alcohol (g/d) 11.8 (15.8) 10.2 (13.7) 9.7 (13.0) 9.7 (13.2) 9.4 (12.5) 
DASH score  22.3 (5.0) 24.4 (5.0) 25.6 (4.9) 26.8 (4.9) 28.1 (4.9) 
FOODS      
Whole grains (g/d) 18.9 (18.4) 23.6 (19.3) 25.3 (20.0) 27.4 (21.2) 28.5 (22.5) 
Total fiber (g/d) 19.6 (6.7) 21.5 (6.7) 22.3 (7.2) 23.2 (7.1) 23.2 (7.8) 
Fruits & vegetables (s/d) 4.8 (2.5) 5.5 (2.7) 6.0 (2.9) 6.5 (3.0) 7.1 (3.5) 
SSB (12 oz. s/d) 0.43 (0.69) 0.35 (0.58) 0.30 (0.49) 0.29 (0.52) 0.27 (0.49) 
Red & processed meats (s/d) 1.28 (0.87) 1.07 (0.77) 1.01 (0.75) 0.92 (0.75) 0.88 (0.80) 
1Values are means (SD) or percentages and are standardized to the age distribution of the study 
population. SSB=sugar-sweetened beverages 
 
 
Table 3.3 illustrates that those in the highest yogurt intake (≥5/week) had the 
highest caloric intake as well as diet quality as measured by the DASH score 
among all three cohorts. This is consistent with higher intakes of foods that are 
associated with a healthy diet such a fruits and vegetables, beans and legumes, 
whole grains, and fiber. Conversely, those in the highest yogurt intake had the 
lowest intakes of foods associated with a lower overall diet quality such as sugar-
sweetened beverages (SSB) and red and processed meats.  
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Table 3.4 Age-standardized nutrient intakes of the NHS, NHS II, and HPFS 
study cohorts at baseline by yogurt intake categories 
 
A. NHS (N=69,351) Yogurt Intake Categories (1 C s/d)1 
 <1/mo 
(N = 22,456) 
1/mo-<1/wk 
(N = 14,700) 
1-<2/wk 
(N = 20,134) 
2-<5/wk 
(N = 10,721) 
≥5/wk 
(N = 1,340) 
Calories (kcals/d) 1539 (504) 1538 (490) 1566 (490) 1639 (500) 1739 (542) 
Total protein (g/d) 72.8 (14.7) 75.3 (14.7) 76.9 (14.8) 78.5 (15.2) 79.4 (15.7) 
Total carbohydrates (g/d) 152 (38.2) 154 (36.2) 156 (35.2) 163 (35.3) 172 (37.1) 
Total fat (g/d) 72.5 (14.0) 70.8 (13.5) 69.1 (13.4) 65.7 (13.4) 61.6 (14.4) 
MINERALS      
Sodium (mg/d) 1287 (290) 1306 (277) 1316 (275) 1331 (274) 1348 (297) 
Potassium (mg/d) 2600 (602) 2719 (596) 2805 (589) 2934 (592) 3066 (647) 
Calcium (mg/d) 628 (348) 680 (350) 729 (354) 830 (393) 997 (525) 
Magnesium(mg/d) 266 (88.8) 280 (89.8) 292 (92.5) 314 (98.4) 338 (109) 
B. NHS II (N=84,368) Yogurt Intake Categories (1C s/d)1 
 
<1/mo  
(N = 23,429) 
1/mo-<1/wk  
(N = 18,196) 
1-<2/wk 
(N=23,540) 
2-<5/wk 
(N=16,598) 
≥5/wk 
(N = 2,605) 
Calories (kcals/d) 1704 (547) 1752 (538) 1810 (534) 1893 (540) 1992 (571) 
Total protein (g/d) 84.6 (16.0) 86.1 (15.0) 86.8 (14.7) 87.9 (14.7) 89.3 (15.9) 
Total carbohydrates (g/d) 220 (36.1) 223 (32.8) 226 (32.1) 230 (31.7) 237 (33.8) 
Total fat (g/d) 65.8 (11.7) 63.8 (10.8) 62.4 (10.6) 60.0 (10.6) 57.1 (11.4) 
MINERALS      
Sodium (mg/d) 2149 (411) 2162 (363) 2159 (343) 2146 (337) 2119 (356) 
Potassium (mg/d) 2763 (546) 2894 (511) 2975 (503) 3098 (506) 3254 (574) 
Calcium (mg/d) 927 (436) 997 (429) 1045 (424) 1111 (421) 1225 (461) 
Magnesium (mg/d) 292 (73.3) 312 (72.8) 322 (71.8) 336 (72.3) 348 (75.0) 
C. HPFS (N=30,512)                     Yogurt Intake Categories (1 C s/d)1 
 
<1/mo  
(N = 15,856) 
1/mo-<1/wk  
(N = 6,201) 
1-<2/wk  
(N = 4,901) 
2-<5/wk  
(N = 2,910) 
≥5/wk  
(N = 644) 
      
Calories (kcals/d) 1969 (617) 1985 (615) 2056 (615) 2123 (627) 2296 (673) 
Total protein (g/d) 90.5 (16.4) 92.8 (16.0) 93.0 (15.6) 94.0 (16.0) 94.2 (16.7) 
Total carbohydrates (g/d) 229 (42.0) 238 (40.7) 244 (39.3) 251 (39.9) 261 (41.6) 
Total fat (g/d) 74.1 (13.7) 70.9 (13.5) 69.1 (13.1) 66.0 (13.3) 62.2 (14.2) 
MINERALS      
Sodium (mg/d) 3348 (1160) 3307 (1124) 3216 (1014) 3104 (997) 2876 (961) 
Potassium (mg/d) 3256 (669) 3431 (671) 3533 (666) 3635 (675) 3770 (729) 
Calcium (mg/d) 741 (379) 795 (383) 867 (390) 938 (399) 1156 (533) 
Magnesium (mg/d) 321 (108) 343 (112) 364 (119) 385 (123) 423 (139) 
1Values are means (SD) or percentages and are standardized to the age distribution of the study 
population. 
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Table 3.4 lists the baseline macro- and micronutrient intake by yogurt intake 
categories among all three cohorts. Those with the highest yogurt intake 
(≥5/week) had the highest total protein and carbohydrate intake as well as all 
four minerals: sodium, potassium, magnesium, and calcium. Conversely, high 
yogurt eaters had the lowest total fat intakes with health professionals (mean fat 
= 71.1 g/d) and NHS (mean fat = 68.4 g/d) participants having a slightly higher 
mean intake than the NHS II (mean total fat= 64.5 g/d). 
 
Table 3.5 Age-standardized dairy of the NHS, NHS II, and HPFS study cohorts 
at baseline by yogurt intake categories 
 
A. NHS (N=69,351) Yogurt Intake Categories (1 C s/d)1 
 <1/mo 
(N = 22,456) 
1/mo-<1/wk 
(N = 14,700) 
1-<2/wk 
(N = 20,134) 
2-<5/wk 
(N = 10,721) 
≥5/wk 
(N = 1,340) 
Total dairy (s/d) 1.2 (0.93) 1.3 (0.92) 1.4 (0.92) 1.8 (0.98) 2.1 (1.2) 
Low-fat dairy (s/d) 0.54 (0.77) 0.69 (0.79) 0.84 (0.82) 1.1 (0.89) 1.52 (1.2) 
High-fat dairy (s/d) 0.51 (0.63) 0.49 (0.58) 0.49 (0.54) 0.50 (0.55) 0.50 (0.60) 
Cheese (1 oz. s/d) 0.35 (0.43) 0.38 (0.42) 0.43 (0.44) 0.45 (0.44) 0.46 (0.52) 
Yogurt (1 C s/d) 0.01 (0.02) 0.05 (0.08) 0.11 (0.19) 0.27 (0.37) 0.61 (0.83) 
Total milk (8 oz. s/d) 0.80 (0.98) 0.87 (0.98) 0.90 (0.96) 0.96 (1.0) 1.1 (1.1) 
% dairy from yogurt 1.6 (8.5) 8.0 (16.5) 12.9 (20.3) 21.3 (24.6) 31.8 (29.1) 
B. NHS II (N=84,368) Yogurt Intake Categories (1 C s/d)1 
 
<1/mo  
(N = 23,429) 
1/mo-<1/wk  
(N = 18,196) 
1-<2/wk 
(N = 23,540) 
2-<5/wk 
(N=16,598) 
≥5/wk 
(N = 2,605) 
Total dairy (s/d) 1.5 (1.2) 1.7 (1.2) 1.8 (1.2) 2.1 (1.2) 2.5 (1.3) 
Low-fat dairy (s/d) 0.94 (1.0) 1.1 (1.0) 1.3 (1.1) 1.6 (1.1) 1.9 (1.2) 
High-fat dairy (s/d) 0.53 (0.58) 0.53 (0.56) 0.55 (0.53) 0.55 (0.54) 0.55 (0.59) 
Cheese (1 oz. s/d) 0.41 (0.42) 0.43 (0.43) 0.46 (0.42) 0.48 (0.44) 0.49 (0.49) 
Yogurt (1 C s/d) 0.01 (0.03) 0.06 (0.07) 0.14 (0.18) 0.29 (0.30) 0.63 (0.63) 
Total milk (8 oz. s/d) 0.96 (1.0) 1.1 (1.0) 1.1 (1.0) 1.2 (1.0) 1.2 (1.1) 
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% dairy from yogurt 1.2 (4.5) 5.4 (8.6) 9.1 (12.4) 15.5 (16.5) 25.9 (21.5) 
C. HPFS (N=30,512)                     Yogurt Intake Categories (1 C s/d)1 
 
<1/mo  
(N = 15,856) 
1/mo-<1/wk  
(N = 6,201) 
1-<2/wk  
(N = 4,901) 
2-<5/wk  
(N = 2,910) 
≥5/wk  
(N = 644) 
Total dairy (s/d) 1.3 (1.1) 1.4 (1.1) 1.6 (1.1) 1.8 (1.2) 2.4 (1.4) 
Low-fat dairy (s/d) 0.72 (0.98) 0.88 (0.97) 1.0 (1.0) 1.2 (1.1) 1.8 (1.5) 
High-fat dairy (s/d) 0.63 (0.75) 0.57 (0.61) 0.59 (0.63) 0.58 (0.64) 0.63 (0.72) 
Cheese (1 oz. s/d) 0.42 (0.47) 0.41 (0.44) 0.44 (0.44) 0.44 (0.44) 0.52 (0.58) 
Yogurt (1 C s/d) 0.01 (0.02) 0.06 (0.08) 0.16 (0.20) 0.30 (0.29) 0.78 (0.76) 
Total milk (8 oz. s/d) 0.85 (1.0) 0.89 (0.98) 0.94 (1.0) 0.97 (1.0) 1.1 (1.1) 
% dairy from yogurt 0.96 (4.63) 6.6 (10.5) 12.7 (16.2) 19.8 (19.9) 34.0 (23.2) 
1Values are means (SD) or percentages and are standardized to the age distribution of the study 
population. 
 
 
From Table 3.5, we observed that those in the highest yogurt intake had higher 
intakes of dairy protein as well as higher intakes of total, low-fat, and high-fat 
dairy. Most of the total dairy intake in all three cohorts were from low-fat dairy, 
with milk comprising most of the low-fat dairy intake.  
Table 3.6 The beneficial effects of higher yogurt intake on incident HBP 
 NHS 
    Multivariable +BMI 
Yogurt Intake P-yrs Cases 
I /100K 
p-yrs HR1 95% CI HR2 95% CI 
            
<1/mo 613915 18014 2934 1.00 - 1.00 - 
1/mo-<1/wk 291261 8998 3089 1.00 (0.98-1.03) 0.99 (0.97-1.02) 
1-<2/wk 271482 9397 3461 0.98 (0.95-1.01) 0.98 (0.96-1.01) 
2-<5/week 141841 4495 3169 0.92 (0.89-0.96) 0.95 (0.92-0.98) 
≥5/week 28333 680 2400 0.80 (0.74-0.87) 0.86 (0.80-0.93) 
P for linear trend3    <0.0001 <0.0001 
Per 1 s/d increase     0.81 (0.76-0.86) 0.87 (0.82-0.92) 
 NHS II 
    Multivariable +BMI 
Yogurt Intake P-yrs Cases 
I /100K 
p-yrs HR1 95% CI HR2 95% CI 
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<1/mo 491776 9422 1916 1.00 - 1.00 - 
1/mo-<1/wk 307914 5668 1841 0.95 (0.92-0.98) 0.96 (0.93-0.99) 
1-<2/wk 300582 5981 1990 0.90 (0.87-0.93) 0.94 (0.91-0.97) 
2-<5/week 228960 4330 1891 0.89 (0.85-0.92) 0.92 (0.89-0.96) 
≥5/week 47026 733 1559 0.83 (0.77-0.90) 0.89 (0.82-0.96) 
P for linear trend3    <0.0001 <0.0001 
Per 1 s/d increase     0.79 (0.74-0.85) 0.86 (0.81-0.92) 
 HPFS 
    Multivariable +BMI 
Yogurt Intake P-yrs Cases 
I /100K 
p-yrs HR1 95% CI HR2 95% CI 
            
<1/mo 265024 7844 2960 1.00 - 1.00 - 
1/mo-<1/wk 107086 3026 2826 0.97 (0.93-1.02) 0.97 (0.93-1.01) 
1-<2/wk 67656 1943 2872 0.93 (0.88-0.98) 0.93 (0.88-0.98) 
2-<5/week 40237 1119 2781 0.92 (0.87-0.98) 0.94 (0.88-1.00) 
≥5/week 10123 258 2549 0.94 (0.83-1.07) 1.01 (0.89-1.14) 
P for linear trend3    0.0172 0.1738 
Per 1 s/d increase     0.89 (0.81-0.98) 0.94 (0.85-1.03) 
 META-ANALYSIS 
    Multivariable +BMI 
Yogurt Intake P-yrs Cases 
I /100K 
p-yrs HR1 95% CI HR2 95% CI 
<1/mo 864199 35280 2605 1.00 - 1.00 - 
1/mo-<1/wk 679150 17692 2710 0.98 (0.96-1.00) 0.98 (0.96-1.00) 
1-<2/wk 438457 17321 2456 0.95 (0.93-0.96) 0.96 (0.94-0.98) 
2-<5/week 115596 9944 2190 0.91 (0.89-0.93) 0.94 (0.92-0.96) 
≥5/week 10123 1671 2549 0.84 (0.79-0.88) 0.89 (0.85-0.94) 
P for linear trend3 <0.0001 <0.0001 
P for heterogeneity4 0.3194 0.5835 
I2 13.4 0.0 
Per 1 s/d increase 0.81 (0.78-0.85) 0.87 (0.84-0.91) 
1Adjusted for age, race, physical activity, energy intake, HBP family history, and intakes of FV, 
total protein, milk, and cheese  
2Adjusted for age, race, physical activity, energy intake, HBP family history, and intakes of FV, 
total protein, milk, and cheese, BMI 
3Linear trend across yogurt intake categories was quantified with a Wald test for linear trend by 
assigning the median value to each category and modeling this variable as a continuous variable. 
4Test for between-study heterogeneity by using a fixed effects meta-analysis model 
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The beneficial effects of increased long-term yogurt intakes are shown in Table 
3.6. After adjusting for race, physical activity, energy intake, family history of 
HTN, and intakes of FV, milk, and cheese, a 20% (95% CI: 0.74-0.87), 17% (95% 
CI: 0.77-0.90), and a 6% (95% CI: 0.83-1.07) HBP risk reduction was observed for 
those who had a usual yogurt intake of 5 or more servings/wk compared to those 
who ate yogurt less than once a month in the NHS, NHS II, and HPFS cohorts 
respectively. 
 
Since BMI may be in the causal pathway between yogurt consumption and HBP 
risk, we included BMI in a separate multivariable model. This led to some 
attenuation of the beneficial effect of yogurt intake in the models for all three 
cohorts. Finally, we carried out a meta-analysis, pooling the results from the 
three cohorts. Here, we observed that those with a usual yogurt intake of 5 or 
more servings/week had an overall 16% decreased risk of long-term incident 
HBP (95% CI: 0.79-0.88) compared to those with a yogurt intake of less than once 
a month. A significant linear decreasing trend of HBP risk with increasing yogurt 
intake was also observed (p for trend <0.0001). We modeled yogurt as a 
continuous variable in order to conceptualize the effect for each one serving 
increase per day. In the multivariable model, we observed a 19% decreased risk 
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(95% CI: 0.78-0.85) of incident HBP for each one-serving increase in yogurt 
consumption. The p value for heterogeneity from the fixed effects meta-analysis 
for both the multivariable model and the BMI-added model were both non-
significant (p>0.05) and suggests that there is no significant heterogeneity among 
the three cohorts. This was further shown by quantification of the heterogeneity 
by the I2 statistic: 13.4% for the multivariable model and 0% when BMI was 
added.  
Figure 3.2 Higher yogurt intake combined with higher DASH diet score is 
linked with a lower risk of incident HBP
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We performed sensitivity analyses on the effects of yogurt intake collapsed into 
three categories (low, moderate, and high) from the original five categories in 
Table 3.6 in order to combine the yogurt intake categories into three groups with 
the DASH diet score and simplify the illustration of the combined effect of 
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yogurt intake and diet quality. Then collapsed yogurt categories are shown in the 
Appendix tables A.1-A.4. 
 
Figure 3.2 shows the combined effect of the DASH diet score and yogurt intake 
on HBP risk across all three cohorts. Compared to those with low yogurt intake 
and a low DASH score (the referent group), those who had a higher DASH score 
alone had a 19% (95%CI: 0.79-0.83) reduction in HBP risk. Higher yogurt intakes 
with a low DASH score led to very modest reductions in HBP risk. In contrast, 
consuming five or more servings of yogurt per week combined with a high 
DASH score (T3) was associated with a 31% reduced risk of HBP (95%CI: 0.65-
0.74). This finding suggests that the effects of yogurt were modified by the 
overall diet pattern, since the joint effect (31% lower risk) was greater than the 
sum of the independent effects of a high yogurt intake (6% reduced risk) and a 
high DASH dietary score (19% reduced risk in tertile 3). The addition of BMI to 
the multivariable model attenuated HBP risk reduction associated with the 
combined yogurt and DASH score to 20% (95%CI: 0.74-0.85). We observed a 
range of heterogeneity estimates in the yogurt and DASH groups when the three 
cohorts were pooled. The cohort-specific results are shown in the Appendix 
Tables A.5-A.7. 
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Figure 3.3 BMI has a greater effect on HBP risk than yogurt  
 
Figure 3.3 illustrates the differential effects of yogurt intake among three 
different BMI groups: lean (BMI < 25 kg/m2), overweight (BMI: 25-<30 kg/m2) and 
obese (BMI ≥ 30 kg/m2). In all three cohorts, the effects of BMI alone are 
substantially greater than the effects of yogurt alone on HBP risk. For example, 
those with the highest yogurt intake (≥5 s/week) who were obese had a non-
statistically significant 1% decreased risk of long-term incident HBP (95% CI: 
0.90-1.10) compared to the referent group of low yogurt (<1/week) and obese. 
However, those with low yogurt intake but were overweight saw a 36 % 
decreased risk (95% CI: 0.62-0.65) and those who were lean and also had a low 
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yogurt intake saw a 64% decreased risk of HBP (95% CI: 0.30-0.35) compared to 
the referent group of low yogurt (<1/week) and obese. Overall, the pooled results 
suggest that the combined effects of yogurt consumption and BMI are 
approximately additive. There was a wide range of heterogeneity observed as 
quantified by the p for heterogeneity and I2 values for each yogurt and BMI 
category. Cohort specific results are illustrated in the Appendix Tables A.8-A.10.  
 
 
Table 3.7 Higher milk intake is associated with a lower risk of HBP  
 META-ANALYSIS 
    Multivariable +BMI 
Milk Intake P-yrs Cases 
I /100K 
p-yrs HR1 95% CI HR2 95% CI 
<4/wk 1364819 35607 2609 1.00 - 1.00 - 
4/wk-<1/d 586561 16424 2800 0.98 (0.96-0.99) 0.98 (0.96-1.00) 
1-<2/d 780951 19469 2493 0.95 (0.93-0.96) 0.96 (0.94-0.98) 
2-<6/d 480886 10408 2164 0.87 (0.85-0.89) 0.92 (0.90-0.94) 
P for linear trend3 <0.0001 <0.0001 
P for heterogeneity4 <0.0001 0.0024 
I2 93.9 84.3 
Per 1 s/d increase       0.94 (0.93-0.95) 0.96 (0.95-0.97) 
1Adjusted for age, race, physical activity, energy intake, HBP family history, and intakes of FV, 
total protein, yogurt, and cheese 
2Adjusted for age, race, physical activity, energy intake, HBP family history, and intakes of FV, 
total protein, yogurt, and cheese, BMI 
3Linear trend across milk intake categories was quantified with a Wald test for linear trend by 
assigning the median value to each category and modeling this variable as a continuous variable.  
4Test for between-study heterogeneity by using a fixed effects model    
           
Table 3.7 shows that increased milk intake has slight, but linear beneficial effects 
on incident HBP across all three cohorts (p for trend<0.001). After adjustment for 
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age, race, physical activity, energy intake, family history of HBP, and intakes of 
total protein, FV, yogurt, and cheese, a high milk intake of 2-<6 s/d was 
associated with a 13% (95% CI: 0.85-0.89) decreased risk of incident HBP with a 
slight attenuation when BMI was added to the model. An increase of 1 s/d of 
milk was associated with a modest 6% risk reduction in HBP. There was a high 
level of heterogeneity among the three studies, with an I2 of 93.9% and 84.3% in 
the multivariable and the BMI-adjusted model, respectively. The cohort specific 
effects are shown in the Appendix Tables A.11-A.13. 
 
Table 3.8 Increased cheese consumption is inversely associated with risk of 
HBP in women 
 META-ANALYSIS 
    Multivariable +BMI 
Cheese Intake1 P-yrs Cases 
I /100K 
p-yrs HR1 95% CI HR2 95% CI 
<1/week 920076 22529 2449 1.00 - 1.00 -   
1-4/week 1746029 46656 2672 0.99 (0.97-1.01) 0.97 (0.95-0.99) 
5/week-<1/d 396193 9672 2441 0.96 (0.94-0.99) 0.94 (0.91-0.96) 
1-4/d 150918 3051 2022 0.92 (0.88-0.96) 0.90 (0.86-0.93) 
P for linear trend3 <0.0001 <0.0001 
P for heterogeneity4 0.0003 0.0552 
I2 88.1 66.3 
Per 1 s/d increase       0.93 (0.90-0.96) 0.90 (0.88-0.93) 
1Adjusted for age, race, physical activity, energy intake, HBP family history, and intakes of FV, 
total protein, yogurt, and milk 
2Adjusted for age, race, physical activity, energy intake, HBP family history, and intakes of FV, 
total protein, yogurt, and milk, BMI 
3Linear trend across cheese intake categories was quantified with a Wald test for linear trend by 
assigning the median value to each category and modeling this variable as a continuous variable  
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4Test for between-study heterogeneity by using a fixed effects model 
 
          
Table 3.8 shows that after adjusting for the covariates in the multivariable model, 
those in the highest cheese intake category (1-4 s/d) experienced a 10% (95%: 
0.84-0.97) and 14% (95%: 0.81-0.91) decreased risk in long-term incident HBP in 
the NHS and NHS II cohorts respectively. The addition of BMI did not change 
these effects in either cohort. Higher cheese intake had no effect on incident HBP 
in the HPFS. After pooling the three cohorts, significant heterogeneity was 
observed (I2=88.1% for the multivariable model and I2=66.3 for the BMI-adjusted 
model). Those with the highest cheese intake had a modest but statistically 
significant 8% (95%: 0.88-0.96) decreased HBP risk compared to the referent 
group consuming <1 s/week, and a significant inverse linear trend was observed 
(p for trend <0.0001). A 1 s/d increase was associated with a 7% HBP risk 
reduction. Cohort specific effects are shown in the Appendix Tables A.14-A.16. 
 
 
Table 3.9 Increased total dairy intake has beneficial effects on HBP risk 
 NHS 
    Multivariable +BMI 
Dairy Intake1 P-yrs Cases 
I /100K 
p-yrs HR1 95% CI HR2 95% CI 
<0.5 232919 6218 2670 1.00 - 1.00 - 
0.5-<1.5 638802 19994 3130 0.97 (0.94-0.99) 0.96 (0.93-0.99) 
1.5-<3 393942 12813 3253 0.91 (0.88-0.94) 0.91 (0.88-0.94) 
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3-<6 81170 2559 3153 0.87 (0.83-0.92) 0.91 (0.86-0.96) 
P for linear trend3    <0.0001 <0.0001 
Per 1 s/d increase 0.95 (0.94-0.97) 0.96 (0.95-0.98) 
 NHS II 
    Multivariable +BMI 
Dairy Intake P-yrs Cases 
I /100K 
p-yrs HR1 95% CI HR2 95% CI 
<0.5 115675 2369 2048 1.00 - 1.00 - 
0.5-<1.5 579951 11728 2022 0.95 (0.91-0.99) 0.95 (0.91-0.99) 
1.5-<3 493490 9380 1901 0.87 (0.83-0.92) 0.90 (0.86-0.95) 
3-<6 187142 2657 1420 0.74 (0.69-0.78) 0.80 (0.75-0.85) 
P for linear trend4    <0.0001 <0.0001 
Per 1 s/d increase 0.91 (0.89-0.92) 0.94 (0.92-0.95) 
 HPFS 
    Multivariable +BMI 
Dairy Intake P-yrs Cases 
I /100K 
p-yrs HR1 95% CI HR2 95% CI 
<0.5 66701 1948 2921 1.00 - 1.00 - 
0.5-<1.5 240324 7118 2962 0.98 (0.93-1.03) 0.96 (0.91-1.01) 
1.5-<3 133590 3763 2817 0.89 (0.84-0.95) 0.89 (0.84-0.94) 
3-<6 49511 1361 2749 0.91 (0.84-0.98) 0.90 (0.83-0.97) 
P for linear trend3    <0.0001 <0.0001 
Per 1 s/d increase 0.96 (0.94-0.98) 0.96 (0.94-0.98) 
 META-ANALYSIS 
    Multivariable +BMI 
Dairy Intake P-yrs Cases 
I /100K 
p-yrs HR1 95% CI HR2 95% CI 
<0.5 415295 10535 2537 1.00 - 1.00 - 
0.5-<1.5 1459077 38840 2662 0.96 (0.94-0.99) 0.96 (0.94-0.98) 
1.5-<3 1021022 25956 2542 0.90 (0.87-0.92) 0.90 (0.88-0.93) 
3-<6 317823 6577 2069 0.83 (0.80-0.86) 0.87 (0.84-0.90) 
P for linear trend3 <0.0001 <0.0001 
P for heterogeneity4 <0.0001 0.0203 
I2 92.3 75.3 
Per 1 s/d increase 0.94 (0.93-0.95) 0.95 (0.94-0.96) 
1Adjusted for age, race, physical activity, FV, total protein, energy intake, HBP family history 
2Adjusted for age, race, physical activity, FV, total protein, energy intake, HBP family history, 
BMI 
3Linear trend across total dairy intake categories was quantified with a Wald test for linear trend 
by assigning the median value to each category and modeling it as a continuous variable 
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4Test for between-study heterogeneity by using a fixed effects model  
 
             
The effects of total dairy intake among the NHS, NHS II, and HPFS cohorts are 
demonstrated in Table 3.9. Compared to the referent group of <0.5 s/d, those in 
the highest intake group (3-<6 s/d) had a statistically significant decreased HBP 
risk of 13% (95% CI: 0.83-0.92), 26% (95% CI: 0.69-0.78), and 9% (95% CI: 0.84-
0.98) in the NHS, NHS II, and HPFS cohorts. The addition of BMI to the 
multivariable model attenuated these effects slightly but they remained 
statistically significant. Using a fixed effects model in the meta-analysis, we 
observed significant heterogeneity (I2=92.3% for the multivariable model) and a 
17% (95% CI: 0.80-0.86) decreased risk of long-term HBP incident to those with a 
total dairy intake of 3-<6 s/d compared to the referent group of <0.5 s/d. The 
addition of BMI decreased the heterogeneity (I2=72.3%) and slightly attenuated 
the beneficial effect to 13% risk reduction (95% CI: 0.84-0.90). A 1 s/d increase 
was linked with a 6% reduced HBP risk. Only the 3-<6 s/d intake group had a 
high I2 (> 80%) whereas the other dairy intake categories had low heterogeneity 
indicators (I2 < 10%).  
 
Figure 3.4 Higher DASH diet scores modifies the beneficial effect of total 
dairy intake on incident risk of HBP  
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Figure 3.4 illustrates the combined effects of total dairy intake and an overall 
healthy dietary pattern as measured by the DASH diet score. When the three 
cohorts were pooled, compared to those with the lowest total dairy intake (<1.5 
s/d) and the lowest DASH score (referent group), those with the highest total 
dairy intake (3-<6 s/d) but the lowest DASH score experienced a 12% decreased 
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HBP risk (95% CI: 0.83-0.92). Those with the lowest dairy intake but the highest 
DASH score had a 19% decreased risk in incident HBP (95% CI: 0.79-0.83). The 
joint effects of both a high total dairy intake and a high DASH score had 
contributed to a 23% decreased risk of HBP compared to the referent group (95% 
CI: 0.77-0.83). The addition of BMI to the model attenuated the effect to a 21% 
decreased HBP risk (95% CI: 0.76-0.83). After performing a meta-analysis to 
combine all three cohorts, we saw a range of within-group heterogeneity 
estimates. Cohort-specific results are shown in the Appendix Tables A.17-A.19. 
 
3.6 DISCUSSION 
 
We observed a 20%, 17%, and a 6% decreased long-term incident HBP risk 
among those who consumed a 1C serving of yogurt ≥5 servings/week in the 
NHS, NHS II, and the HPFS cohorts, respectively. The beneficial effects of yogurt 
consumption were generally weaker in the HPFS cohort, which may be due to 
the low number of men in the highest yogurt intake category (≥5/week). The men 
in the HPFS were also older compared to the women in both NHS cohorts. 
Therefore, many men were excluded at baseline due to prevalent HBP, limiting 
statistical power in the HPFS. Since age is a strong determinant of HBP risk, it is 
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possible that the remaining non-hypertensive men at baseline reflect those who 
are relatively resistant to the development of HBP.  
 
Yogurt has been shown to have inverse associations with several cardiometabolic 
risk factors such as weight gain46, metabolic syndrome139, common carotid artery 
intima-media thickness28, as well as incidence of CVD70 and diabetes140. A cross-
sectional study using NHANES data reported a lower SBP and prevalence of 
metabolic syndrome among those with higher yogurt intake44. We observed that 
those who have the highest usual yogurt intake had an overall healthier diet as 
measured by the DASH diet score. Those in the highest yogurt intake category 
combined with a high DASH diet score, experienced the greatest reduction in 
HBP risk. A previous analysis of the Framingham Offspring and Third 
Generation cohorts found that higher yogurt consumers tended to have lower 
risks of developing cardiometabolic abnormalities such as HBP, lower circulating 
triglycerides, glucose, and insulin resistance even after adjusting for diet 
quality.52 The Framingham study only dichotomized yogurt intake as consumers 
and non-consumers whereas our study had enough statistical power to observe a 
linear trend of HBP risk reduction across categories of yogurt consumption for 
both NHS cohorts.  
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For total dairy, those with a high intake (3-<6 s/d) had an overall 17% risk 
reduction in incident HBP risk among the three cohorts. This observation is in 
alignment with other longitudinal studies across several populations such as the 
Framingham Offspring Study121, middle-aged Caucasian men and women in the 
ARIC cohort111, and a middle-aged (30-65 years) free-living French cohort,45 all of 
which demonstrated modest decreases in BP associated with an increased dairy 
consumption. Recent clinical trials have also shown reductions in BP among 
hypertensives individuals with a dairy intervention141,142. Stancliffe and 
colleagues designed a 12-week randomized, parallel clinical trial in 40 
overweight and obese middle-aged American adults, who were randomized to 
either a low-dairy (<0.5 dairy serving/d and <600 mg calcium/d) or adequate-
dairy (>3.5 dairy servings/d from milk and/or yogurt, ≥1200 mg calcium/d) 
weight-maintenance diet. The investigators found a dairy intervention to lower 
SBP and DBP throughout the study, as well as lower levels of inflammatory 
markers such as tumor necrosis factor-α and interleukin-6141. Although there is a 
moderate amount of evidence from both observational and intervention studies 
that supports a BP-lowering effect of dairy intake, several observational studies 
found no association with dairy intake on BP28,30. These null association may be 
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explained by having different types of dairy in varying proportions across 
studies. In our analyses, milk was the primary source of dairy (61.7% of dairy 
coming from milk) and yogurt constituting a small portion (8.4%). With the 
combination of all dairy subtypes serving as the exposure of interest in these 
analyses, the independent effects of each type of dairy may be underestimated. 
For example, our pooled analysis estimated the beneficial effect of a one- serving- 
per- day increase in milk intake was not as robust as the magnitude of effect 
associated with a one-serving-per-day increase in yogurt intake (6% risk 
reduction with milk vs. 19% risk reduction with yogurt).  
 
In accordance with the 2010 DGAC report, we observed that high intakes of total 
dairy alone and combined with an overall healthy diet (high DASH score) were 
linked with lower risk of HBP in all three cohorts110. Several observational studies 
and clinical trials26,112,143, including the original DASH trial22, observed a BP-
lowering effect of increased low-fat dairy intake combined with a DASH dietary 
pattern. This was similarly observed in our analyses where those with high dairy 
intake and a high DASH diet score had a 41% reduced risk of HBP. Our results 
suggest that all dairy products have modest beneficial effects on HBP incidence. 
Individuals who consume more yogurt (and more dairy) were also consuming 
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less red and processed meats, SSB, refined carbohydrates, and added sugars in 
our cohorts. Therefore, the observed beneficial effects of dairy could be 
interpreted as a replacement effect: high dairy consumers ate less refined 
carbohydrates and SSB, which may affect their risk of HBP. We controlled for 
many potential dietary confounders, including SSB, red meats, processed meats, 
and refined grains, but none of them seem to confound the associations, which is 
why they were not included in the final multivariable model. The observational 
nature of our analyses limits the interpretation of whether the observed 
beneficial effects of dairy on BP was because of the higher dairy intake or 
because of the lower SSB, refined grains, red and processed meats, or other foods 
that are associated with a poor overall diet.  
 
BP is affected by a variety of mechanisms. Potassium is concentrated in certain 
foods, including many fruits, vegetables, and dairy products and has been 
shown to lower BP in a dose-response manner among both normotensive and 
hypertensive individuals144. Hyperpolarization of endothelial cells relies on 
adequate potassium levels and results in a lower concentration of calcium in the 
cytosol, which results in smooth muscle cell relaxation and vasodilation, which 
lowers BP145. During fermentation, biologically active peptides are formed when 
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milk proteins are catalyzed by proteolytic lactic acid bacteria, such as 
Lactobacillus helveticus146. Two of these peptides that have been extensively 
studied for their BP-lowering effects are isoleucine-proline-proline (IPP) and 
valine-proline-proline (VPP). Both have been shown to acutely reduce BP in 
spontaneously hypertensive rats (SHR) after a single administration40. A long-
term study in SHR showed that fermented milk with added IPP and VPP and 
antihypertensive minerals magnesium, calcium, and potassium attenuated HBP 
development more effectively than just fermented alone, fermented milk with 
magnesium, calcium, potassium only, or fermented milk with IPP and VPP but 
without minerals. This suggests that the overall nutrient profile of fermented 
dairy may have the most potent antihypertensive effects147. A meta-analysis on 14 
randomized feeding trials with duration from 4-24 weeks in both normotensive 
and hypertensive adults aged 35-75 years estimated a 2 mm Hg decrease in SBP 
with a fermented milk intervention compared to the control placebo148. Although 
these human trials are of short duration, they suggest a potential, non-
pharmacologic route to lower BP. 
 
The main mechanism that has been studied extensively with regards to the BP-
lowering effects of milk-derived peptides is the inhibition of the angiotensin-
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converting enzyme (ACE). ACE is the rate-determining enzyme in the function 
of the renin-angiotensin system (RAS), a key regulator of BP, fluid, and 
electrolyte balance149. In the RAS, ACE converts angiotensin I to angiotensin II, 
which is a potent vasoconstrictor that induces aldosterone release, increases 
sodium levels, and leads to higher BP levels. IPP and VPP from casein-derived 
peptides have exhibited ACE inhibiting properties150 by reducing the rate of 
production of angiotensin II151 and promoting the vasodilator release151. IPP and 
VPP-specific ACE inhibition has been shown in-vitro94 and in SHR152 via 
increasing renin concentrations during long-term HTN treatment. 
Antihypertensive milk-derived peptides have also been observed to have no 
ACE-inhibitor activity in those without HTN153, which suggests that these 
peptides could affect BP via ACE-independent mechanisms. Figure 8 below 
shows a diagram adapted from Erdmann et al,154 depicting how these dairy-
derived biopeptides affect BP mechanistically. 
 
Figure 8. An overview of the renin-angiotensin system and the potential 
hypotensive effects of dairy biopeptides (adapted from Erdmann et al., 2008).  
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ACE not only converts angiotensin I to angiotensin II but it also hydrolyzes bradykinin, 
which has vasodilatory effects. 
 
Weight loss has been observed to have a major beneficial impact on HBP risk. 
Our results correlate with that hypothesis as those who were normal weight at 
baseline had significantly lower incident HBP risk regardless of yogurt intake 
compared with overweight and obese subjects. In fact, previous analyses in these 
same three cohorts showed an inverse association between yogurt consumption 
and weight gain46. The addition of BMI as a potential confounder in our 
multivariable model partially attenuated the beneficial effects of yogurt intake 
alone and combined with the DASH diet (as a marker of an overall healthy diet) 
on HBP risk, suggesting a potential intermediate effect of yogurt on body weight. 
A recent systematic review of 6 prospective cohort and 7 cross-sectional studies 
linked higher dairy, especially yogurt on lower long-term weight grain155. 
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Although some intervention trials showed a beneficial effect of dairy intake on 
weight loss33, via increased fat loss156 and prevention of lean body mass,157 others 
reported no evidence that a diet high in dairy enhanced weight loss during 
energy restriction in obese individuals158,159. It should be noted that incorporation 
of dairy into a weight loss regimen had no adverse effect on weight loss across 
the majority of the trials33,156,157. Although there are inconsistencies between 
epidemiologic and intervention studies on the effects of dairy on weight loss, 
evidence suggests a modest short-term weight loss of increased dairy intake. A 
recent meta-analysis of 29 randomized controlled trials of over 2400 participants 
(median age=41.4 years) found no long-term benefits of increased dairy 
consumption on body weight and body fat160. The meta-analysis did suggest that 
increased dairy intake may have facilitate weight loss in short-term or energy-
restricted RCTs160. The observational nature of our study limits our interpretation 
of the role of body composition as either a confounder or a potential causal 
intermediate in the association of dairy on HBP, although it seems likely that the 
true effect may lie somewhere between the effects seen with and without BMI in 
the model.  
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Aside from their BP-lowering mechanism, milk proteins have also been shown to 
stimulate insulin secretion161. Insulin secretion may directly affect food intake 
regulation by suppressing appetite, which consequently, indirectly affects body 
weight161. Dairy protein also contains a high amount of the three branched-chain 
amino acids (BCAAs) leucine, valine, and isoleucine, which have a unique role in 
protein synthesis and lean body mass preservation during weight loss162. Milk 
proteins have also been shown to increase plasma concentrations of satiety 
hormones such as cholecystokinin (CCK) and glucagon-like peptide-1 (GLP-1)163. 
Whey and casein have differing effects on appetite regulation: whey has been 
classified to suppress food intake in the short-term164 while casein, a bigger 
protein that whey, have a delayed transit time through the GI tract, delaying 
digestion time165. The literature supports the obesity-lowering effects of dairy but 
the exact mechanism of actions by different types of dairy (milk, cheese, or 
yogurt) remains unclear.  
 
Our study has several methodologic strengths including a large sample size that 
enabled us to study a wide range of yogurt intakes. The high follow-up rates and 
availability of repeated measures of dietary intake as well as demographic and 
lifestyle variables are also important strengths. To our knowledge, this is the first 
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longitudinal study with sufficient power to estimate the long-term dose-response 
relation of usual yogurt intake and incident HBP risk. A recent study by Wang et 
al using FOS data found that for every additional serving of yogurt per week, 
there was a 4% reduction in HBP risk121. The wider range of intakes and greater 
statistical power across our three cohorts enabled us to estimate with notable 
precision a 19% reduction in HBP risk for each additional one serving of yogurt 
consumed per day. 
 
Our study is also subject to several limitations. First, the NHS, NHS II, and HPFS 
cohorts consisted predominantly of Caucasian nurses and health professionals of 
European ancestry. While the homogeneity of racial, educational and 
socioeconomic status may help to reduce confounding, our results cannot be 
generalized to other populations. There is strong evidence of racial differences in 
HBP risk in the literature166 but our results are limited to middle-aged 
Caucasians. Although our study suffers from a lack of generalizability, the 
relatively high educational status of our participants is also a strength because of 
the increased likelihood that the data collected were reliable. Dietary assessment 
by FFQs have been shown to suffer from measurement and random error. 
However, the FFQs used in our cohorts were validated against multiple diet 
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records, and reasonable correlation coefficients were observed for dairy foods. 
Moreover, cumulative averages of all dietary variables were calculated in order 
to minimize the random measurement error cause by within-person variation 
and to accommodate diet and secular changes over time. Although we had 
ample statistical power (particularly in women) to observed associations of usual 
yogurt intake up to what is recommended by the USDA (1 s/d), the type and 
brand name of yogurt consumed was not available from the FFQs. Therefore, it is 
difficult to attribute the observed benefits to various components of yogurt such 
as protein or probiotic content, that have been observed in other lines of research 
to have antihypertensive effects. Although we adjusted for known and potential 
risk factors for HBP and even created a DASH diet score to consider possible 
confounding and effect modification by a healthy dietary pattern associated with 
yogurt intake, unmeasured and residual confounding is still a possibility.  
 
We carried out a meta-analysis of the three cohorts in this study to estimate the 
overall effect of total dairy and the individual dairy components on incident HBP 
risk. We observed a wide range of heterogeneity estimates for most of the meta-
analyses except for yogurt. This could be due to the inherent differences among 
the cohorts in terms of various BP-related risk factors such as sex and age (mean 
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baseline ages were 45, 36, and 51 years in the NHS, NHS II, and HPFS cohorts 
respectively). Additionally, men have a higher risk of HBP than women until age 
45 and women having a higher risk of HBP at age 65 years and above167, which 
highlights how age is a strong predictor of HBP risk especially between men and 
women. Yogurt is usually eaten as an individual food and may be susceptible to 
less bias and misreporting compared to milk and cheese, which has been shown 
to be susceptible to under-reporting and misclassification when eaten as part of 
mixed dishes168. These reasons may have contributed to the high heterogeneity 
estimates for milk (I2=93.9%) and cheese (I2=88.1%). All of these factors suggest 
that the effect estimates from the meta-analyses may not necessarily be from the 
same underlying population, pooling all three cohorts may suffer from excess 
heterogeneity, and less heterogeneity may be observed if the cohorts were 
presented separately. 
 
The only dairy exposure in which there was little to no heterogeneity when the 
results were pooled for all three cohorts was for yogurt intake. This is consistent 
with the finding that yogurt was associated with a healthy diet pattern. Yogurt 
eaters tend to eat higher intakes of FV, fiber, lean meats, and dairy52. As we 
observed, yogurt eaters also tend to consumer fewer SSB and eat less red and 
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processed meats. Having a similar underlying dietary pattern would reduce the 
heterogeneity among the yogurt eaters, which may explain the low heterogeneity 
in our meta-analysis of yogurt intake categories. 
 
3.7 CONCLUSION 
We found that higher usual intakes of total dairy and all subtypes (low-fat, high-
fat, milk, cheese, and yogurt) was associated with a lower risk of HBP across the 
NHS, NHS II, and HPFS cohorts, with yogurt having the greatest effect of all 
dairy foods. The effects of each dairy exposure seemed to be strongest in the 
younger women in NHS II. The consistent findings for yogurt suggest that this 
specific dairy food can be recommended with confidence for inclusion into a 
healthy dietary pattern, which may lessen the necessity of pharmacologic HBP 
treatment. However, more long-term studies are needed to further elucidate 
what bioactive component(s) in yogurt are driving its antihypertensive effects. 
Randomized clinical trials are also warranted to further examine the causal 
effects of yogurt consumption, its bioactive nutrient profile, as well as its 
probiotic content on body weight and HBP. Finally, these results suggest that 
regular intake of yogurt may have important public health benefits in terms of 
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reducing the burden of HBP and its consequences, as least within Caucasian 
adults.  
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CHAPTER 4: THE BENEFICIAL EFFECTS OF INCREASED YOGURT 
CONSUMPTION ON RISK OF CARDIOVASCULAR DISEASE AMONG 
MIDDLE-AGED ADULTS WITH HIGH BLOOD PRESSURE 
 
4.1 ABSTRACT 
Background: High blood pressure (HBP) is a major risk factor for cardiovascular 
disease (CVD), the leading cause of worldwide mortality. Short-term clinical 
trials have indicated beneficial effects of higher dairy intakes, especially yogurt, 
among those with HBP on CVD, but long-term observational data among 
hypertensives have not been published. 
Objective: To estimate the independent effects of total dairy and yogurt on risk of 
incident CVD among middle-aged female nurses in the Nurses’ Health Study 
(NHS) and male health professionals in the Health Professionals Follow-Up 
Study (HPFS) with HBP.  
Methods: Analyses include subjects from NHS and HPFS participants (age 30-55 
years, n=57,768 and age 40-75 years, n=18,593, respectively) with reported HBP 
and without prevalent CVD, diabetes, type 2 diabetes (T2DM), or cancer were 
used. Cumulative average dairy intakes were derived from validated, semi-
quantitative food frequency questionnaires. CVD, defined as myocardial 
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infarction (MI) and stroke, was ascertained via self-report and validated by 
medical record review. NHS and HPFS subjects were followed for development 
of CVD over a maximum period of 30 and 26 years, respectively. Time 
dependent Cox proportional hazard’s models were used to calculate hazard 
ratios (HR) and 95% confidence intervals (CI) while controlling for potential 
confounding by age, race, family history of HBP or MI, BP medication use, 
smoking, alcohol, energy intake, physical activity, BMI, and intakes of fiber and 
trans fats.  
Results: Yogurt intake was inversely associated with risk of CVD among these 
hypertensive participants (p for linear trend <0.01 for both NHS and HPFS). 
Participants who had a usual yogurt intake of ≥2 s/wk in the NHS and HPFS had 
17% (95% CI: 0.75-0.92) and 18% (95% CI: 0.68-0.97) CVD risk reductions, 
respectively. The effect of yogurt was further modified by a healthy diet pattern 
as measured by a DASH score. Regular yogurt consumers (≥2 s/wk in the NHS; 
≥1 s/wk in the HPFS) who also had higher DASH diet scores, had 19% (95% CI: 
0.71-0.92) and 31% (95% CI: 0.57-0.83) lower risks of CVD, respectively. Men 
consuming 2-<5 s/d of milk had a 16% (95% CI: 0.72-0.98) lower risk of CVD 
while in women, higher cheese intake (1-4 s/d) was linked with an 8% (95% CI: 
0.83-1.01) lower risk of CVD. Total dairy intake was not associated with risk of 
  107
CVD in women but HPFS men with intakes of 2-<6 s/d of total dairy had a 15% 
(95% CI: 0.75-1.05) CVD risk reduction. Those with a high dairy intake (1-<6 s/d) 
combined with a high DASH score (≥22) experienced a 12% (95% CI: 0.79-0.97) 
and a 16% (95% CI: 0.73-0.97) lower risk of CVD in NHS and HPFS subjects, 
respectively. 
Conclusion: In both women and men with prevalent HBP, higher usual yogurt 
intake was associated with a lower risk of developing CVD. Milk and total dairy 
were associated with a modest CVD risk reduction in hypertensive men while 
cheese consumption was associated with a small CVD risk reduction in 
hypertensive women. When combined with a higher DASH score, higher total 
dairy and yogurt intakes led to statistically significant reductions in risk of CVD 
in both men and women. These results suggest that the incorporation of yogurt 
into a healthy diet pattern in hypertensive adults may provide a non-
pharmacological approach to CVD prevention.   
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4.2 BACKGROUND 
 
While the prevalence of high blood pressure (HBP) in the American adult 
population of 18 years and older is currently estimated to be approximately 33%, 
this figure is projected to increase to around 41% by 20302. In 2010, HBP-related 
health care costs and productivity losses in the US were estimated at $76.6 
billion169.  HBP remains one of the major critical risk factors for cardiovascular 
disease (CVD), which is the leading cause of death amongst Americans,5 and 
makes up 17% of overall national health spending170. The total medical costs for 
CVD exceed $273 billion and are projected to triple to $818 billion by 2030 with 
an additional $276 billion in indirect costs.104 Recent health metrics estimate that 
40.6% of CVD mortality in the US population is attributable to HBP171. A meta-
analysis of 29 prospective cohort studies with over 1 million participants, found 
that HBP and pre-HBP were associated with stroke, myocardial infarction (MI), 
and CVD incidence.172 HBP not only affects about one billion people worldwide 
but there is compelling evidence that it is a major cause of cardiovascular 
morbidity and overall mortality2, making it a widespread and significant health 
concern. As the key risk factor for CVD, HBP is a particularly valuable target for 
the control of future total costs of CVD.104 
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According to the American Heart Association (AHA), 69%, 77%, and 74% of 
those who experienced their first heart attack, stroke, or congestive heart failure, 
respectively, had HBP4. Starting with a systolic blood pressure (SBP) level of 155 
mm Hg or a diastolic blood pressure (DBP) level of 75 mm Hg, Lewington et al 
observed that across 61 longitudinal studies, an increase of 20/10 mm Hg in 
SBP/DBP levels was associated with more than a twofold increase in death rates 
from stroke, ischemic heart disease and other vascular causes.173 Previous studies 
found that those who were pre-hypertensive (SBP of 130–139; DBP 85–89 mm 
Hg) had an elevated risk of CVD174, especially stroke, cardiovascular death, and 
MI175 compared with those with BP levels <120/80 mmHg.174,175  
HBP is linked to an increased risk of CVD through a variety of mechanisms. 
Arterial stiffness, which is associated with atherogenesis176, is also an 
independent predictor of cardiovascular morbidity and mortality in 
hypertensives177 and may lead to higher BP levels178. A higher SBP reflects the 
stiffening of arterial walls in the areas that are exposed to the increased BP178. 
Adequate blood flow to the myocardium depends on the myocardial perfusion 
pressure during diastole179. Higher overall BP levels can be attributed in part to 
arterial stiffening, which could lead to increased systemic circulatory load and 
subsequent risk of CVD death.180 Another pathway by which HBP can affect 
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CVD progression is through its deteriorating effect on vascular endothelial 
function181.  Vascular endothelial cells protect blood vessels and prevent 
arteriosclerosis by releasing various BP-regulating substances that have the 
ability to inhibit monocyte adhesion and/or thrombus formation182.  
While the Dietary Guidelines for Americans (DGA) called for limiting saturated fat 
(SFA) intake in order to lower CVD risk167, increased dairy consumption, 
particularly from yogurt, has paradoxically been shown to have beneficial effects 
on CVD-related comorbidities. These include: antihypertensive effects183,184, lower 
abdominal body fat184,185, lower risk of type 2 diabetes and insulin resistance185,186, 
and higher high density lipoprotein cholesterol (HDL-C) levels184. Yogurt intake 
in the US has increased significantly within the past decade123. According to 
NHANES, 4.7% of American adults consumed yogurt on a given day in 1999-
2000, which doubled to 9.3% by 2011-2012123.  With a recent significant rise in 
yogurt intake, it’s important to recognize yogurt’s unique health benefits. Earlier 
studies suggested that regular consumption of fermented dairy products such as 
yogurt was associated with a lower risk of atherosclerotic vascular disease 
(ASVD)187 and a reduction in arterial stiffness188 in hypertensive subjects. In one 
study, investigators recruited 89 hypertensive Danish adults (mean age=49 years) 
to participate in a 24-week randomized, placebo-controlled, double-blind parallel 
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trial where they observed a reduction in augmentation index (a surrogate marker 
of arterial stiffness) with Lactobacillus helveticus-fermented milk containing 
bioactive peptides (valine-proline-proline (VPP) and isoleucine-proline-proline 
(IPP)) compared to fermented milk without the bioactive peptides189. 
 A meta-analysis performed by Dong et al on 13 randomized controlled trials in 
both normotensive and hypertensive adults 35 years or older found that an 
intervention containing fermented milk was associated with an overall 2 mm Hg 
decrease in SBP.148 This decrease in SBP was found to be associated with 7% and 
10% lower CHD and stroke mortality risks, respectively173. The trials among 
hypertensives in the meta-analysis by Dong and colleagues had an overall 4 mm 
Hg decrease in SBP with fermented milk supplementaion148, suggesting a greater 
CVD benefit among hypertensives compared to non-hypertensives173. Hirota et al 
showed that fermented milk tripeptides VPP and IPP improved vascular 
endothelial function independent of their BP-lowering effects in a randomized 
trial of hypertensive males,190 suggesting that fermented dairy products have 
CVD-lowering capabilities that are independent of their BP-lowering effects. 
While yogurt is known to be a nutrient-rich food as well as a potential source of 
probiotic bacteria, there are few, large, longitudinal studies that substantiate the 
health effects of yogurt. Studies have often included yogurt within overall dairy 
  112
consumption and therefore, its potential unique effects may be underestimated 
due to the varying nutrient profiles of other dairy foods. To our knowledge, 
there is no published evidence on the effects of long-term yogurt intake on CVD 
risk among those with HBP. 
Several longitudinal studies have examined the effects of total dairy intake on 
incident CVD among those without HBP. Their findings have been conflicting: 
several reported that total milk was inversely associated with stroke69,191-193 and 
CHD191, while other studies suggest that milk intake is associated with an 
increased risk of both CHD194 and stroke195. Additionally, a few reported no 
appreciable association between total dairy intake and CHD196,197.  The use of 
differing categories of dairy intake in observational studies as well as differences 
in the population groups across studies make the results difficult to compare. 
Most studies used quintiles or quartiles of intake to estimate the distribution of 
milk consumption, thus making it difficult to compare the dose-response effects 
across studies. Also, the likely misclassification of reported dairy intakes 
inherent in dietary assessment is another potential source of inconsistency in 
findings due to measurement error. Finally, there is the potential for biased 
reports of dairy exposure given the long-term public health messaging associated 
with dairy products and heart disease in the US198.   
  113
The Dietary Approaches to Stop Hypertension (DASH) Trial was a landmark 
trial that showed that a diet rich in fruits and vegetables (FV), whole grains, and 
low-fat dairy products (particularly low-fat milk and yogurt) had a strong BP-
lowering effect22. It should be noted that along with 2-3 servings of low-fat dairy, 
the DASH diet had higher servings of full-fat dairy (0.7 s/d) compared to the 
control and FV only groups (0.4 and 0.3 s/d respectively).22 This suggests that 
moderate consumption of full-fat dairy, in conjunction with a DASH diet that 
already contains 2-3 s/d of low-fat dairy, may have beneficial effects on BP. The 
original DASH intervention trial lowered SBP by 11 mm Hg, on average, 
compared to the typical American diet   among hypertensive participants22. The 
DASH diet has been incorporated into the recommended lifestyle changes for 
those with HBP by the Eighth Joint National Committee on Prevention, 
Detection, Evaluation, and Treatment of High Blood Pressure (JNC)199.  
In observational research, a prospective cohort study of 5,532 hypertensive 
adults in the Third National Health and Nutrition Examination Survey 
(NHANES III) were followed up for an average of 8.2 years for incidence of all-
cause mortality, along with mortality associated with overall CVD, stroke, and 
ischemic heart disease200. The investigators found that individuals who 
consumed an eating pattern that was similar to the DASH diet experienced 31% 
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and 89% lower risk of all-cause and stroke-related mortality, respectively200. 
Taken together, the evidence supports an association between a DASH diet, 
which includes low-fat dairy and a modest amount of full-fat dairy, and lower 
CVD risk among those with or without HBP. 
The literature supports the strong correlation between HBP and CVD but there 
are limited long-term data on the specific effects of dairy subtypes such as 
cheese, milk, and especially yogurt among non-hypertensives and no studies 
among hypertensives. Therefore, using two large prospective cohorts, our 
objective is to estimate the effects of total dairy, milk, cheese, and yogurt intakes 
on risk of CVD among those with HBP and evaluate if the dairy-specific effects 
are modified by an overall healthy diet. 
 
4.3 METHODS 
4.3.1 Study Population 
The participants included in these analyses were subjects from the Nurses’ 
Health Study (NHS, N=121,741, aged 30-55 at the time of cohort inception) and 
the Health Professionals Follow-Up Study (HPFS, N =51,529, aged 40-75 at cohort 
inception) who had reported prevalent HBP. Participants in both cohorts were 
mailed questionnaires every two years inquiring about any physician-diagnosed 
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conditions such as stroke, MI, and HBP as well as other lifestyle habits. 
Participants also answered semi-quantitative food frequency questionnaires 
(FFQs) every four years, reporting their usual daily intake of more than 130 foods 
and beverages124.  
 
The date of the first-reported HBP served as the baseline for these analyses. 
Hence, participants entered the study at different time points depending on 
when they first reported HBP. The enrollment exam was 1980 for NHS and 1986 
for the HPFS subjects in these analyses. Since our goals was to study CVD risk 
among those with prevalent HBP, subjects who did not report a diagnosis of 
HBP at enrollment or during follow-up were excluded from these analysis. Other 
exclusions included: those who were missing dairy or yogurt intake, those who 
died or had prevalent cancer, diabetes, or cardiovascular disease (including 
coronary artery bypass grafting (CABG), angina, myocardial infarction (MI), or 
stroke) at or before the time of first report of HBP, and those with missing or 
implausible daily caloric intake (<500 or ≥3500 kcals/d for NHS and <800 or ≥4200 
kcals/d in the HPFS). Figure 4.1 below illustrates the sample selection for the 
NHS and HPFS cohorts. The resulting study population consisted of 57,768 
women with HBP from the NHS and 18,593 men with HBP from the HPFS. The 
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Institutional Review Board of Boston University School of Medicine approved 
the study. By virtue of voluntarily returning their questionnaires, participants 
provided implied consent. 
 
Figure 4.1 Study Diagram: Sample Selection for NHS and HPFS Cohorts for 
Analyses of Subsequent CVD Risk among Hypertensives 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
121,741 Initial NHS Cohort 
CVD at or before 1980 
enrollment (n=518) 
Death at or before 1980 
enrollment (n=765) 
 
Total dairy ≥6 s/d (n=3) 
57,768 nurses in final analysis 
Missing dairy intake (n=11) 
CVD at or before first 
reported HBP (n=1,361) 
 
First reported HBP at 
final exam (n=2,906) 
Never reported HBP 
(n=44,782) 
 
Cancer while HBP (n=5,415) 
T2DM while HBP (n=3,673) 
No reported FFQ while 
HBP (n=4,371) 
 
Missing yogurt intake (n=128) 
Duplicated records (n=40) 
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4.3.2 Assessment of Dairy and Yogurt Intake 
In 1980, a 61-item FFQ was mailed to NHS participants inquiring about their 
habitual dietary intake in the preceding year. An expanded, 131-item 
questionnaire was then sent in 1984, 1986, and every four years thereafter until 
2006. Similar expanded FFQs were mailed every four years beginning in 1986 for 
HPFS124 through 2006. Participants answered how often, on average, they 
51,529 Initial HPFS Cohort 
CVD at or before 1986 
enrollment (n=4,198) 
Death at or before 1986 
enrollment (n=12) 
 
18,593 men in final analysis 
CVD at or before first 
reported HBP (n=1,052) 
 
First reported HBP at final 
exam (n=905) 
Never reported HBP (n=20,137) 
Cancer while HBP (n=2,467) 
T2DM while HBP (n=1,358) 
No reported FFQ while 
HBP (n=1,166) 
Duplicated records (n=1,596) 
Total dairy ≥ 6 s/d (n=9) 
Missing yogurt (n=36) 
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consumed each listed food item from the questionnaire using nine possible 
response categories. These ranged from: “never or less than once a month” to “6 
or more a day”.  
 
The frequency of usual consumption was multiplied by the nutrient composition 
from the USDA food composition database in order to calculate nutrient intake 
from each food item201.  The following food items were included as part of the 
dairy variable in our analyses: skim milk, low-fat and reduced-fat milk, whole 
milk, yogurt, ice cream, sherbet, frozen yogurt, cottage/ricotta cheese, and other 
cheese. MyPyramid servings as defined by the USDA were derived for each of 
these food items and summed to estimate total dairy servings per day85. For 
example, ice cream, sherbet, and frozen yogurt FFQ servings (of ½ cup) were 
divided by 3 to derive a standard USDA serving of dairy. Cream cheese and 
cream were excluded from the dairy variable creation as they did not meet the 
MyPyramid definition of dairy: foods that are made from milk and retain their 
calcium content85.  
 
The reproducibility and validity of the 131-item FFQ were evaluated in both the 
NHS124,126 and HPFS128 cohorts by comparing reported intake with multiple one-
  119
week diet records. For example, the deattenuated correlation coefficients 
between FFQs and a seven-day dietary record in 173 women from NHS were 
0.97 for yogurt, 0.81 for skim milk, 0.62 for whole milk, 0.57 for cheese126. In the 
HPFS, a similar validation study was conducted in which 127 participants 
answered the 131-item FFQ and completed two, one-week diet records. Specific 
deattenuated Pearson correlation coefficients were 0.88 for skim milk, 0.86 for 
yogurt, and 0.56 for cheese.128  
 
4.3.3 Assessment of High Blood Pressure 
A participant was considered to have prevalent HBP if she or he reported this 
diagnosis on the enrollment questionnaire in 1980 (NHS) or 1986 (HPFS). Those 
without HBP at the first exam were asked again on each biennial questionnaire to 
report new diagnoses of HBP. Once a participant reported HBP, they were 
considered to have prevalent HBP throughout the rest of the study. 
 
The validity of self-reported diagnoses of HBP was examined in both the NHS 
and HPFS cohorts129,202. In NHS, 77% of 51 cases of self-reported HBP in the 
validation study had a SBP greater than 160 mm Hg or DBP above 95 mm Hg via 
standard measured BP measurement129. In the HPFS, medical records from all of 
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the randomly selected sample of 100 participants reporting a diagnosis of HBP 
on the 1988 questionnaire confirmed that all of them had HBP or were receiving 
antihypertensive treatment131. In addition, self-reported HBP by the validation 
study participants was shown to be highly predictive of subsequent 
cardiovascular events202. 
 
4.3.4 CVD Outcome Ascertainment 
Assessment of CVD in these cohorts was previously described203. In brief, CVD 
outcomes in these analyses include CHD (comprised of nonfatal MI and fatal 
MI), and stroke (nonfatal and fatal cases). Participants were asked to report if 
they had been diagnosed by a physician with any chronic illnesses, including MI 
and stroke, within the past two years (since the last exam). Permission was then 
requested to access medical records to confirm reported new diagnoses of MI or 
stroke. The World Health Organization’s criteria (presence of typical symptoms 
along with either diagnostic/electrocardiographic findings or elevated cardiac 
enzyme concentrations) was used to confirm nonfatal MI204. Study physicians 
reviewed computed tomography or magnetic resonance imaging to confirm 
nonfatal stroke cases. In accordance with the National Survey of Stroke, a stroke 
diagnosis was made if medical records showed a neurological deficit with 
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sudden or rapid onset that persisted more than 24 hours or until death205. Fatal 
MI and stroke were validated via a physician review of death or medical records. 
CVD events in which there were no medical records available to check self-
reported diagnosis were deemed probable and were included in these analyses. 
Previous CVD analyses by Sun et al. in NHS and HPFS, excluded probable CVD 
cases and the exclusion showed no effect on CVD risk.203 Thus, to increase 
statistical power, probable CVD cases were retained in these analyses.  
4.3.5 Assessment of Covariates 
A wide range of potential confounding variables were explored including socio-
demographic factors, family history, and other diet and lifestyle factors. While 
most of the participants were Caucasian (97.0% and 94.5% for NHS and HPFS 
respectively), analyses were adjusted for self-reported race. Family history of 
HBP was assessed in 1992 for the NHS and 1990 and 1992 for HPFS. Family 
history of MI was asked on the 1976 and 1996 questionnaires for NHS and the 
1986 and 1996 questionnaires for HPFS. The FFQs were used to ascertain 
participants’ intakes of foods and nutrients such as fruits and vegetables, whole 
grains, dietary fat, and total energy intake. On biennial questionnaires, NHS and 
HPFS participants were asked to report updated information on smoking status, 
physical activity (estimated as metabolic equivalent tasks [METs] per week) and 
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other lifestyle factors. Body mass index (BMI) was calculated as the self-reported 
weight (in kg) divided by the height squared (in meters). Self-reported weight 
was validated in 123 men in the HPFS and 140 women in the NHS with 
standardized weight measurements during at-home visits by study technicians206 
and physical activity was validated against 7-day activity records134. The 
correlation coefficient between self-reported and measured estimates was 0.97 for 
weight206 and 0.79 for physical activity134. 
 
Since yogurt intake is likely to be associated with a healthy diet pattern52, we 
calculated a DASH eating pattern score for each subject and combined this with 
yogurt intake categories as a potential effect modifier of the relationship between 
yogurt (and other dairy-related exposure variables) and CVD outcomes. Creation 
of the DASH diet score has been previously described107. In brief, the following 
eight foods are reflected in the DASH diet score: high intakes of low-fat dairy 
products, fruits, vegetables, nuts and legumes, whole grains, and low intakes of 
red and processed meats, sugar-sweetened beverages (SSB) and sodium135. A 
DASH diet score was calculated from each FFQ by classifying participants into 
quintiles of intake for each of the 8 aforementioned DASH food components. For 
whole grains, low-fat dairy, fruits, vegetables, and nuts and legumes, those in the 
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highest quintile received a score of 5 and those in the lowest quintile of intake 
received a score of 1. For sodium, SSB, and red and processed meats, those in the 
lowest quintile of intake received a score of 5 and those in the highest quintile of 
intake received a score of 1. The DASH score was calculated by summing the 
quintile rankings of the 8 components, yielding a score that ranged from 8-40, 
with 40 being the score that most closely resembled a DASH diet.  
 
4.4 STATISTICAL ANALYSIS 
Cumulative average intake levels of total dairy, yogurt, and other dietary 
variables were calculated starting at the time of the first-reported HBP 
occurrence to the time of first occurrence of one of the following censoring 
events: date of CVD diagnosis, date of death, loss to follow-up, or end of follow-
up (30 June 2010 for NHS and 31 January 2010 for HPFS). The calculation of 
cumulative averages has been previous explained138 but in brief, the nutrient 
intakes at each dietary questionnaire year when a subject reported HBP had 
equal weight in the calculation of cumulative average of dietary intakes. Figure 
4.2 below illustrates how participants were followed up for these analyses and 
how their cumulative averages were calculated. In the first example, a nurse first 
reported HBP on the 1984 questionnaire. Thus, the calculation of her cumulative 
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average of dietary intake began with her reported intake on the 1984 
questionnaire. She did not report any of the final end points of the study (CVD, 
death, or lost to follow-up) thus, subsequent reported dietary intakes were also 
used, given equal weight, in calculating her cumulative average intake. In the 
second example, a health professional first reported HBP in 1994, which marks 
the commencement of his follow-up time and the first reported dietary intake 
used for calculating his cumulative average intake. He reports an MI on the 2002 
questionnaire, which is when his follow-up time is stopped and his reported 
dietary intakes from the previous questionnaire (1998) are carried forward to 
2002. 
Nutrient and food intakes were not updated when participants first reported 
angina, coronary artery bypass grafting (CABG), or high cholesterol since these 
diagnoses may influence subsequent dietary behaviors138,207. For these 
participants, cumulative averages of dietary intake were carried forward before 
the occurrence of the aforementioned disease diagnoses (see Figure 4.2 for 
illustration). We conducted a further secondary analysis by allowing the update 
of dietary information after participants reported angina, CABG, or high 
cholesterol (No Diet Update). This was done to see if there was potential bias or 
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misreporting of dietary intakes once subjects developed CABG, angina, or high 
cholesterol.  
Figure 4.2 Illustration of Two Hypothetical Follow-Up and Cumulative 
Average Calculation Scenarios for the CVD Analyses 
#1: Nurse first reports HBP at 1984 questionnaire and does not develop CVD, nor dies throughout the rest 
of the study 
 
1980     ‘82      ‘84    ‘86       ‘88      ‘90     ‘92     ‘94     ‘96    ‘98   2000   ‘02    ‘04    ‘06   ‘08   ‘10 
 
 
 
 
 
 
#1: Male health professional first reports HBP at 1994 questionnaire and suffers an MI and reports it in the 
2002 questionnaire 
 
      HPFS   1986     ‘88    ‘90     ‘92     ‘94    ‘96    ‘98    2000    ‘02     ‘04     ‘06     ‘08    ‘10 
  
 
 
 
 
 
After evaluating the direct effects of yogurt and other dairy products on CVD 
risk among hypertensives, potential effect modification by the DASH diet score 
Cumulative avg. of diet at 2006 = mean(diet84+ diet86+ diet90+ diet94+ diet98+ diet02+ diet06) 
Cumulative avg. of diet at 2002 = mean(diet94+ diet98+ diet98) 
*Note that diet98 is carried forward to diet02 as the participant reported an MI in 2002, 
thus his 2002 reported dietary intakes are substituted by his 1998 dietary intakes 
Diet              Diet    Diet               Diet             Diet           Diet           Diet           Diet             
  
Diet             Diet            Diet           Diet             Diet              Diet       
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was examined using stratified multivariate analysis. To do this, dichotomous 
categories (low vs. high) for each dairy exposure variable were determined using 
sensitivity analyses and then combined with dichotomous (low vs. high) 
categories of the DASH diet scores. Since yogurt and dairy foods are components 
of the DASH score, the score used in these analyses was modified to exclude 
yogurt and other dairy products for the respective analyses. Thus, we combined 
each dairy-related exposure with the DASH score excluding that dairy variable 
from its calculation. In this way, four exposure categories were created. For 
example, the yogurt analyses yielded these four independent categories: (1) low 
yogurt + low DASH score (ref); (2) low yogurt + high DASH score; (3) high 
yogurt + low DASH score; (4) high yogurt + high DASH score. The cutpoints for 
NHS were as follows: yogurt (<2 servings/week vs. ≥2 servings/week) and DASH 
score without yogurt (<25 vs. ≥25). These cutpoints were selected by considering 
the sensitivity analysis results for both yogurt and the DASH score, while 
optimizing analytical power. 
 
Time-dependent Cox proportional hazards regression models were used to 
calculate the hazard ratios (HR) and 95% confidence intervals (CI) for subsequent 
total CVD, CHD, and stroke risks. The following potential confounders were 
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analyzed individually and together: age, race, family history of HBP, family 
history of MI, anti-hypertensive medication use, hypercholesterolemia, physical 
activity, smoking status, alcohol intake, post-menopausal hormone use (NHS), 
aspirin and multivitamin use, BMI (baseline and updated every two years), 
family history of diabetes, and cumulative updates of the following dietary 
components: energy intake, carbohydrates, total fat and fat subtypes (saturated, 
monounsaturated, polyunsaturated, omega-3, trans), protein (total, animal, and 
plant), whole grains, fiber (total, cereal), nuts, FV, sugar-sweetened beverages, 
potatoes, beans, red meat, processed meat, red and processed meats, sodium, 
potassium, calcium, and magnesium. Only covariates that changed the HRs by 
>10% were retained in the final models. These included: age, race, physical 
activity, energy intake, family history of hypertension and MI, anti-hypertensive 
medication use, and intakes of total fiber and trans fats. We also adjusted for the 
other dairy subtypes. In the yogurt analyses, we adjusted for milk and cheese, 
while in the milk analyses, we adjusted for yogurt and cheese. Next, we included 
the dairy variables on a continuous scale in the multivariable Cox regression 
analyses to estimate the risk of CVD associated with each additional serving per 
day. All analyses were performed with SAS software (version 9.4; SAS Institute 
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Inc, Cary, NC). All P values are two-sided and a P value < 0.05 is considered 
statistically significant. 
4.5 RESULTS 
With over 30 years of follow-up in the NHS and 26 years in the HPFS, there were 
5,421 total CVD cases in both cohorts, with 3,631 and 1,790 incident CVD cases in 
the NHS and HPFS, respectively. Of the 3,631 cases of CVD in NHS, there were 
1,946 CHD events and 1,685 strokes. In HPFS, there were 1,267 CHD events and 
523 incident strokes. 
Table 4.1 Age-standardized characteristics of the NHS and HPFS study 
subjects with prevalent HBP by yogurt intake categories 
 
A. NHS (N=57,768) Yogurt Intake Categories (1 C s/d)1 
 <1/mo 
(N = 22,126) 
1/mo-<1/wk 
(N = 10,920) 
1-<2/wk 
(N = 12,262) 
≥2/wk 
(N = 12,460) 
Age (years)2 48.4 (6.9) 47.2 (7.0) 46.5 (7.0) 45.3 (7.0) 
Activity (MET-hrs/wk) 13.0 (17.8) 14.5 (19.0) 15.9 (21.8) 18.3 (22.3) 
BMI (kg/m2) 26.8 (5.3) 27.1 (5.4) 27.0 (5.1) 27.0 (5.3) 
Current smoker, % 22.8 14.9 12.3 11.0 
Anti-hypertensive medication 
use, % 
45.3 47.3 48.7 50.4 
Family history HBP, % 48.0 52.8 55.2 53.1 
Family history MI, % 21.2 20.7 20.1 20.4 
T2DM, % 15.5 16.0 14.8 12.0 
Cancer, % 16.3 16.3 16.4 13.8 
Postmenopausal hormone use, % 21.2 24.6 26.2 27.6 
B. HPFS (N=18,593) Yogurt Intake Categories (1 C s/d)1 
 
<1/mo 
(N = 9,992) 
1/mo-<1/wk 
(N = 3,452) 
1-<2/wk 
(N = 2,877) 
≥2/wk 
(N = 2,272) 
Age (years)* 54.6 (9.3) 52.8 (9.2) 52.4 (9.0) 52.4 (9.3) 
Activity (MET-hrs/wk) 25.9 (35.5) 28.2 (33.3) 31.1 (34.8) 34.5 (42.2) 
BMI (kg/m2) 24.6 (7.8) 24.7 (7.9) 24.7 (7.7) 24.2 (8.0) 
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Current smoker, % 8.4 3.9 3.5 2.7 
Anti-hypertensive medication 
use, % 
55.0 52.4 51.6 49.5 
Family history HBP, % 47.8 48.8 53.3 49.1 
Family history MI, % 33.8 32.8 33.0 35.8 
T2DM, % 12.1 12.0 12.7 9.9 
Cancer, % 19.1 19.0 19.2 18.7 
1Values are means (SD) or percentages and are standardized to the age distribution of the study 
population; C=cup; s/d=serving/day; mo=month; wk=week. 
2Value is not age adjusted 
 
Table 4.1 illustrates the baseline characteristics of the NHS and HPFS participants 
at the time of their first report of HBP. Those with the highest yogurt intakes (≥2 
s/wk) tended to be non-smokers, more physically active, and had lower cancer 
and diabetes prevalences.  
Table 4.2 Age-standardized diet and food intakes of the NHS and HPFS 
subjects at baseline by yogurt intake categories 
A. NHS (N=57,768) Yogurt Intake Categories (1 C s/d)1 
 <1/mo 
(N = 22,126) 
1/mo-<1/wk 
(N = 10,920) 
1-<2/wk 
(N = 12,262) 
≥2/wk 
(N = 12,460) 
Alcohol (g/d) 6.8 (12.3) 6.2 (11.2) 6.0 (10.4) 5.8 (9.6) 
DASH diet score 22.4 (4.6) 23.7 (4.5) 24.5 (4.4) 25.7 (4.4) 
Total fiber (g/d) 17.3 (5.1) 18.3 (5.3) 18.7 (5.3) 19.4 (5.4) 
Fruits & vegetables (s/d) 4.3 (2.0) 4.7 (2.0) 5.1 (2.0) 5.6 (2.2) 
Red & processed meats (s/d) 1.2 (0.94) 1.1 (0.86) 1.1 (0.84) 0.93 (0.76) 
B. HPFS (N=18,593) Yogurt Intake Categories (1 C s/d)1 
 <1/mo 
(N = 9,992) 
1/mo-<1/wk 
(N = 3,452) 
1-<2/wk 
(N = 2,877) 
≥2/wk 
(N = 2,272) 
Alcohol (g/d) 13.9 (17.7) 11.6 (15.0) 11.2 (13.9) 10.9 (14.0) 
DASH diet score 22.6 (4.9) 24.4 (4.8) 25.2 (4.7) 26.7 (4.6) 
Total fiber (g/d) 20.8 (7.4) 22.5 (6.8) 23.3 (7.1) 24.3 (7.3) 
Fruits & vegetables (s/d) 5.1 (2.4) 5.8 (2.6) 6.1 (2.6) 6.7 (3.0) 
Red & processed meats (s/d) 1.2 (0.83) 1.0 (0.80) 0.99 (0.75) 0.87 (0.72) 
1Values are means (SD) or percentages and are standardized to the age distribution of the study 
population; C=cup; s/d=serving/day; mo=month; wk=week. 
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Table 4.2 shows the intakes of selected dietary factors according to yogurt 
categories in the NHS and HPFS. Higher yogurt intake was associated with a 
healthier diet as indicated by a higher DASH score, higher fiber and FV intakes, 
as well as lower intakes of red and processed meats and alcohol.  
Table 4.3 Age-standardized nutrient intakes of the NHS and HPFS subjects at 
baseline by yogurt intake categories 
A. NHS (N=57,768) Yogurt Intake Categories (1 C s/d)1 
 <1/mo 
(N = 22,126) 
1/mo-<1/wk 
(N = 10,920) 
1-<2/wk 
(N = 12,262) 
≥2/wk 
(N = 12,460) 
Energy intake (kcals/d) 1597 (529) 1628 (520) 1702 (524) 1806 (543) 
Total protein (g/d) 71.6 (14.9) 73.5 (14.4) 74.4 (13.9) 75.7 (13.9) 
Total fat (g/d) 61.6 (14.6) 59.3 (14.2) 57.6 (13.4) 53.6 (12.8) 
Trans fats (g/d) 1.91 (0.75) 1.79 (0.71) 1.71 (0.68) 1.54 (0.62) 
Total carbohydrates (g/d) 183 (44.2) 188 (43.1) 192 (40.5) 202 (38.0) 
Sodium (mg/d) 1722 (597) 1745 (553) 1767 (539) 1788 (500) 
Potassium (mg/d) 2801 (619) 2929 (604) 3011 (588) 3167 (595) 
Calcium (mg/d) 673 (340) 740 (340) 810 (360) 964 (399) 
Magnesium(mg/d) 276 (95.6) 296 (96.6) 315 (102) 346 (108) 
B. HPFS (N=18,593) Yogurt Intake Categories (1 C s/d)1 
 
<1/mo 
(N = 9,992) 
1/mo-<1/wk 
(N = 3,452) 
1-<2/wk 
(N = 2,877) 
≥2/wk 
(N = 2,272) 
Energy intake (kcals/d) 1917 (598) 1965 (602) 2017 (601) 2131 (631) 
Total protein (g/d) 88.9 (16.6) 91.7 (16.4) 91.6 (15.9) 91.9 (15.8) 
Total fat  71.7 (14.5) 68.8 (13.8) 67.6 (13.6) 63.6 (14.4) 
Trans fats (g/d 3.3 (1.4) 3.1 (1.3) 3.0 (1.4) 2.8 (1.3) 
Total carbohydrates (g/d) 233 (45.3) 242 (42.2) 247 (40.8) 258 (43.0) 
Sodium (mg/d) 2774 (1076) 2772 (1059) 2604 (901) 2494 (820) 
Potassium (mg/d) 3347 (649) 3504 (641) 3573 (658) 3742 (675) 
Calcium (mg/d) 719 (343) 789 (345) 850 (378) 1008 (414) 
Magnesium(mg/d) 322 (110) 349 (112) 363 (120) 398 (130) 
1Values are means (SD) or percentages and are standardized to the age distribution of the study 
population; C=cup; s/d=serving/day; mo=month; wk=week; kcals=kilocalories. 
 
Table 4.3 highlights several macro and micronutrients in the NHS and HPFS by 
categories of yogurt intake. In both cohorts, those with the highest yogurt intakes 
  131
(≥2 s/wk) consumed the most protein, carbohydrates, and potassium but had the 
lowest intakes of total fat and trans fats.  
Table 4.4 Age-standardized dairy intakes of the NHS and HPFS study cohorts 
at baseline by yogurt intake categories 
A. NHS (N=57,768) Yogurt Intake Categories (1 C s/d)1 
 <1/mo 
(N = 22,126) 
1/mo-<1/wk 
(N = 10,920) 
1-<2/wk 
(N = 12,262) 
≥2/wk 
(N = 12,460) 
Dairy fat (g/d) 11.5 (7.2) 11.2 (6.6) 11.2 (6.4) 11.0 (5.9) 
Total dairy (s/d) 1.1 (0.99) 1.3 (0.99) 1.5 (1.0) 1.9 (1.2) 
Low-fat dairy (s/d) 0.71 (0.89) 0.92 (0.91) 1.1 (0.98) 1.6 (1.1) 
High-fat dairy (s/d) 0.42 (0.57) 0.37 (0.51) 0.38 (0.51) 0.36 (0.49) 
Cheese (1 oz s/d) 0.35 (0.36) 0.36 (0.34) 0.38 (0.36) 0.40 (0.37) 
Total milk (8 oz s/d) 0.80 (0.89) 0.89 (0.90) 0.96 (0.92) 1.04 (0.95) 
Yogurt (1 C s/d) 0.00 (0.02) 0.06 (0.06) 0.14 (0.16) 0.46 (0.45) 
B. HPFS (N=18,593) Yogurt Intake Categories (1 C s/d)1 
 
<1/mo 
(N = 9,992) 
1/mo-<1/wk 
(N = 3,452) 
1-<2/wk 
(N = 2,877) 
≥2/wk 
(N = 2,272) 
Dairy fat (g/d) 12.7 (7.3) 12.2 (6.5) 12.1 (6.2) 12.3 (6.4) 
Total dairy (s/d) 1.3 (1.0) 1.4 (1.0) 1.5 (1.0) 2.0 (1.2) 
Low-fat dairy (s/d) 0.74 (0.89) 0.91 (0.91) 1.1 (0.91) 1.5 (1.1) 
High-fat dairy (s/d) 0.51 (0.60) 0.46 (0.53) 0.44 (0.50) 0.45 (0.55) 
Cheese (1 oz s/d) 0.39 (0.43) 0.39 (0.39) 0.40 (0.38) 0.42 (0.43) 
Total milk (8 oz s/d) 0.81 (0.92) 0.88 (0.92) 0.91 (0.91) 1.02 (1.00) 
Yogurt (1 C s/d) 0.00 (0.01) 0.06 (0.06) 0.15 (0.16) 0.47 (0.40) 
1Values are means (SD) or percentages and are standardized to the age distribution of the study 
population; C=cup; s/d=serving/day; mo=month; wk=week. 
 
Table 4.4 shows the dairy intakes of hypertensive NHS and HPFS participants by 
yogurt intake categories. Those with the highest usual yogurt intake (≥2 s/wk) 
also consumed the highest amounts of total dairy and all dairy subtypes (milk 
and cheese) but had a lower high-fat dairy intake. The average yogurt 
consumption in each yogurt intake category was similar in the two cohorts 
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although women had a higher overall mean yogurt (0.139 s/d) than the men 
(0.094 s/d) since many more women were in the highest yogurt consumption 
category. Overall average milk intake was slightly higher for women (0.91 s/d) 
than men (0.88 s/d) whereas men and women had similar mean cheese intake 
(HPFS: 0.39 s/d; NHS: 0.38 s/d). 
Table 4.5 The beneficial effects of yogurt intake on CVD risk in NHS and 
HPFS  
NHS 
    Multivariable No Diet Update 
Yogurt Intake P-yrs 
CVD 
Cases 
I /100K 
py HR1 95% CI HR2 95% CI 
            
<1/mo 338120 1875 555 1.00 - 1.00 - 
1/mo-<1/wk 156546 698 446 0.91 (0.83-0.99) 0.90 (0.82-0.98) 
1-<2/wk 135973 561 413 0.84 (0.76-0.93) 0.87 (0.79-0.95) 
≥2/wk 131054 497 379 0.83 (0.75-0.92) 0.83 (0.75-0.92) 
P for linear trend3    0.0004 0.0005 
Per one serving/day     0.64 (0.50-0.82) 0.65 (0.51-0.83) 
HPFS   
    Multivariable No Diet Update 
Yogurt Intake P-yrs 
CVD 
Cases 
I /100K 
py HR1 95% CI HR2 95% CI 
            
<1/mo 118814 1143 962 1.00 - 1.00 - 
1/mo-<1/wk 40780 309 758 0.92 (0.81-1.04) 0.90 (0.79-1.02) 
1-<2/wk 27580 186 674 0.80 (0.68-0.94) 0.84 (0.72-0.98) 
≥2/wk 21512 152 707 0.82 (0.68-0.97) 0.83 (0.70-0.99) 
P for linear trend3    0.0083 0.0200 
Per one serving/day     0.57 (0.38-0.87) 0.62 (0.41-0.93) 
1Adjusted for age, race, smoking, energy intake, family history of MI, physical activity, BMI, anti-
hypertensive medication use, and intakes of alcohol, trans fat, fiber, milk and cheese. 
2Diet not updated upon report of CABG, angina, or high cholesterol. 
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3Linear trend across yogurt intake categories was quantified with a Wald test for linear trend by 
assigning the median value to each category and modeling this variable as a continuous variable. 
mo=month; wk=week; p-yrs=person years. 
 
 
Table 4.5 shows an inverse linear association between increasing yogurt intakes 
and CVD risk among the NHS (p for trend=0.0004) and HPFS (p for trend=0.0083) 
participants. Hypertensive nurses and health professionals who had the highest 
yogurt intakes (≥2 s/wk) had a 17% (95% CI: 0.75-0.92) and an 18% (95% CI: 0.68-
0.97) reduced risk of CVD compared to with those who consumed the lowest 
yogurt intakes (<1 s/mo). In the second multivariable model, dietary intakes were 
not updated following a reported diagnosis of CABG, angina, or 
hypercholesterolemia; the effects were similar across yogurt categories in both 
cohorts. Results from the linear regression analysis show that for every 
additional serving per day of yogurt, the risk of CVD declined by 36% (95% CI: 
0.50-0.82) in women and 50% (95% CI: 0.33-0.74) in men. Similar associations 
were observed for CHD (see table A.9 in the appendix) and stroke (see table A.10 
in the appendix) for both cohorts. 
Table 4.6 Higher yogurt intake combined with a higher DASH score lowered 
risk of CVD  
NHS 
    Multivariable No Diet Update 
Yogurt, DASH score1 
P-yrs 
CVD 
Cases 
I /100K 
p-yrs HR2 95% CI HR3 95% CI 
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<2/wk, <25 391385 1953 499 1.00 - 1.00 - 
<2/wk, ≥25 239254 1181 494 0.91 (0.84-0.98) 0.88 (0.81-0.95) 
≥2/wk, <25 54791 206 376 0.87 (0.75-1.01) 0.88 (0.76-1.01) 
≥2/wk, ≥25 76263 291 382 0.81 (0.71-0.92) 0.78 (0.68-0.88) 
            
HPFS 
    Multivariable No Diet Update 
Yogurt, DASH score1 
P-yrs 
CVD 
Cases 
I /100K 
p-yrs HR2 95% CI HR3 95% CI 
            
<1/wk, <25 105289 908 862 1.00 - 1.00 - 
<1/wk, ≥25 64103 554 864 0.87 (0.77-0.97) 0.88 (0.78-0.99) 
≥1/wk, <25 16465 155 941 1.07 (0.90-1.27) 1.07 (0.90-1.27) 
≥1/wk, ≥25 25736 210 816 0.79 (0.67-0.92) 0.80 (0.68-0.93) 
1Adjusted for age, race, smoking, energy intake, family history of MI, physical activity, BMI, anti-
hypertensive medication use, and intakes of alcohol, and trans fat. 
2Diet not updated upon report of CABG, angina, or high cholesterol. 
wk=week; p-yrs=person years. 
 
Table 4.6 shows the independent and combined effects of a high yogurt intake 
with overall diet quality as measured by the DASH diet score. Women who 
consumed 2 or more yogurt servings per week, despite a low DASH score (<25) 
had a 13% (95% CI: 0.75-1.01) lower CVD risk compared with the referent group 
(low yogurt and low DASH score). Women who had a higher DASH score (≥25) 
but a lower yogurt intake (<2 s/wk) experienced a 9% (95% CI: 0.84-0.98) 
reduction in CVD risk compared to the referent group. The effect modification of 
yogurt intake by the DASH score was approximately additive since those with 
both a high yogurt intake and a high DASH score had a 19% (95% CI: 0.71-0.92) 
CVD risk reduction compared to the referent group. Among men, higher DASH 
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score alone led to a 13% lower risk compared to the referent group (yog<1/wk + 
DASH<25). We had insufficient power to use the previous cutoff value of 2 or 
more servings per week of yogurt for these analyses in men. Those consuming 
one or more servings of yogurt alone had no beneficial effect. However, the 
combined effects among men consuming one or more servings of yogurt with a 
higher DASH score were stronger (a 31% lower risk of CVD) than those seen in 
women and reflect effect modification that is more than additive.   
Table 4.7 Higher milk intake is associated with a lower risk of CVD in men 
NHS 
    Multivariable No Diet Update 
Milk Intake1 P-yrs 
CVD 
Cases 
I /100K 
p-yrs HR1 95% CI HR2 95% CI 
<0.5/d 295869 1337 452 1.00 - 1.00 - 
0.5-<2/d 362604 1763 486 1.05 (0.97-1.13) 1.04 (0.97-1.12) 
2-<5/d 103219 531 514 1.10 (0.99-1.22) 1.07 (0.96-1.20) 
P for linear trend3    0.0830 0.1844 
Per one serving/day       1.04 (0.99-1.09) 1.03 (0.99-1.08) 
HPFS 
    Multivariable No Diet Update 
Milk Intake1 P-yrs 
CVD 
Cases 
I /100K 
p-yrs HR1 95% CI HR2 95% CI 
<0.5/d 91811 783 853 1.00 - 1.00 - 
0.5-<2/d 87511 753 860 0.94 (0.85-1.04) 0.93 (0.84-1.04) 
2-<5/d 29363 254 865 0.84 (0.72-0.98) 0.86 (0.74-1.00) 
P for linear trend3    0.0235 0.0426 
Per one serving/day       0.93 (0.87-0.99) 0.94 (0.88-1.00) 
1Adjusted for age, race, smoking, energy intake, family history of MI, physical activity, BMI, anti-
hypertensive medication use, and intakes of alcohol, trans fats, fiber, yogurt and cheese.   
2Diet not updated upon report of CABG, angina, or high cholesterol.     
3Linear trend across milk intake categories was quantified with a Wald test for linear trend by 
assigning the median value to each category and modeling this variable as a continuous variable. 
d=day; p-yrs=person years. 
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Table 4.7 shows that increasing milk consumption was associated with a lower 
CVD risk in men (p for trend=0.0235) but not women. Men who consumed 2-<5 
s/d of milk had a 16% (95% CI: 0.72-0.98) lower CVD risk that those who 
consumed <0.5 s/d. Each 1 s/d increase in intake was associated with a 7% 
reduced risk of CVD in men. The effects of milk intake were slightly attenuated 
in women when diet was not updated for the occurrence of CABG, angina, or 
diagnoses of high cholesterol.  
Table 4.8 Higher milk intake combined with a higher DASH diet score is 
associated with a lower risk of CVD in men 
 NHS     
    Multivariable No Diet Update 
Milk, DASH score P-yrs 
CVD 
Cases 
I /100K 
p-yrs HR1 95% CI HR2 95% CI 
            
<1/d, <22 294335 1351 459 1.00 - 1.00 - 
<1/d, ≥22 171783 790 460 0.97 (0.88-1.06) 0.94 (0.86-1.04) 
1-<5/d, <22 161691 834 516 1.10 (1.01-1.20) 1.10 (1.01-1.21) 
1-<5/d, ≥22 133884 656 490 1.01 (0.91-1.12) 0.97 (0.87-1.07) 
            
 HPFS     
    Multivariable No Diet Update 
Milk, DASH score P-yrs 
CVD 
Cases 
I /100K 
p-yrs HR1 95% CI HR2 95% CI 
            
<1/d, <22 79673 696 874 1.00 - 1.00 - 
<1/d, ≥22 55250 471 852 0.87 (0.76-0.98) 0.83 (0.73-0.95) 
1-<5/d, <22 41409 347 838 0.88 (0.77-1.00) 0.87 (0.76-0.99) 
1-<5/d, ≥22 32353 276 853 0.80 (0.67-0.93) 0.79 (0.68-0.92) 
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1Adjusted for age, race, smoking, energy intake, family history of MI, physical activity, BMI, anti-
hypertensive medication use, and intakes of alcohol, trans fat, yogurt, and cheese. 
2Diet not updated upon report of CABG, angina, or high cholesterol. 
d=day; p-yrs=person years. 
 
 
Table 4.8 shows the independent and combined effects of milk intake and 
adherence to the DASH diet on CVD risk. In men, those with a higher milk 
intake but a lower DASH score (<22) had a 12% reduced risk of CVD whereas 
those with lower milk intakes (<1 s/d) and a higher DASH score (≥22) had a 13% 
lower risk compared to the referent group. The combined effect of a high milk 
and a high DASH score (HR: 0.80, 95% CI: 0.67-0.93) indicates a slight 
modification of the effect of milk consumption on CVD risk by the DASH diet 
score. In the NHS, a high milk intake (1-<5 s/d) combined with a low DASH score 
(<22) was associated with a 10% increased risk of CVD. There was also no 
beneficial effect of a higher DASH score, either alone or in combination with milk 
consumption.  
Table 4.9 Higher cheese intake is associated with a lower CVD Risk in women 
 
NHS 
    Multivariable No Diet Update 
Cheese Intake P-yrs 
CVD 
Cases 
I /100K 
p-yrs HR1 95% CI HR2 95% CI 
<0.25/d 369440 1823 493 1.00 - 1.00 - 
0.25-<0.5/d 251516 1180 469 0.93 (0.87-1.01) 0.93 (0.86-1.01) 
0.5-4/d 140737 628 446 0.92 (0.83-1.01) 0.91 (0.82-1.00) 
P for linear trend3    0.0476 0.0301 
Per one serving/day       0.85 (0.72-1.00) 0.84 (0.71-0.98) 
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HPFS 
    Multivariable No Diet Update 
Cheese Intake P-yrs 
CVD 
Cases 
I /100K 
p-yrs HR1 95% CI HR2 95% CI 
<0.25/d 87370 725 830 1.00 - 1.00 - 
0.25-<0.5/d 71476 616 862 1.06 (0.94-1.18) 1.08 (0.96-1.20) 
0.5-4/d 49840 449 901 1.10 (0.97-1.25) 1.10 (0.97-1.25) 
P for linear trend3    0.1210 0.1355 
Per one serving/day       1.16 (0.96-1.39) 1.16 (0.95-1.41) 
1Adjusted for age, race, smoking, energy intake, family history of MI, physical activity, BMI, anti-
hypertensive medication use, and intakes of alcohol, trans fat, fiber, yogurt and milk.   
2Diet not updated upon report of CABG, angina, or high cholesterol.     
3Linear trend across cheese intake categories was quantified with a Wald test for linear trend by 
assigning the median value to each category and modeling this variable as a continuous variable. 
d=day; p-yrs=person years. 
 
Results in Table 4.9 are in some ways opposite to those of Table 4.8. Here, there is 
a suggestion that higher cheese intakes (0.5-4 s/d) among hypertensive women 
may be associated with a slightly lower risk of CVD (HR: 0.92; 95% CI: 0.83-1.01). 
There was also an inverse linear trend across categories of cheese intake in 
women (p for trend=0.0476). In contrast, higher cheese intake among men was 
not associated with CVD risk. In the multiple linear regression modeling, each 
additional serving of cheese in women was linked with a 15% lower CVD risk 
(95% CI: 0.72-1.00) and a non-statistically significant 16% increased risk in men 
(95% CI: 0.96-1.39).  
Table 4.10 Higher cheese consumption with a higher DASH diet score is 
associated with a lower risk of CVD in women  
 NHS     
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    Multivariable No Diet Update 
Cheese, DASH score P-yrs 
CVD 
Cases 
I /100K 
p-yrs HR1 95% CI HR2 95% CI 
            
<0.25/d, <22 219639 1084 494 1.00 - 1.00 - 
<0.25/d, ≥22 149801 739 493 0.96 (0.87-1.06) 0.93 (0.84-1.03) 
0.25-4/d, <22 236387 1101 466 0.94 (0.86-1.02) 0.94 (0.86-1.03) 
0.25-4/d, ≥22 155866 707 454 0.87 (0.79-0.97) 0.84 (0.76-0.93) 
            
 HPFS     
    Multivariable No Diet Update 
Cheese, DASH score P-yrs 
CVD 
Cases 
I /100K 
p-yrs HR1 95% CI HR2 95% CI 
            
<0.25/d, <22 47525 391 823 1.00 - 1.00 - 
<0.25/d, ≥22 39845 334 838 0.91 (0.78-1.07) 0.88 (0.75-1.02) 
0.25-4/d, <22 73557 652 886 1.11 (0.98-1.27) 1.11 (0.97-1.26) 
0.25-4/d, ≥22 47758 413 865 0.96 (0.83-1.11) 0.94 (0.81-1.09) 
1Adjusted for age, race, smoking, energy intake, family history of MI, physical activity, BMI, anti-
hypertensive medication use, and intakes of alcohol, trans fat, yogurt, and milk. 
2Diet not updated upon report of CABG, angina, or high cholesterol. 
d=day; p-yrs=person years. 
 
Table 4.10 shows the independent and combined effects of cheese intake and the 
DASH score on risk of CVD. Hypertensive women with a high cheese intake but 
a low DASH score (<22) had a 6% lower CVD risk compared to those with low 
intakes of both (ref). A high DASH score alone led to only a 4% lower CVD risk. 
The combined effect of higher cheese intakes and a higher DASH score was 
slightly more than additive, that is a statistically significant 13% reduced risk of 
CVD (95% CI: 0.79-0.97). In men, there was no effect of higher cheese intake 
alone, a higher DASH score alone, or the combination of the two.   
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Table 4.11 Total dairy intake is inversely associated with CVD Risk in men 
 
 NHS     
    Multivariable No Diet Update 
Dairy Intake P-yrs 
CVD 
Cases 
I /100K 
p-yrs HR1 95% CI HR2 95% CI 
<0.5/d 111941 573 512 1.00 - 1.00 - 
0.5-<1/d 167657 801 478 0.93 (0.83-1.03) 0.91 (0.82-1.02) 
1-<2/d 294401 1319 448 0.88 (0.80-0.98) 0.88 (0.79-0.98) 
2-<6/d 187694 938 500 0.98 (0.87-1.11) 0.97 (0.86-1.09) 
P for linear trend3    0.5437 0.6691 
Per one serving/day     1.01 (0.97-1.06) 1.01 (0.97-1.06) 
 HPFS     
    Multivariable No Diet Update 
Dairy Intake P-yrs 
CVD 
Cases 
I /100K 
p-yrs HR1 95% CI HR2 95% CI 
<0.5/d 31914 263 824 1.00 - 1.00 - 
0.5-<1/d 51527 434 842 1.00 (0.85-1.16) 1.01 (0.86-1.19) 
1-<2/d 79041 695 879 0.99 (0.85-1.15) 1.04 (0.89-1.21) 
2-<6/d 46204 398 861 0.89 (0.75-1.05) 0.93 (0.78-1.10) 
P for linear trend3    0.0832 0.2187 
Per one serving/day     0.95 (0.89-1.01) 0.96 (0.91-1.02) 
1Adjusted for age, race, smoking, energy intake, family history of MI, physical activity, BMI, anti-
hypertensive medication use, and intakes of alcohol, trans fat, and fiber. 
2Diet not updated upon report of CABG, angina, or high cholesterol.     
3Linear trend across total dairy intake categories was quantified with a Wald test for linear trend 
by assigning the median value to each category and modeling it as a continuous variable. 
d=day; p-yrs=person years. 
 
Finally, we examined the effects of total dairy intake and CVD risk as shown in 
Table 4.11. Overall, there was little effect of total dairy intake on CVD risk among 
these hypertensive men and women. Men who reported consuming 2-<6 s/d had 
a non-statistically significant 11% (95% CI: 0.75-1.05) lower CVD risk compared 
to men with the lowest dairy intake (<0.5 s/d).  A weak J-shaped association was 
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observed for women with HBP, with the lowest CVD risk found in those 
reporting an intake of 1-<2 servings per day.  
Table 4.12 High total dairy intake combined with a high DASH diet score is 
associated with a lower risk of CVD in women and men 
 NHS     
    Multivariable No Diet Update 
Dairy, DASH score P-yrs 
CVD 
Cases 
I /100K 
p-yrs HR2 95% CI HR3 95% CI 
            
<1/d, <22 184373 901 489 1.00 - 1.00 - 
<1/d, ≥22 95226 473 497 0.95 (0.85-1.07) 0.92 (0.82-1.04) 
1-<6/d, <22 271653 1284 473 0.97 (0.88-1.06) 0.97 (0.89-1.06) 
1-<6/d, ≥22 210441 973 462 0.88 (0.79-0.97) 0.86 (0.77-0.95) 
            
 HPFS     
    Multivariable No Diet Update 
Dairy, DASH score P-yrs 
CVD 
Cases 
I /100K 
p-yrs HR2 95% CI HR3 95% CI 
            
<1/d, <22 50984 420 824 1.00 - 1.00 - 
<1/d, ≥22 32456 277 853 0.90 (0.76-1.05) 0.86 (0.73-1.02) 
1-<6/d, <22 70098 623 889 1.00 (0.88-1.14) 1.02 (0.90-1.16) 
1-<6/d, ≥22 55147 470 852 0.84 (0.73-0.97) 0.85 (0.73-0.98) 
1Adjusted for age, race, smoking, energy intake, family history of MI, physical activity, anti-
hypertensive medication use, and intakes of alcohol, and trans fat. 
2Diet not updated upon report of CABG, angina, or high cholesterol.  
d=day; p-yrs=person years. 
 
 
The combined effects of total dairy intake and adherence to the DASH diet is 
shown in Table 4.12. Both men and women who consumed one or more servings 
of dairy per day and had a higher DASH score (≥22) had the lowest risk of 
developing CVD. Among hypertensive women, the risk of CVD was 12% lower 
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(95% CI: 0.79-0.97) than that of subjects in the referent group while for men, the 
risk of CVD in this same category was 16% lower (95% CI: 0.73-0.97). For both 
men and women, there was evidence of effect modification (more than additive) 
of dairy intake by the DASH score.  
 
4.6 DISCUSSION 
In these analyses, higher yogurt consumption (≥ 2 s/week) among hypertensive 
women and men in the NHS and HPFS was associated with a reduced risk of 
total CVD (17% and 18% lower risks, respectively), CHD (26% and 18% lower 
risks, respectively), and stroke (6% and 19% lower risks, respectively). These 
beneficial effects were also observed when higher yogurt intakes were combined 
with the DASH diet score, a healthy diet that has been linked with BP-lowering 
effects.   
Observational studies examining the effect of yogurt intake on risk of CVD 
among hypertensives have not been published. To our knowledge, this is the first 
and largest prospective study to estimate the independent effect of yogurt intake 
on risk of CVD among those with HBP. Several randomized controlled feeding 
trials have recruited hypertensive individuals to assess the effects of fermented 
milk products on CVD risk factors188-190. Jauhianen et al conducted a randomized, 
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placebo-controlled, double-blind, parallel group trial with 89 hypertensive 
subjects; they observed that treatment with 200 ml/d of Lactobacillus helveticus-
fermented milk containing 1.2 mg of IPP/100 g and 1.3 mg of VPP/100 g for the 
first 12 weeks and increasing to 5.8 mg IPP/100 g and 6.6 mg VPP/100 g for the 
final 12 weeks had beneficial effects on the augmentation index (a measure of 
arterial stiffness) compared to those who had Lactobacillus helveticus-fermented 
milk without IPP or VPP189.  
Aortic stiffness has been shown to be an independent predictor of coronary 
events in a longitudinal study of over 1,000 hypertensive French adults (mean 
age=51 years) followed for six years208. A similar randomized, double-blind 
placebo-controlled, parallel feeding trial of 25 Japanese hypertensives male 
subjects (mean age=54 years) found an improvement of endothelial function after 
ingestion of 1.25 g of casein hydrolysate powder containing 3.42 mg of VPP and 
3.87 mg of IPP per day for 1 week190. Another randomized crossover clinical trial 
on 70 Caucasian adults with pre-hypertension or hypertension examined the 
effects of daily consumption of 15 mg IPP (consumed in capsules of milk protein 
hydrolysate twice per day for four weeks) without dairy-related minerals and 
found that IPP led to 3.8 mm Hg reductions in SBP and 2.3 mm Hg reductions in 
DBP among subjects with stage 1 hypertension209. Taken together, these 
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randomized trials in hypertensive subjects showed a beneficial effect of the 
casein-derived tripeptides IPP and VPP on blood pressure and other CVD risk 
factors.  
These tripeptides could play a potential role in platelet aggregation and clot 
formation via their inhibition of the angiotensin converting enzyme (ACE) in the 
renin-angiotensin system (RAS)154, one of the major BP regulators in the body. 
Inhibition of ACE, leads to lower concentrations of angiotensin II, a potent 
vasoconstrictor154. Angiotensin II has also been shown to increase intracellular 
calcium concentration in vascular smooth muscle cells (VSMC) and pH in 
platelets from hypertensive patients210, which may be associated with enhanced 
platelet aggregation211. When platelets aggregate, they release different growth 
factors that take part in the development of atherosclerosis by promoting VSMC 
proliferation212. Platelets from hypertensive patients produce more reactive 
oxygen species (ROS)213,214. ROS enhance platelet activity by reducing the 
bioavailability of nitric oxide (NO)213, an important vasodilator215 and inhibitor of 
platelet aggregation216,217. Fermented dairy-derived peptides have been shown to 
improve vascular response in vitro possibly by the stimulation of NO release in 
spontaneously hypertensive rats (SHR)152. Thus, biopeptides from fermented 
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dairy have been linked to different platelet signaling pathways (such as RAS) 
and may play a role in hypertension-associated CVD.  
 
Several prospective studies among those without HBP observed an inverse 
association of yogurt intake on markers of CVD28,218. A 5-year prospective study 
of 1,080 Caucasian women >70 years old in Australia showed that those who 
consumed >100 g/d (> 0.4 c/d) of yogurt had significantly less common carotid 
artery intima-media thickness28, a predictor of stroke and MI219,220, compared with 
those who consumed <100 g/d of yogurt. The investigators did not observe 
comparable beneficial effects with other dairy foods, suggesting that yogurt has 
unique effects on CVD risk factors28. A 4-year case-control study in 885 Italian 
patients observed a 45% lower odds of acute MI among those who consumed 7 
or more cups of yogurt per week compared with non-yogurt consumers.218 
Similar to the Australian cohort, the effects of yogurt were greater than those for 
milk (OR: 0.78) and cheese (OR: 0.77)218.  
 
No long-term observational studies have examined the effect of dairy intake on 
CVD risk among individuals with prevalent HBP. Studies of dairy intake in 
general, irrespective of HBP status, suggest that higher dairy intake is associated 
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with a lower CVD risk198,221. A meta-analysis of total dairy intake found an 
inverse association with risk of stroke that may be due to the BP-lowering effects 
of dairy.222 These findings are in agreement with our analyses in which we saw 
that increased dairy intake was linked with lower risks of HBP and stroke in the 
NHS (Chapter 3). Overall, there is a moderate amount of evidence that links 
dairy intake with a beneficial effect on risk of CVD. 
 
When high yogurt intakes were combined with a high DASH score, we observed 
a greater beneficial effect compared with the independent effects of yogurt or the 
DASH eating pattern alone in both cohorts. The independent effect of a DASH 
diet intervention was observed in the ENCORE (Exercise and Nutrition 
interventions for CardiOvasculaR hEalth) study, where investigators recruited 
overweight (BMI between 25-40 kg/m2) middle-aged (mean age=52 years) 
hypertensive men and women223. They found that those randomized to the 
DASH diet intervention had lower BP, brachial artery flow-mediated dilation, 
baroreflex sensitivity, and left ventricular mass after a 4-month study period 
compared with those consuming a typical American diet223. Increased left 
ventricular mass predicts left ventricular hypertrophy, a structural consequence 
of HBP and one of the strongest known predictors of cardiovascular morbidity 
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and mortality among hypertensives224, independent of other CVD risk factors. 
Sensitivity of the baroreflex system is an early consequence of HBP225 and may 
reflect reduced viscoelastic properties of the vascular wall, which contains the 
baroafferent stretch receptors owing to arterial stiffness and atherosclerosis226,227. 
The DASH diet intervention in the ENCORE study improved BRS by 33%223, 
perhaps as a result of reduced vascular stiffness among hypertensives228. An 
analysis of a subset of the original DASH trial with stage 1 hypertension229 found 
that approximately 75% of the 131 hypertensive participants in the DASH 
intervention arm experienced a BP-lowering effect compared to only a quarter or 
half of the participants in the control and FV groups, respectively, after 24-weeks 
in the randomized, cross-over, feeding trial229. 
In terms of the biochemical mechanisms of the DASH diet on CVD risk factors, 
high inorganic nitrates from fruits and leafy vegetables have been implicated as 
playing a role in the non-enzymatic generation of NO230. The DASH diet was 
estimated to have contributed approximately 1200 mg nitrate/d231. A meta-
analysis and systematic review of randomized controlled trials in adults 
demonstrated a significant effect of inorganic nitrate supplementation on SBP 
(decrease of 4.4 mm Hg) and DBP (decrease of 1.1 mm Hg)232. In addition to high 
amounts of inorganic nitrate, the DASH diet promotes increased consumption of 
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hypotensive minerals such as magnesium, calcium, and potassium233,234. These 
minerals have been shown to have protective effects on CVD risk factors via their 
antioxidant capacity to lower oxidative stress235, inflammatory response and 
coagulation abnormalities in type 2 diabetics236, increased sodium excretion in 
pre-hypertensive adults237, and sympathetic activation238 and endothelial 
function223 among adults with HBP.  
 
Yogurt was the only dairy product that had measurable CVD-lowering effects for 
both hypertensive men and women in our analyses. One reason for this 
consistency could be the inherent nature of how yogurt is usually eaten (as a 
food by itself) which may impact the accuracy of the reported intake levels with 
the FFQ. I propose that for several reasons, yogurt is the dairy product least 
prone to misreporting. Other dairy subtypes such as milk and cheese are often 
eaten as a part of mixed dishes (e.g., soups, pizza, sandwiches, casseroles, mixed 
beverages) and thus, are more susceptible to error in the estimation of intake 
both from misreporting and from the nature of the food list on the FFQ itself.  
The validity of the reported intakes of dairy (comparing the FFQ with 7-day food 
diaries of 173 NHS participants and 127 male health professionals) in these two 
cohorts was examined in previous analyses. The correlations of reported intakes 
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of milk with the two methods in NHS and HPFS were 0.81 and 0.88, respectively; 
those for cheese were 0.57 and 0.59, respectively, and for yogurt were 0.97 and 
0.86, respectively).126,128 These results support the possibility that yogurt intake 
may have been reported more accurately and/or completely than other forms of 
dairy. Bingham et al found lower reported intakes of foods such as cakes, milk, 
and desserts in under-reporters in a validation study of weighed records, FFQs, 
and 24-hour recalls against the urinary nitrogen technique.239 Pryer et al found 
the largest differences between reporters and low-energy reporters (under-
reporters) for foods such as confectionery, biscuits and cakes, and high-fat dairy 
products (including high-fat milk and cheese).168 Both of these studies suggest 
that cheese, milk and milk-containing foods and dishes may be under-reported 
in a variety of dietary assessment techniques that rely on participant recall. If 
milk and cheese intakes are legitimately associated with lower CVD risk, then 
under-reporting of these dietary exposures could lead to underestimation of the 
beneficial effects on CVD outcomes as a consequence of subjects from the higher-
intake groups potentially being misclassified.  
It is possible that the intake of dairy was reported with error in this study and 
that misreporting could differ by type of dairy product (e.g., milk, cheese) and by 
the actual amount consumed. This is more likely to be a problem here since the 
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subjects had prevalent HBP, and as health care professionals, the cohort 
participants may have been aware of their own increased risk of CVD. During 
the 1980s through the 1990s, there were many public health messages targeted at 
middle-aged women recommending that they increase their dairy consumption 
to prevent hip fractures240 and osteoporosis241. At the same time, however, 
messages about dairy intake were conflicting194,195 with many clinicians and 
cardiologists recommending the avoidance of milk and other dairy products to 
avoid hypothesized adverse effects on weight and CVD risk. The majority of the 
dairy reportedly consumed by the NHS women was low-fat dairy (64%), and the 
majority of that (79.5%) was skim or semi-skim milk. The many public health 
messages combined with the subjects’ personal demographic and risk status 
could have led to biased reporting of the amount and type of dairy consumed by 
study participants, which could in turn have attenuated the true effects of dairy 
on CVD risk. Previous evidence suggests that higher milk intakes are inversely 
associated with risk of CVD among non-hypertensives70,186. If subjects with 
higher intakes of dairy in this study under-reported their actual intakes, this 
could have falsely attenuated the effects of dairy on CVD risk (as a result of the 
inclusion of nurses and health professionals with higher dairy intakes in the 
referent group).  
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This study had several strengths including its prospective design and the use of 
updated repeated measures of diet for the estimation of long-term dietary 
intakes and repeated measures of potential confounding variables. The sample 
size allowed us to estimate the overall effects of each dairy subtype among those 
with HBP. The use of medical records to confirm CHD and stroke was also a 
strength of the study.  
 
This study is also subject to several limitations. Since yogurt is highly correlated 
with an overall healthy diet and lifestyle, it is possible that some potential 
confounder associated with an overall healthy lifestyle was not measured. 
Yogurt is a complex dairy product and we were not able to ascertain the effects 
of specific types of yogurts especially those with different added bacterial strains. 
The evidence on the effects of specific strains is scarce but studies148 have shown 
that different combinations of bacterial strains added to yogurt have unique 
effects on BP and CVD risk factors. Future studies are needed to assess the effects 
of different types of yogurt.  
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Our participants were predominantly Caucasians of European ancestry, which 
limits the generalizability of our findings. Although this is also a strength in that 
the potential confounding of race is virtually eliminated from our analyses, our 
results cannot be applied to other racial or ethnic groups, which may have 
different risk factors for developing chronic diseases than our cohorts. The 
number of stroke cases in the HPFS was lacking ample statistical power to 
provide stable effect estimates in many of our exposures. Therefore, a larger 
cohort of men with ample statistical power is warranted in order to 
independently examine the effects of each dairy type on risk of stroke. Another 
key limitation for these analyses is the lack of participants with high regular 
yogurt intakes. In order to maximize statistical power, the highest yogurt 
category for both NHS and HPFS cohorts was  limited to 2 or more servings per 
week, far below the usual dairy recommendation for yogurt and dairy (2-3 
servings/day with emphasis on one serving from each type of dairy such as 
yogurt, cheese, and milk)167. This limits the interpretability of the estimates for 1 
serving/day increase of yogurt as the estimates were extrapolated from 2 or more 
servings/week. 
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4.7 CONCLUSION 
The results of this study suggest that higher long-term yogurt intakes are 
associated with lower risks of CVD, CHD, and stroke in hypertensive women 
and men. We found no adverse effects of consuming milk, cheese, or dairy on 
risk of CVD. Higher yogurt and total dairy intake in combination with an overall 
healthy diet as measured by the DASH score was also associated with a lower 
risk of CVD, CHD, and stroke in both hypertensive men and women. Our 
findings suggest that incorporation of yogurt into a healthy diet pattern among 
those with HBP may aid in the secondary prevention of CVD prevention. 
Further, these results add to the growing body of evidence showing that there is 
no basis for avoidance of dairy products in the diet because of its cholesterol and 
SFA content as intake levels as consumed by [educated, Caucasian, hypertensive] 
adults in this study do not confer any increased risk. Future studies on the 
specific types of yogurt and its effects on CVD among those with HBP in 
populations with larger demographic diversity are warranted.  
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CHAPTER 5: GENERAL DISCUSSION 
 
High blood pressure (HBP) is a major cause of heart disease, stroke, and renal 
failure and thereby a major cause of disability and premature death2. Major 
strides have been made over the past several decades in the treatment of high 
blood pressure but with rising rates of obesity worldwide, the rates of incident 
high blood pressure have continued to rise. By the age of 55, 54% of adults have 
HBP and among the obese, rates are even higher2. HBP is not just a disease of 
older adults; the rate of HBP development rises steadily from the adolescent 
years into older adulthood (≥75 years)2. Therefore, prevention or delay in the 
onset of HBP is the key to stemming the rising tide of death and disability from 
blood pressure-related diseases. 
 
Blood pressure levels are affected by many factors. Genetics, aging, and sex are 
some of the major non-modifiable risk factors but diet, activity, and smoking 
have also been shown to be strong behavioral, modifiable determinants of BP2. 
Furthermore, obesity, which is impacted by the same modifiable and non-
modifiable risk factors, is an important cause of HBP2. It was estimated that as 
much as 65% of HBP cases are attributable to obesity2. Cross-sectional studies 
indicate that more than 85% of hypertensive individuals are overweight or 
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obese.47 Thus, these modifiable risk factors exert epigenetic effects on likelihood 
of developing HBP and secondary outcomes such as CVD. 
 
Evidence from systematic reviews14,15 and meta-analyses16,17 suggest that dietary 
protein consumption seems to benefit BP. Observational studies, which have 
been largely cross-sectional, have shown weak beneficial effects of plant proteins 
in particular on BP.14 There are few observational studies that have addressed the 
long-term effects of total protein or animal and plant proteins on BP level or 
long-term risk of HBP, and results have been conflicting.18-20  
 
The first study for this dissertation addressed the questions associated with long-
term effects of total protein as well as animal and plant protein intakes on blood 
pressure using data from the Framingham Offspring Study. We found that 
protein intake (from both animal and plant sources) had independent, beneficial 
effects on mean SBP and DBP, and lowered the long-term risk of incident HBP 
among middle-aged adults. The effects were even stronger for individuals with a 
healthy diet as indicated by selected dietary factors such as higher intakes of 
fruits and vegetables (FV) or fiber. This study adds much-needed long-term 
evidence that both animal and plant proteins have similar beneficial effects on 
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risk of HBP. The use of dietary records for determining protein intakes among 
healthy normotensive adults in this prospective study provides convincing 
evidence of unbiased effects of protein on HBP risk. 
 
In 1997, a landmark clinical trial testing the impact of a dietary intervention on 
blood pressure was published. This eating pattern was characterized by higher 
intakes of fruits and vegetables as well as low-fat dairy, and came to be known 
by the acronym DASH, or Dietary Approaches to Stop Hypertension57. In the 
DASH trials, the greatest reductions in BP have been seen with the “combined” 
diet that had both higher intakes of FV and higher intakes of low-fat dairy 
products rather than a high FV diet alone. Dairy products are an important 
source of dietary protein and so it has been hypothesized that the protein content 
of dairy may explain at least some of its beneficial effects on blood pressure.  
 
The 2010 Dietary Guidelines Advisory Committee (DGAC) reviewed the 
evidence for the association between dairy intake and BP. They concluded that 
overall, there is a moderate body of evidence pointing to an inverse relationship 
between the intake of milk and milk products and BP, particularly SBP; the 
evidence for a reduction in DBP is weaker.24 The DGAC summary suggests that 
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the evidence is not completely consistent and that differences in results across 
studies may result from actual differences in effects of different types of dairy 
products or from residual confounding associated with other dietary factors, and 
demographic factors.24  Dairy intake has been inversely associated with BP and 
HBP risk in several prospective studies such as the CARDIA study25, the 
Women’s Health Study26, and the Rotterdam study27. However, some studies 
such as one in elderly women28,29, the Hoorn Study19, and the general Dutch 
population30 found no association between dairy intake and BP. Most studies of 
dairy intake and BP have combined all types of dairy into one exposure, which 
could mask differential effects of individual types of dairy (milk, cheese, or 
yogurt). The nutrient profiles of the different dairy subtypes vary which may be 
responsible for variable effects of dairy subtypes on BP. Observational studies 
that specifically evaluate yogurt consumption in relation to BP are scarce but 
beginning to emerge. A cross-sectional analysis from NHANES 1999-2004 data,44 
and a few long-term studies from an elderly Mediterranean population in the 
PREDIMED study120 and the Framingham Offspring Study Cohort121 all linked 
yogurt intake with a lower risk of HBP. These observational studies did not have 
ample statistical power to capture effects of usual daily intakes of yogurt. Thus, 
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we decided to evaluate the effects of usual yogurt intake on HBP risk among a 
total of 184,231subjects in three large prospective cohorts. 
 
The second study for this dissertation uses data from two NHS cohorts and the 
HPFS to examine the effects of different amounts of yogurt consumed and risk of 
incident HBP among middle-aged and older adults. First, we observed that those 
with higher intakes of total dairy had a lower risk for developing HBP compared 
to those with lower dairy intakes in all three cohorts—NHS, NHS II, and HPFS. 
We then evaluated the specific effects of yogurt consumption, while controlling 
for other forms of dairy that were also consumed. We found that men and 
women who consumed yogurt regularly (5 or more servings per week) had 
lower risks of incident HBP than those consuming higher amounts of milk and 
cheese. These results support the hypothesis that yogurt may have specific 
properties that contribute stronger BP-lowering effects than milk and cheese.  
 
In addition to the effects of yogurt on risk of incident HBP, there is some 
evidence that yogurt and other forms of fermented dairy products may play a 
hypotensive role in BP control.40 A meta-analysis by Dong et al of 13 randomized 
controlled trials, mostly of 4-8 weeks duration, in both normotensive and 
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hypertensive adults ages 35 years or older, derived a summary estimate for the 
beneficial effects of fermented milk of about 2 mm Hg decrease in SBP148. This 
decrease in SBP was found to be associated with 7% and 10% lower CHD and 
stroke mortality risks, respectively173. The trials among subjects with prevalent 
hypertension in the meta-analysis by Dong and colleagues found a 4 mm Hg 
decrease in SBP associated with fermented milk supplementation148, suggesting a 
greater CVD benefit among hypertensives compared with normotensives173.  
 
The current hypothesis in terms of yogurt’s biochemical effect on BP relates to its 
modulation of the renin-angiotensin pathway. Specifically, casein derived 
tripeptides (IPP and VPP) from certain fermented milk products inhibit the rate 
determining enzyme of RAS36, which slows down vasoconstriction and 
simultaneously increases vasodilation. This inhibition has been shown in several 
experimental models characterized by varying concentrations and type(s) of 
lactic-acid producing bacterial strains37-39. Hirota et al showed that fermented 
milk tripeptides VPP and IPP improved vascular endothelial function 
independent of its BP-lowering effects in hypertensive subjects in a randomized 
trial of hypertensive males,190 suggesting that fermented dairy products may 
have CVD-lowering capabilities that are independent of its BP-lowering effects. 
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Since most previous studies of fermented dairy products have been of short 
duration, there is a need for longer-term, well-controlled prospective studies to 
evaluate the effects of fermented dairy consumption on CVD risk among 
individuals with prevalent HBP.  
 
A number of studies of total dairy intake have found that higher consumption is 
associated with a lower CVD risk198,221. A meta-analysis of total dairy intake 
found an inverse association with risk of stroke and concluded that this may be 
due to the BP-lowering effects of dairy222. Some prospective studies among those 
without prevalent HBP observed an inverse association of yogurt intake on 
markers of CVD28,218 that were not found in association with other dairy foods 
such as milk and cheese, which again may suggest that yogurt has unique effects 
on CVD risk factors28. In contrast, it is also possible that reported yogurt intake 
may be less susceptible to bias in these historical cohort studies than are other 
forms of dairy, since dairy consumption was considered by many to be a risk 
factor for CVD at that time. 
 
Diet patterns are also associated with CVD risk. A recent meta-analysis of 
longitudinal studies by Salehi et al showed that those with higher adherence to a 
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DASH-like diet have reduced risks of CVD, CHD, stroke, and heart failure by 
20%, 21%, 19% and 29%, respectively242. DASH diet adherence has also been 
associated with beneficial effects on diabetes, fasting glucose243,244, total 
cholesterol, and LDL-cholesterol,243,245,246 all of which are risk factors for CVD. 
Thus, the evidence suggests that both diet and HBP may independently promote 
the development of CVD. Therefore, we hypothesized that yogurt intake may 
lower the risk of CVD both directly and indirectly (by lowering risk for HBP) and 
that these effects may be stronger than those found for other forms of dairy. 
 
The final chapter evaluates the effects of yogurt consumption the risk of CVD 
among adults in the NHS and HPFS cohorts with prevalent HBP. These analyses 
add important new evidence suggesting that yogurt consumption lowers the risk 
of CVD in this high-risk population. To our knowledge, our analyses were 
among the first to analyze the effects of dairy intake on CVD risk among those 
with prevalent hypertension. The majority of previous studies have focused on 
estimating effects of dairy intake on risk of incident CVD among those who are 
healthy and free from HBP. Our results suggest that even among those who have 
HBP, consuming more yogurt is associated with lower risk for incident CVD, 
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CHD and stroke alone or in combination with an overall healthy diet as 
measured by the DASH diet score. 
 
Our longitudinal analyses are among the first to have adequate statistical power 
to be able to estimate and independent effect of long-term regular yogurt 
consumption on HBP. The Dietary Guidelines for Americans recommend 2-3 
servings/day (s/d) of dairy, with an emphasis on low-fat dairy and consuming a 
variety of dairy sources110. The majority of previous studies lacked sufficient 
statistical power to estimate the effect of a 1 s/d increase of yogurt, hence yogurt 
was usually combined with other dairy foods into a total dairy exposure. As a 
result, the yogurt-specific effects on cardiovascular outcomes have been 
unknown.115 This dissertation therefore addresses this important gap in the 
evidence.  
 
Our results call for future studies focusing on different types of yogurt, such as 
yogurts with varying fat content, Greek yogurt (with twice the amount of 
protein, the most potent nutrient regulator of BP,148 but half the carbohydrate 
content of regular yogurt), and yogurt with added probiotics, to see if there are 
different effects of specific types of yogurt on BP.  
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Finally, another important contribution of this dissertation is the observation that 
the effects of protein, dairy, and yogurt on BP were modified by the overall diet 
pattern. We found that individuals with a healthier overall eating pattern had 
even greater benefits from the added intakes of protein and other dairy products. 
In the NHS and HPFS cohorts, each participant was characterized according to 
the degree to which their pattern was consistent with that of the DASH eating 
pattern. We then examined the effects of yogurt consumption among individuals 
whose diet was more or less consistent with a DASH pattern. In these analyses, 
we found that the combined effects were approximately additive (i.e., risk 
reductions for those with higher yogurt intake plus DASH eating pattern = risk 
reductions for higher yogurt alone + risk reduction for DASH diet pattern alone). 
These results echo the most recent Dietary Guidelines for Americans that emphasize 
the need to consider the overall diet pattern rather than just focusing on 
individual foods for lowering risks of chronic disease and improving overall 
health. 
 
Animal models have found specific biochemical mechanisms by which yogurt 
components may modulate BP. Our studies indicate that the time is right for 
randomized controlled trials of humans to examine the mechanisms by which 
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yogurt consumption impacts BP and CVD risk factors. Future studies should also 
examine direct effects of probiotics on HBP.  It would be very difficult to 
accurately calculate the amount of probiotics in commercially-produced yogurt 
as the probiotic concentration is affected by several variable factors such as: 
handling and transport time shelf-life, refrigeration temperatures, etc. This adds 
to the complex problem of what type(s) and amounts of probiotics would be 
feasible to add to commercially produced yogurt in order to have any 
meaningful public health impact. Although this question seems to be a difficult 
one to answer and could certainly take many more years of research both in the 
basic and population-based sciences, our study provides evidence that yogurt 
consumption (of any type) may have a meaningful public health difference in 
terms of lowering risk of HBP, one of the major risk factors for CVD. 
 
Our analyses provide longitudinal data supporting beneficial effects of long-term 
protein, dairy, and yogurt intakes on risk of incident HBP. These results also 
suggest that yogurt consumption among those with prevalent HBP lowers the 
risk of myocardial infarction and stroke. Future studies are needed to examine 
the effects of specific types of yogurt on cardiovascular outcomes as well as the 
applicability of these results to other racial/ethnic populations. The overall 
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message of this dissertation is that dairy consumption, especially yogurt, is a 
beneficial part of a healthy dietary pattern, and regular intake may reduce the 
necessity of pharmacologic HBP treatment. 
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APPENDIX 
Table A.1 The beneficial effects of high yogurt intake on incident HBP 
(sensitivity analysis) 
 NHS 
    Multivariable +BMI 
Yogurt Intake P-yrs Cases 
I /100K 
p-yrs HR1 95% CI HR2 95% CI 
<1/wk 905176 27012 2984 1.00 - 1.00 - 
1-<5/wk 413323 13892 3361 0.96 (0.94-0.98) 0.98 (0.96-1.00) 
≥5/wk 28333 680 2400 0.80 (0.74-0.87) 0.86 (0.80-0.93) 
P for linear trend5    <0.0001 <0.0001 
Per 1 s/d increase       0.80 (0.75-0.86) 0.87 (0.81-0.93) 
 NHS II 
    Multivariable +BMI 
Yogurt Intake P-yrs Cases 
I /100K 
p-yrs HR1 95% CI HR2 95% CI 
<1/wk 799690 15090 1887 1.00 - 1.00 - 
1-<5/wk 529542 10311 1947 0.92 (0.89-0.94) 0.95 (0.92-0.97) 
≥5/wk 47026 733 1559 0.85 (0.79-0.92) 0.90 (0.84-0.97) 
P for linear trend5    <0.0001 <0.0001 
Per 1 s/d increase      0.77 (0.71-0.83) 0.85 (0.79-0.92) 
 HPFS 
    Multivariable +BMI 
Yogurt Intake P-yrs Cases 
I /100K 
p-yrs HR1 95% CI HR2 95% CI 
<1/wk 372110 10870 2921 1.00 - 1.00 - 
1-<5/wk 107893 3062 2838 0.93 (0.90-0.97) 0.94 (0.90-0.98) 
≥5/wk 10123 258 2549 0.95 (0.84-1.08) 1.02 (0.90-1.15) 
P for linear trend5    0.0170 0.1733 
Per 1 s/d increase      0.86 (0.77-0.97) 0.92 (0.81-1.04) 
 META-ANALYSIS 
    Multivariable +BMI 
Yogurt Intake P-yrs Cases 
I /100K 
p-yrs HR1 95% CI HR2 95% CI 
<1/wk 2076976 52972 2550 1.00 - 1.00 - 
1-<5/wk 1050758 27265 2595 0.94 (0.93-0.96) 0.96 (0.95-0.98) 
≥5/wk 85482 1671 1955 0.85 (0.80-0.89) 0.90 (0.86-0.95) 
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P for linear trend4 <0.0001 <0.0001 
P for heterogeneity5 0.2907 0.5740 
I2 20.4 0.0 
Per 1 s/d increase 0.80 (0.76-0.84) 0.87 (0.83-0.91) 
1Adjusted for age, race, physical activity, energy intake, HBP family history, and intakes of FV, 
total protein, milk, and cheese  
2 Adjusted for age, race, physical activity, energy intake, HBP family history, and intakes of FV, 
total protein, milk, cheese, and BMI 
3Linear trend across yogurt intake categories was quantified with a Wald test for linear trend by 
assigning the median value to each category and modeling this variable as a continuous variable. 
4Test for between-study heterogeneity by using a fixed effects meta-analysis model 
 
Table A.2 Higher yogurt intake combined with higher DASH diet score is 
linked with a lower risk of incident HBP 
 NHS 
    Multivariable +BMI 
Yogurt + DASH 
score tertiles P-yrs Cases 
I /100K 
p-yrs HR1 95% CI HR2 95% CI 
<1/wk+T1 321204 10251 3191 1.00 - 1.00 - 
<1/wk+T2 376295 10587 2813 0.94 (0.91-0.97) 0.96 (0.93-0.99) 
<1/wk+T3 207677 6174 2973 0.86 (0.83-0.89) 0.91 (0.88-0.94) 
1-<5/wk+T1 76999 2821 3664 1.00 (0.96-1.04) 1.01 (0.97-1.05) 
1-<5/wk+T2 150923 4865 3223 0.90 (0.87-0.93) 0.92 (0.89-0.96) 
1-<5/wk+T3 185402 6206 3347 0.84 (0.81-0.87) 0.90 (0.87-0.93) 
≥5/wk+T1 2787 84 3014 0.94 (0.76-1.16) 1.01 (0.82-1.26) 
≥5/wk+T2 10224 225 2201 0.78 (0.68-0.89) 0.84 (0.73-0.96) 
≥5/wk+T3 15323 371 2421 0.68 (0.61-0.75) 0.76 (0.69-0.85) 
 NHS II 
    Multivariable +BMI 
Yogurt + DASH 
score tertiles P-yrs Cases 
I /100K 
p-yrs HR1 95% CI HR2 95% CI 
<1/wk+T1 341608 7244 2121 1.00 - 1.00 - 
<1/wk+T2 269405 5074 1883 0.91 (0.88-0.94) 0.97 (0.94-1.01) 
<1/wk+T3 188677 2772 1469 0.71 (0.68-0.74) 0.81 (0.77-0.84) 
1-<5/wk+T1 103617 2353 2271 0.93 (0.89-0.98) 0.95 (0.91-1.00) 
1-<5/wk+T2 182891 3787 2071 0.85 (0.82-0.88) 0.92 (0.88-0.96) 
1-<5/wk+T3 243034 4171 1716 0.71 (0.68-0.74) 0.82 (0.78-0.85) 
≥5/wk+T1 4463 78 1748 0.85 (0.68-1.06) 0.91 (0.73-1.13) 
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≥5/wk+T2 11818 200 1692 0.78 (0.68-0.90) 0.84 (0.73-0.97) 
≥5/wk+T3 30745 455 1480 0.69 (0.62-0.76) 0.81 (0.74-0.89) 
 HPFS 
    Multivariable +BMI 
Yogurt + DASH 
score tertiles P-yrs Cases 
I /100K 
p-yrs HR1 95% CI HR2 95% CI 
<1/wk+T1 144259 4463 3094 1.00 - 1.00 - 
<1/wk+T2 124348 3595 2891 0.89 (0.85-0.93) 0.91 (0.87-0.95) 
<1/wk+T3 103503 2812 2717 0.82 (0.78-0.86) 0.87 (0.83-0.92) 
1-<5/wk+T1 18735 571 3048 0.93 (0.85-1.02) 0.92 (0.85-1.01) 
1-<5/wk+T2 36432 1071 2940 0.87 (0.81-0.92) 0.88 (0.82-0.94) 
1-<5/wk+T3 52726 1420 2693 0.77 (0.73-0.82) 0.83 (0.78-0.88) 
≥5/wk+T1 1063 38 3576 1.17 (0.85-1.61) 1.24 (0.90-1.70) 
≥5/wk+T2 2500 65 2600 0.89 (0.69-1.13) 0.95 (0.74-1.21) 
≥5/wk+T3 6560 155 2363 0.75 (0.64-0.89) 0.85 (0.72-1.00) 
 META-ANALYSIS 
    Multivariable +BMI 
Yogurt + DASH 
score tertiles P-yrs Cases 
I /100K 
p-yrs HR1 95% CI HR2 95% CI 
<1/wk+T1 807071 21958 2721 1.00 -   1.00 -   
<1/wk+T2 770048 19256 2501 0.92 (0.92-0.94) 0.95 (0.93-0.97) 
<1/wk+T3 499857 11758 2352 0.81 (0.79-0.83) 0.87 (0.85-0.89) 
1-<5/wk+T1 199351 5745 2882 0.96 (0.94-0.99) 0.98 (0.95-1.00) 
1-<5/wk+T2 370246 9723 2626 0.88 (0.86-0.90) 0.92 (0.89-0.94) 
1-<5/wk+T3 481162 11797 2452 0.78 (0.76-0.80) 0.86 (0.84-0.88) 
≥5/wk+T1 8313 200 2406 0.94 (0.82-1.08) 1.01 (0.88-1.16) 
≥5/wk+T2 24542 490 1997 0.79 (0.72-0.87) 0.85 (0.78-0.93) 
≥5/wk+T3 52628 981 1864 0.69 (0.65-0.74) 0.80 (0.75-0.85) 
P for heterogeneity4 <0.0001-0.6262 <0.0001-0.6693 
I2 0-96.2 0-89.8 
1Adjusted for age, race, physical activity, total protein, energy, HBP family history 
2Adjusted for age, race, physical activity, total protein, energy, HBP family history, and BMI 
3Test for between-study heterogeneity by using a fixed effects model 
 
Table A.3 BMI has a greater effect on HBP risk than yogurt  
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 NHS 
    Multivariable 
Yogurt Intake+ BMI P-yrs Cases 
I /100K  
p-yrs HR1 95% CI 
<1/wk + BMI≥30 103217 5861 5678 1.00 - 
<1/wk + BMI: 25-<30 247660 9494 3833 0.68 (0.66-0.70) 
<1/wk + BMI<25 554299 11657 2103 0.41 (0.40-0.43) 
1-<5/wk + BMI≥30 47582 2971 6244 0.97 (0.93-1.01) 
1-<5/wk + BMI: 25-<30 120436 5059 4201 0.66 (0.63-0.68) 
1-<5/wk + BMI<25 245305 5862 2390 0.41 (0.39-0.42) 
≥5/wk + BMI≥30 2106 103 4891 0.85 (0.70-1.03) 
≥5/wk + BMI: 25-<30 6502 236 3630 0.64 (0.56-0.73) 
≥5/wk + BMI<25 19725 341 1729 0.34 (0.30-0.38) 
 NHS II 
    Multivariable 
Yogurt Intake+ BMI P-yrs HBP Cases 
I /100K  
p-yrs HR1 95% CI 
<1/wk + BMI≥30 133516 5909 4426 1.00 - 
<1/wk + BMI: 25-<30 199728 4748 2377 0.56 (0.54-0.58) 
<1/wk + BMI<25 466445 4433 950 0.26 (0.25-0.27) 
1-<5/wk + BMI≥30 83322 3877 4653 0.97 (0.93-1.01) 
1-<5/wk + BMI: 25-<30 140712 3281 2332 0.50 (0.48-0.53) 
1-<5/wk + BMI<25 305508 3153 1032 0.25 (0.24-0.26) 
≥5/wk + BMI≥30 6420 284 4424 1.03 (0.91-1.16) 
≥5/wk + BMI: 25-<30 11572 208 1797 0.45 (0.39-0.51) 
≥5/wk + BMI<25 29034 241 830 0.23 (0.20-0.27) 
 HPFS 
    Multivariable 
Yogurt Intake+ BMI P-yrs Cases 
I /100K  
p-yrs HR1 95% CI 
<1/wk + BMI≥30 24786 1240 5003 1.00 - 
<1/wk + BMI: 25-<30 144034 4852 3369 0.70 (0.66-0.74) 
<1/wk + BMI<25 203291 4778 2350 0.50 (0.47-0.54) 
1-<5/wk + BMI≥30 7137 356 4988 0.95 (0.85-1.07) 
1-<5/wk + BMI: 25-<30 39782 1307 3285 0.65 (0.60-0.71) 
1-<5/wk + BMI<25 60974 1399 2294 0.47 (0.44-0.51) 
≥5/wk + BMI≥30 361 23 6367 1.36 (0.90-2.05) 
≥5/wk + BMI: 25-<30 2883 85 2948 0.65 (0.52-0.81) 
≥5/wk + BMI<25 6878 150 2181 0.51 (0.43-0.60) 
1Adjusted for age, race, physical activity, energy, HBP family history, intakes of total protein, 
fruits and vegetables, milk, and cheese 
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Table A.4 High milk intake is associated with a lower risk of HBP 
 NHS 
    Multivariable +BMI 
Milk Intake P-yrs Cases 
I /100K  
p-yrs HR1 95% CI HR2 95% CI 
<4/wk 603863 17991 2979 1.00 - 1.00 - 
4/wk-<1/d 238967 8290 3469 1.00 (0.97-1.03) 1.00 (0.97-1.02) 
1-<2/d 334198 10355 3098 0.97 (0.95-1.00) 0.97 (0.95-1.00) 
2-<6/d 169805 4948 2914 0.93 (0.90-0.96) 0.96 (0.93-0.99) 
P for linear trend4    <0.0001 0.0054 
Per 1 s/d increase     0.97 (0.95-0.98) 0.98 (0.97-0.99) 
 NHS II 
    Multivariable +BMI 
Milk Intake P-yrs Cases 
I /100K  
p-yrs HR1 95% CI HR2 95% CI 
<4/wk 528292 10761 2037 1.00 - 1.00 - 
4/wk-<1/d 258533 5365 2075 0.95 (0.91-0.98) 0.95 (0.92-0.98) 
1-<2/d 348874 6405 1836 0.92 (0.89-0.95) 0.95 (0.92-0.98) 
2-<6/d 240559 3603 1498 0.80 (0.77-0.84) 0.88 (0.84-0.91) 
P for linear trend4    <0.0001 <0.0001 
Per 1 s/d increase     0.91 (0.89-0.92) 0.94 (0.93-0.96) 
 HPFS 
    Multivariable +BMI 
Milk Intake P-yrs Cases 
I /100K  
p-yrs HR1 95% CI HR2 95% CI 
<4/wk 232664 6855 2946 1.00 - 1.00 - 
4/wk-<1/d 89061 2769 3109 0.96 (0.92-1.01) 0.97 (0.92-1.01) 
1-<2/d 97879 2709 2768 0.92 (0.88-0.96) 0.93 (0.89-0.98) 
2-<6/d 70522 1857 2633 0.87 (0.82-0.92) 0.89 (0.84-0.94) 
P for linear trend4    <0.0001 <0.0001 
Per 1 s/d increase     0.94 (0.92-0.96) 0.95 (0.93-0.97) 
 META-ANALYSIS 
    Multivariable +BMI 
Milk Intake P-yrs Cases 
I /100K  
p-yrs HR1 95% CI HR2 95% CI 
<4/wk 1364819 35607 2609 1.00 - 1.00 - 
4/wk-<1/d 586561 16424 2800 0.98 (0.96-0.99) 0.98 (0.96-1.00) 
1-<2/d 780951 19469 2493 0.95 (0.93-0.96) 0.96 (0.94-0.98) 
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2-<6/d 480886 10408 2164 0.87 (0.85-0.89) 0.92 (0.90-0.94) 
P for linear trend4 <0.0001 <0.0001 
P for heterogeneity5 <0.0001 0.0024 
I2 93.9 84.3 
Per 1 s/d increase       0.94 (0.93-0.95) 0.96 (0.95-0.97) 
1Adjusted for age, race, physical activity, energy intake, HBP family history, and intakes of FV, 
total protein, yogurt, and cheese 
2Adjusted for age, race, physical activity, energy intake, HBP family history, and intakes of FV, 
total protein, yogurt, and cheese, BMI 
3Linear trend across milk intake categories was quantified with a Wald test for linear trend by 
assigning the median value to each category and modeling this variable as a continuous variable  
4Test for between-study heterogeneity by using a fixed effects model 
 
Table A.5 Increased cheese consumption is inversely associated with risk of 
HBP in women 
 NHS 
    Multivariable +BMI 
Cheese Intake P-yrs Cases 
I /100K 
p-yrs HR1 95% CI HR2 95% CI 
<1/week 555905 14218 2558 1.00 - 1.00 - 
1-4/week 670158 23229 3466 0.98 (0.96-1.01) 0.97 (0.95-1.00) 
5/week-<1/d 94484 3310 3503 0.95 (0.91-0.99) 0.93 (0.89-0.97) 
1-4/d 26285 827 3146 0.89 (0.83-0.96) 0.89 (0.83-0.96) 
P for linear trend4    0.0003 <0.0001 
Per 1 s/d increase     0.92 (0.87-0.96) 0.90 (0.86-0.94) 
 NHS II 
    Multivariable +BMI 
Cheese Intake P-yrs Cases 
I /100K 
p-yrs HR1 95% CI HR2 95% CI 
<1/week 236141 4777 2023 1.00 - 1.00 -   
1-4/week 808058 15515 1920 0.98 (0.95-1.01) 0.96 (0.93-1.00) 
5/week-<1/d 234890 4400 1873 0.95 (0.91-1.00) 0.93 (0.89-0.98) 
1-4/d 97169 1442 1484 0.86 (0.81-0.91) 0.85 (0.79-0.90) 
P for linear trend3    <0.0001 <0.0001 
Per 1 s/d increase     0.88 (0.84-0.93) 0.87 (0.83-0.92) 
 HPFS 
    Multivariable +BMI 
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Cheese Intake P-yrs Cases 
I /100K 
p-yrs HR1 95% CI HR2 95% CI 
<1/week 128030 3534 2760 1.00 - 1.00 - 
1-4/week 267813 7912 2954 1.02 (0.97-1.06) 0.98 (0.94-1.02) 
5/week-<1/d 66819 1962 2936 1.01 (0.95-1.07) 0.95 (0.89-1.00) 
1-4/d 27464 782 2847 1.08 (0.99-1.17) 1.00 (0.92-1.09) 
P for linear trend3    0.1557 0.3415 
Per 1 s/d increase     1.05 (0.98-1.12) 0.97 (0.90-1.04) 
 META-ANALYSIS 
    Multivariable +BMI 
Cheese Intake P-yrs Cases 
I /100K 
p-yrs HR1 95% CI HR2 95% CI 
<1/week 920076 22529 2449 1.00 - 1.00 -   
1-4/week 1746029 46656 2672 0.99 (0.97-1.01) 0.97 (0.95-0.99) 
5/week-<1/d 396193 9672 2441 0.96 (0.94-0.99) 0.94 (0.91-0.96) 
1-4/d 150918 3051 2022 0.92 (0.88-0.96) 0.90 (0.86-0.93) 
P for linear trend3 <0.0001 <0.0001 
P for heterogeneity4 0.0003 0.0552 
I2 88.1 66.3 
Per 1 s/d increase       0.93 (0.90-0.96) 0.90 (0.88-0.93) 
1Adjusted for age, race, physical activity, energy intake, HBP family history, and intakes of FV, 
total protein, yogurt, and milk 
2Adjusted for age, race, physical activity, energy intake, HBP family history, and intakes of FV, 
total protein, yogurt, and milk, BMI 
3Linear trend across cheese intake categories was quantified with a Wald test for linear trend by 
assigning the median value to each category and modeling this variable as a continuous variable  
4Test for between-study heterogeneity by using a fixed effects model 
 
 
Table A.6 Low-fat dairy intake is linked with lower risks of HBP in NHS II 
and HPFS 
 NHS 
    Multivariable +BMI 
Low-fat dairy 
intake (s/d) P-yrs Cases 
I /100K 
p-yrs HR1 95% CI HR2 95% CI 
<0.5 554021 15605 2817 1.00 - 1.00 - 
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0.5-<1.5 538999 17604 3266 1.00 (0.98-1.02) 0.99 (0.97-1.02) 
1.5-<2.5 151434 5417 3577 0.97 (0.96-0.98) 0.97 (0.96-0.99) 
2.5-<6 102378 2958 2889 1.00 (0.95-1.05) 1.03 (0.98-1.09) 
P for linear trend4    <0.0001 0.0004 
Per 1 s/d increase      0.96 (0.95-0.98) 0.97 (0.96-0.99) 
 NHS II 
    Multivariable +BMI 
Low-fat dairy 
intake (s/d) P-yrs Cases 
I /100K 
p-yrs HR1 95% CI HR2 95% CI 
<0.5 345352 6882 1993 1.00 - 1.00 - 
0.5-<1.5 602083 11735 1949 0.93 (0.90-0.96) 0.95 (0.92-0.98) 
1.5-<2.5 212301 4444 2093 0.89 (0.85-0.92) 0.93 (0.90-0.97) 
2.5-<6 216522 3073 1419 0.76 (0.72-0.79) 0.83 (0.80-0.87) 
P for linear trend4    <0.0001 <0.0001 
Per 1 s/d increase      0.91 (0.89-0.92) 0.94 (0.92-0.95) 
 HPFS 
    Multivariable +BMI 
Low-fat dairy 
intake (s/d) P-yrs Cases 
I /100K 
p-yrs HR1 95% CI HR2 95% CI 
<0.5 191325 5509 2879 1.00 - 1.00 - 
0.5-<1.5 196755 5789 2942 0.95 (0.91-0.98) 0.95 (0.91-0.98) 
1.5-<2.5 47413 1517 3200 0.91 (0.86-0.96) 0.92 (0.87-0.98) 
2.5-<6 54633 1375 2517 0.85 (0.80-0.91) 0.87 (0.81-0.92) 
P for linear trend4    <0.0001 <0.0001 
Per 1 s/d increase      0.94 (0.92-0.96) 0.95 (0.93-0.97) 
 META-ANALYSIS 
    Multivariable +BMI 
Low-fat dairy 
intake (s/d)1 P-yrs Cases 
I /100K 
py HR1 95% CI HR2 95% CI 
<0.5 1090698 27996 2567 1.00 - 1.00 - 
0.5-<1.5 1337837 35128 2626 0.97 (0.96-0.99) 0.97 (0.96-0.99) 
1.5-<2.5 411148 11378 2767 0.96 (0.95-0.97) 0.97 (0.95-0.98) 
2.5-<6 373533 7406 1983 0.86 (0.83-0.88) 0.91 (0.88-0.96) 
P for linear trend3 <0.0001 <0.0001 
P for heterogeneity4 <0.0001 0.0034 
I2 94.0 83.2 
Per 1 s/d increase       0.94 (0.93-0.95) 0.96 (0.95-0.97) 
1Adjusted for age, race, physical activity, energy intake, HBP family history, and intakes of FV, 
total protein, and high-fat dairy    
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2Adjusted for age, race, physical activity, energy intake, HBP family history, intakes of FV, total 
protein, and high-fat dairy, BMI   
3Linear trend across low-fat dairy categories was quantified with a Wald test for linear trend by 
assigning the median value to each category and modeling this variable as a continuous variable  
4Test for between-study heterogeneity by using a fixed effects model 
 
Table A.7 High-fat dairy consumption is inversely associated with risk of HBP 
in NHS and NHS II 
 NHS 
    Multivariable +BMI 
High-fat Dairy 
intake P-yrs Cases 
I /100K 
p-yrs HR1 95% CI HR2 95% CI 
<0.5 885924 27422 3095 1.00 - 1.00 - 
0.5-<1.5 399668 12552 3141 0.97 (0.95-0.99) 0.97 (0.94-0.99) 
1.5-<6 61241 1610 2629 0.90 (0.85-0.95) 0.92 (0.87-0.97) 
P for linear trend3    <0.0001 <0.0001 
Per 1 s/d increase      0.95 (0.92-0.97) 0.95 (0.92-0.97) 
 NHS II 
    Multivariable +BMI 
High-fat dairy 
intake P-yrs Cases 
I /100K 
p-yrs HR1 95% CI HR2 95% CI 
<0.5 900424 17829 1980 1.00 - 1.00 - 
0.5-<1.5 432059 7647 1770 0.95 (0.92-0.97) 0.94 (0.91-0.97) 
1.5-<6 43775 658 1503 0.87 (0.80-0.94) 0.88 (0.81-0.95) 
P for linear trend3    <0.0001 <0.0001 
Per 1 s/d increase      0.91 (0.88-0.95) 0.91 (0.88-0.95) 
 HPFS 
    Multivariable +BMI 
High-fat dairy 
intake P-yrs Cases 
I /100K 
p-yrs HR1 95% CI HR2 95% CI 
<0.5 313244 9236 2949 1.00 - 1.00 - 
0.5-<1.5 153357 4304 2807 0.99 (0.96-1.03) 0.96 (0.93-1.00) 
1.5-<6 23525 650 2763 0.99 (0.91-1.07) 0.97 (0.89-1.05) 
P for linear trend4    0.7220 0.2001 
Per 1 s/d increase       0.99 (0.95-1.03) 0.97 (0.94-1.01) 
 META-ANALYSIS 
    Multivariable +BMI 
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High-fat dairy 
intake P-yrs Cases 
I /100K 
p-yrs HR1 95% CI HR2 95% CI 
<0.5 2099592 54487 2595 1.00 - 1.00 - 
0.5-<1.5 985084 24503 2487 0.97 (0.95-0.98) 0.96 (0.94-0.97) 
1.5-<6 128541 2918 2270 0.91 (0.87-0.94) 0.92 (0.88-0.96) 
P for linear trend3 <0.0001 <0.0001 
P for heterogeneity4 0.0095 0.0606 
I2 80.0 66.4 
Per 1 s/d increase       0.95 (0.93-0.97) 0.95 (0.93-0.96) 
1Adjusted for age, race, physical activity, FV, total protein, energy intake, low-fat dairy, HBP 
family history 
2Adjusted for age, race, physical activity, FV, total protein, energy intake, low-fat dairy, HBP 
family history, BMI 
3Linear trend across high-fat dairy intake categories was quantified with a Wald test for linear 
trend by assigning the median value to each category and modeling it as a continuous variable  
4Test for between-study heterogeneity by using a fixed effects model  
            
Table A.8 Higher DASH diet scores modifies the beneficial effect of total dairy 
intake on incident risk of HBP 
 NHS 
    Multivariable +BMI 
Total Dairy + DASH 
score tertiles1 P-yrs Cases 
I /100K 
p-yrs HR2 95% CI HR3 95% CI 
<1.5/d + T1 275267 9051 3288 1.00 - 1.00 - 
<1.5/d + T2 368640 10376 2815 0.92 (0.89-0.95) 0.95 (0.92-0.97) 
<1.5/d + T3 227815 6785 2978 0.83 (0.81-0.86) 0.88 (0.85-0.91) 
1.5-<3/d + T1 103700 3527 3401 0.94 (0.90-0.98) 0.94 (0.90-0.98) 
1.5-<3/d + T2 148257 4645 3133 0.87 (0.83-0.90) 0.89 (0.86-0.92) 
1.5-<3/d + T3 141985 4641 3269 0.80 (0.77-0.83) 0.85 (0.82-0.89) 
≥3/d + T1 19702 652 3309 0.91 (0.84-0.99) 0.93 (0.86-1.01) 
≥3/d + T2 30522 932 3054 0.86 (0.80-0.92) 0.92 (0.85-0.98) 
≥3/d + T3 30945 975 3151 0.75 (0.70-0.81) 0.84 (0.78-0.90) 
 NHS II 
    Multivariable +BMI 
Total Dairy Intake+ 
DASH score1 P-yrs Cases 
I /100K  
p-yrs HR2 95% CI HR3 95% CI 
<1.5/d + T1 215537 4894 2271 1.00 - 1.00 - 
<1.5/d + T2 332267 6498 1956 0.94 (0.90-0.98) 1.01 (0.97-1.05) 
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<1.5/d + T3 147822 2705 1830 0.77 (0.73-0.80) 0.88 (0.84-0.92) 
1.5-<3/d + T1 107107 2351 2195 0.94 (0.89-0.98) 0.97 (0.92-1.02) 
1.5-<3/d + T2 241556 4446 1841 0.87 (0.83-0.91) 0.95 (0.91-0.99) 
1.5-<3/d + T3 144826 2583 1784 0.71 (0.67-0.74) 0.83 (0.79-0.87) 
≥3/d + T1 36253 566 1561 0.77 (0.71-0.84) 0.83 (0.76-0.91) 
≥3/d + T2 92882 1331 1433 0.75 (0.70-0.80) 0.86 (0.80-0.92) 
≥3/d + T3 58008 760 1310 0.59 (0.54-0.63) 0.72 (0.67-0.78) 
 HPFS 
    Multivariable +BMI 
Total Dairy Intake+ 
DASH score1 P-yrs Cases 
I /100K  
p-yrs HR2 95% CI HR3 95% CI 
<1.5/d + T1 104074 3236 3109 1.00 - 1.00 - 
<1.5/d + T2 101450 3118 3073 0.94 (0.90-0.99) 0.96 (0.92-1.01) 
<1.5/d + T3 101501 2712 2672 0.81 (0.77-0.86) 0.87 (0.82-0.92) 
1.5-<3/d + T1 39299 1195 3041 0.93 (0.87-1.00) 0.94 (0.87-1.00) 
1.5-<3/d + T2 45988 1306 2840 0.84 (0.78-0.89) 0.86 (0.80-0.91) 
1.5-<3/d + T3 48303 1262 2613 0.76 (0.71-0.81) 0.82 (0.76-0.87) 
≥3/d + T1 16039 485 3024 0.97 (0.88-1.07) 0.96 (0.87-1.06) 
≥3/d + T2 16155 442 2736 0.85 (0.77-0.94) 0.87 (0.79-0.97) 
≥3/d + T3 17317 434 2506 0.76 (0.69-0.84) 0.82 (0.74-0.91) 
 META-ANALYSIS 
    Multivariable +BMI 
Total Dairy Intake+ 
DASH score1 P-yrs Cases 
I /100K  
p-yrs HR2 95% CI HR3 95% CI 
<1.5/d + T1 594878 17181 2888 1.00 -   1.00 -   
<1.5/d + T2 802357 19992 2492 0.93 (0.91-0.95) 0.97 (0.95-0.99) 
<1.5/d + T3 477138 12202 2557 0.81 (0.79-0.83) 0.88 (0.86-0.90) 
1.5-<3/d + T1 250106 7073 2828 0.94 (0.91-0.96) 0.95 (0.92-0.97) 
1.5-<3/d + T2 435801 10397 2386 0.86 (0.84-0.88) 0.90 (0.88-0.93) 
1.5-<3/d + T3 335114 8486 2532 0.76 (0.74-0.78) 0.84 (0.81-0.86) 
≥3/d + T1 71994 1703 2365 0.88 (0.83-0.92) 0.90 (0.86-0.95) 
≥3/d + T2 139559 2705 1938 0.81 (0.77-0.84) 0.88 (0.85-0.92) 
≥3/d + T3 106270 2169 2041 0.77 (0.73-0.80) 0.79 (0.76-0.83) 
P for heterogeneity4 <0.0001-0.9966 <0.0001-0.9335 
I2 0-87.3 0-76.8 
1Adjusted for age, race, physical activity, total protein, energy intake, HBP family history 
2Adjusted for age, race, physical activity, total protein, energy intake, HBP family history, BMI  
3Test for between-study heterogeneity by using a fixed effects model 
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Table A.9 Higher yogurt intake is linked with lower CHD risk in women and 
men 
NHS 
    Multivariable No Diet Update 
Yogurt Intake P-yrs 
CHD 
Cases 
I /100K 
p-yrs HR3 95% CI HR5 95% CI 
            
<1/mo 338759 1052 311 1.00 - 1.00 - 
1/mo-<1/wk 156811 366 233 0.85 (0.75-0.96) 0.85 (0.75-0.96) 
1-<2/wk 136193 284 209 0.79 (0.69-0.90) 0.83 (0.72-0.94) 
≥2/wk 131244 244 186 0.74 (0.64-0.86) 0.76 (0.66-0.88) 
P for linear trend4    <0.0001 0.0003 
Per one serving/day     0.49 (0.35-0.70) 0.53 (0.37-0.75) 
HPFS 
    Multivariable No Diet Update 
Yogurt Intake P-yrs 
CHD 
Cases 
I /100K 
p-yrs HR3 95% CI HR5 95% CI 
            
<1/mo 119120 794 667 1.00 - 1.00 - 
1/mo-<1/wk 40850 221 541 0.94 (0.80-1.09) 0.92 (0.79-1.07) 
1-<2/wk 27612 145 525 0.89 (0.74-1.07) 0.90 (0.75-1.07) 
≥2/wk 21553 107 496 0.82 (0.66-1.01) 0.84 (0.68-1.04) 
P for linear trend4    0.0439 0.0815 
Per one serving/day     0.61 (0.37-0.99) 0.65 (0.41-1.05) 
 
 
1Adjusted for age, race, smoking, energy intake, family history of MI, physical activity, BMI, anti-
hypertensive medication use, and intakes of alcohol, trans fat, fiber, milk and cheese 
2Diet was not updated upon report of CABG, angina, or high cholesterol     
3Linear trend across yogurt intake categories was quantified with a Wald test for linear trend 
by assigning the median value to each category and modeling this variable as a continuous 
variable  
 
Table A.10 Increased yogurt intake is associated with lower risk of stroke in 
women and men 
NHS 
    Multivariable No Diet Update 
Yogurt Intake P-yrs 
Stroke 
Cases 
I /100K 
p-yrs HR1 95% CI HR2 95% CI 
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<1/mo 338825 823 243 1.00 - 1.00 - 
1/mo-<1/wk 156784 332 212 0.98 (0.86-1.11) 0.97 (0.85-1.10) 
1-<2/wk 136169 277 203 0.91 (0.79-1.05) 0.92 (0.80-1.05) 
≥2/wk 131215 253 193 0.94 (0.81-1.09) 0.92 (0.79-1.07) 
P for linear trend3    0.3707 0.2450 
Per one serving/day     0.85 (0.60-1.21) 0.81 (0.57-1.15) 
HPFS 
    Multivariable No Diet Update 
Yogurt Intake P-yrs 
Stroke 
Cases 
I /100K 
p-yrs HR1 95% CI HR2 95% CI 
            
<1/mo 119242 349 293 1.00 - 1.00 - 
1/mo-<1/wk 40927 88 215 0.88 (0.69-1.12) 0.84 (0.66-1.07) 
1-<2/wk 27654 41 148 0.59 (0.43-0.83) 0.71 (0.53-0.96) 
≥2/wk 21581 45 209 0.81 (0.59-1.12) 0.81 (0.59-1.12) 
P for linear trend3    0.0760 0.1085 
Per one serving/day     0.49 (0.22-1.08) 0.53 (0.24-1.15) 
1Adjusted for age, race, smoking, energy, family history of MI, physical activity, BMI, anti-
hypertensive medication use, and intakes of alcohol, trans fat, fiber, milk and cheese 
2Diet was not updated upon report of CABG, angina, or high cholesterol     
3Linear trend across yogurt intake categories was quantified with a Wald test for linear trend by 
assigning the median value to each category and modeling this variable as a continuous variable  
 
Table A.11 Higher yogurt combined with a higher DASH diet score is linked 
with a lower risk of CHD in women and men 
 NHS 
    Multivariable No Diet Update 
Yogurt, DASH score P-yrs 
CHD 
Cases 
I /100K 
p-yrs HR1 95% CI HR2 95% CI 
            
<2/wk, <25 392084 1067 272 1.00 - 1.00 - 
<2/wk, ≥25 239680 635 265 0.90 (0.81-1.00) 0.87 (0.78-0.96) 
≥2/wk, <25 54880 95 173 0.75 (0.61-0.93) 0.78 (0.63-0.96) 
≥2/wk, ≥25 76364 149 195 0.77 (0.65-0.93) 0.75 (0.62-0.90) 
            
 HPFS 
    Multivariable No Diet Update 
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Yogurt, DASH score P-yrs 
CHD 
Cases 
I /100K 
p-yrs HR1 95% CI HR2 95% CI 
            
<1/wk, <25 105527 643 609 1.00 - 1.00 - 
<1/wk, ≥25 64231 389 606 0.87 (0.76-1.00) 0.90 (0.78-1.03) 
≥1/wk, <25 16500 115 697 1.13 (0.92-1.38) 1.13 (0.93-1.37) 
≥1/wk, ≥25 25796 147 570 0.79 (0.65-0.96) 0.79 (0.65-0.96) 
1Adjusted for age, race, smoking energy, family history of MI, physical activity, anti-hypertensive 
medication use, and intakes of alcohol and trans fat 
2Diet was not updated upon report of CABG, angina, or high cholesterol 
Table A.12 Higher yogurt intake combined with a higher DASH score is 
associated with a lower risk of stroke in women and men 
NHS 
    Multivariable No Diet Update 
Yogurt, DASH score P-yrs 
STR 
Cases 
I /100K 
p-yrs HR1 95% CI HR2 95% CI 
            
<2/wk, <25 392086 886 226 1.00 - 1.00 - 
<2/wk, ≥25 239692 546 228 0.91 (0.81-1.03) 0.89 (0.79-1.00) 
≥2/wk, <25 54846 111 202 1.02 (0.83-1.24) 0.99 (0.81-1.21) 
≥2/wk, ≥25 76369 142 186 0.84 (0.70-1.02) 0.81 (0.67-0.98) 
HPFS 
    Multivariable No Diet Update 
Yogurt, DASH score 
P-yrs 
STR 
Cases 
I /100K 
p-yrs HR1 95% CI HR2 95% CI 
            
<1/wk, <25 105651 265 251 1.00 - 1.00 - 
<1/wk, ≥25 64324 165 257 0.85 (0.69-1.05) 0.84 (0.68-1.04) 
≥1/wk, <25 16532 40 242 0.93 (0.67-1.31) 0.93 (0.67-1.30) 
≥1/wk, ≥25 25817 63 244 0.77 (0.58-1.04) 0.81 (0.61-1.08) 
1Adjusted for age, race, smoking energy, family history of MI, physical activity, anti-hypertensive 
medication use, and intakes of alcohol and trans fat 
2Diet was not updated upon report of CABG, angina, or high cholesterol 
 
Table A.13 Increased milk consumption is linked with a higher risk of CHD in 
women but a lower risk of CHD in men 
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NHS 
    Multivariable No Diet Update 
Milk Intake P-yrs 
CHD 
Cases 
I /100K 
p-yrs HR1 95% CI HR2 95% CI 
<0.5/d 296355 700 236 1.00 - 1.00 - 
0.5-<2/d 363260 942 259 1.10 (1.00-1.22) 1.09 (0.98-1.21) 
2-<5/d 103393 304 294 1.23 (1.06-1.42) 1.19 (1.03-1.38) 
P for linear trend3    0.0045 0.0152 
Per one serving/day       1.09 (1.03-1.16) 1.08 (1.01-1.15) 
HPFS 
    Multivariable No Diet Update 
Milk Intake P-yrs 
CHD 
Cases 
I /100K 
p-yrs HR1 95% CI HR2 95% CI 
<0.5/d 92010 554 602 1.00 - 1.00 - 
0.5-<2/d 87682 548 625 0.97 (0.86-1.10) 0.96 (0.85-1.08) 
2-<5/d 29443 165 560 0.76 (0.63-0.91) 0.78 (0.65-0.93) 
P for linear trend3    0.0044 0.0088 
Per one serving/day       0.90 (0.83-0.97) 0.90 (0.84-0.97) 
1Adjusted for age, race, smoking, energy, family history of MI, physical activity, BMI, anti-
hypertensive medication use, and intakes of alcohol, trans fat, fiber, yogurt and cheese  
2Diet was not updated upon report of CABG, angina, or high cholesterol     
3Linear trend across milk intake categories was quantified with a Wald test for linear trend by 
assigning the median value to each category and modeling this variable as a continuous variable 
 
Table A.14 Higher milk intake is not associated with risk of stroke 
 
 NHS     
    Multivariable No Diet Update 
Milk Intake P-yrs 
Stroke 
Cases 
I /100K 
p-yrs HR1 95% CI HR2 95% CI 
<0.5/d 296343 637 215 1.00 - 1.00 - 
0.5-<2/d 363239 821 226 0.99 (0.89-1.10) 0.99 (0.88-1.10) 
2-<5/d 103410 227 220 0.96 (0.81-1.13) 0.95 (0.80-1.11) 
P for linear trend3    0.6076 0.5090 
Per one serving/day       0.98 (0.92-1.05) 0.98 (0.91-1.05) 
 HPFS     
    Multivariable No Diet Update 
Milk Intake P-yrs 
Stroke 
Cases 
I /100K 
p-yrs HR1 95% CI HR2 95% CI 
<0.5/d 92140 229 249 1.00 - 1.00 - 
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0.5-<2/d 87814 205 233 0.87 (0.71-1.05) 0.88 (0.73-1.07) 
2-<5/d 29450 89 302 1.06 (0.82-1.38) 1.07 (0.82-1.39) 
P for linear trend3    0.8248 0.7437 
Per one serving/day       1.01 (0.90-1.14) 1.02 (0.91-1.14) 
1Adjusted for age, race, smoking, energy, family history of MI, physical activity, BMI, anti-
hypertensive medication use, and intakes of alcohol, trans fat, fiber, yogurt and cheese  
2Diet was not updated upon report of CABG, angina, or high cholesterol    
3Linear trend across milk intake categories was quantified with a Wald test for linear trend by 
assigning the median value to each category and modeling this variable as a continuous variable 
 
Table A.15 Higher milk consumption combined with a high DASH diet score 
is associated with a lower risk of CHD in men 
 NHS     
    Multivariable No Diet Update 
Milk Intake + DASH 
score1 P-yrs 
CHD 
Cases 
I /100K 
p-yrs HR2 95% CI HR3 95% CI 
            
Milk<1/d+DASH<22 294827 725 246 1.00 - 1.00 - 
Milk<1/d+DASH≥22 172085 400 232 0.93 (0.82-1.06) 0.92 (0.81-1.05) 
Milk:1-<5/d+DASH<22 161983 462 285 1.13 (1.00-1.28) 1.15 (1.02-1.30) 
Milk:1-<5/d+DASH≥22 134113 359 268 1.06 (0.92-1.22) 1.01 (0.88-1.16) 
  1946          
 HPFS     
    Multivariable No Diet Update 
Milk Intake + DASH 
score1 P-yrs 
CHD 
Cases 
I /100K 
p-yrs HR2 95% CI HR3 95% CI 
            
Milk<1/d+DASH<22 79848 508 636 1.00 - 1.00 - 
Milk<1/d+DASH≥22 55358 329 594 0.84 (0.72-0.98) 0.82 (0.71-0.96) 
Milk:1-<5/d+DASH<22 41510 234 564 0.81 (0.69-0.95) 0.80 (0.69-0.94) 
Milk:1-<5/d+DASH≥22 32419 196 605 0.78 (0.65-0.94) 0.78 (0.65-0.93) 
1Adjusted for age, race, smoking energy, family history of MI, physical activity, anti-hypertensive 
medication use, and intakes of alcohol, yogurt, cheese, and trans fat 
2Diet not updated upon report of CABG, angina, or high cholesterol  
Table A.16 Higher milk intake with a high DASH diet score is linked with a 
lower risk of stroke in men 
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 NHS     
    Multivariable No Diet Update 
Milk Intake + DASH 
score1 P-yrs 
Stroke 
Cases 
I /100K 
p-yrs HR2 95% CI HR3 95% CI 
            
Milk<1/d+DASH<22 294807 626 212 1.00 - 1.00 - 
Milk<1/d+DASH≥22 172058 390 227 1.00 (0.88-1.15) 0.97 (0.85-1.11) 
Milk:1-<5/d+DASH<22 161986 372 230 1.07 (0.83-1.22) 1.05 (0.92-1.20) 
Milk:1-<5/d+DASH≥22 134141 297 221 0.95 (0.82-1.11) 0.92 (0.79-1.07) 
            
 HPFS     
    Multivariable No Diet Update 
Milk Intake + DASH 
score1 P-yrs 
Stroke 
Cases 
I /100K 
p-yrs HR2 95% CI HR3 95% CI 
            
Milk<1/d+DASH<22 79966 188 235 1.00 - 1.00 - 
Milk<1/d+DASH≥22 55440 142 256 0.93 (0.73-1.18) 0.86 (0.68-1.10) 
Milk:1-<5/d+DASH<22 41541 113 272 1.06 (0.84-1.35) 1.06 (0.83-1.34) 
Milk:1-<5/d+DASH≥22 32457 80 246 0.85 (0.64-1.13) 0.82 (0.62-1.09) 
1Cumulative average of milk intake and DASH score (no dairy) was calculated up to the first of 
the following events: stroke diagnosis, lost to follow up, death, end of study 
2Adjusted for age, race, smoking energy, family history of MI, physical activity, anti-hypertensive 
medication use, and intakes of alcohol, yogurt, cheese, and trans fat 
3Diet not updated upon report of CABG, angina, or high cholesterol 
Table A.17 Higher cheese intake is associated with a modest beneficial effect 
on CHD risk in women 
NHS 
    Multivariable No Diet Update 
Cheese Intake P-yrs 
CHD 
Cases 
I /100K 
p-yrs HR1 95% CI HR2 95% CI 
<0.25/d 370105 994 269 1.00 - 1.00 - 
0.25-<0.5/d 251940 621 246 0.94 (0.84-1.04) 0.94 (0.84-1.04) 
0.5-4/d 140963 331 235 0.92 (0.80-1.05) 0.91 (0.79-1.04) 
P for linear trend3    0.1529 0.1178 
Per one serving/day       0.85 (0.68-1.06) 0.84 (0.67-1.05) 
HPFS 
    Multivariable No Diet Update 
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Cheese Intake P-yrs 
CHD 
Cases 
I /100K 
p-yrs HR1 95% CI HR2 95% CI 
<0.25/d 87528 520 594 1.00 - 1.00 - 
0.25-<0.5/d 71650 423 590 1.02 (0.89-1.16) 1.04 (0.91-1.19) 
0.5-4/d 49958 324 649 1.10 (0.95-1.28) 1.10 (0.94-1.27) 
P for linear trend3    0.2143 0.2314 
Per one serving/day       1.15 (0.92-1.43) 1.15 (0.91-1.45) 
1Adjusted for age, race, smoking, energy, family history of MI, physical activity, BMI, anti-
hypertensive medication use, and intakes of alcohol, trans fat, fiber, yogurt and milk  
2Diet was not updated upon report of CABG, angina, or high cholesterol    
3Linear trend across cheese intake categories was quantified with a Wald test for linear trend by 
assigning the median value to each category and modeling this variable as a continuous variable   
 
Table A.18 Higher cheese intake is inversely associated with risk of stroke in 
women 
 NHS     
    Multivariable No Diet Update 
Cheese Intake P-yrs 
Stroke 
Cases 
I /100K 
p-yrs HR1 95% CI HR2 95% CI 
<0.25/d 370112 829 224 1.00 - 1.00 - 
0.25-<0.5/d 251932 559 222 0.93 (0.83-1.04) 0.93 (0.83-1.04) 
0.5-4/d 140949 297 211 0.92 (0.79-1.06) 0.91 (0.79-1.05) 
P for linear trend4    0.1790 0.1416 
Per one serving/day       0.85 (0.67-1.08) 0.84 (0.66-1.06) 
 HPFS     
    Multivariable No Diet Update 
Cheese Intake P-yrs 
Stroke 
Cases 
I /100K 
p-yrs HR1 95% CI HR2 95% CI 
<0.25/d 87688 205 234 1.00 - 1.00 - 
0.25-<0.5/d 71696 193 269 1.16 (0.95-1.43) 1.17 (0.95-1.43) 
0.5-4/d 50020 125 250 1.11 (0.88-1.41) 1.11 (0.87-1.41) 
P for linear trend3    0.3117 0.3267 
Per one serving/day       1.19 (0.85-1.68) 1.20 (0.83-1.72) 
1Adjusted for age, race, smoking, energy, family history of MI, physical activity, BMI, anti-
hypertensive medication use, and intakes of alcohol, trans fat, fiber, yogurt and milk  
2Diet was not updated upon report of CABG, angina, or high cholesterol     
3Linear trend across cheese intake categories was quantified with a Wald test for linear trend by 
assigning the median value to each category and modeling this variable as a continuous variable 
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Table A.19 Higher cheese intake combined with a high DASH diet score is 
associated with a lower risk of CHD in women and men 
NHS 
    Multivariable No Diet Update 
Cheese, DASH score P-yrs 
CHD 
Cases 
I /100K 
p-yrs HR1 95% CI HR2 95% CI 
            
<0.25/d, <22 220021 592 269 1.00 - 1.00 - 
<0.25/d, ≥22 150084 402 268 0.98 (0.86-1.12) 0.95 (0.83-1.08) 
0.25-4/d, <22 236789 595 251 0.96 (0.85-1.09) 0.96 (0.85-1.08) 
0.25-4/d, ≥22 156114 357 229 0.85 (0.74-0.99) 0.83 (0.72-0.95) 
            
HPFS 
    Multivariable No Diet Update 
Cheese, DASH score P-yrs 
CHD 
Cases 
I /100K 
p-yrs HR1 95% CI HR2 95% CI 
            
<0.25/d, <22 
 
47610 289 607 1.00 - 1.00 - 
<0.25/d, ≥22 39918 231 579 0.87 (0.73-1.04) 0.85 (0.71-1.02) 
0.25-4/d, <22 73748 453 614 1.05 (0.90-1.23) 1.06 (0.91-1.23) 
0.25-4/d, ≥22 47860 294 614 0.93 (0.78-1.11) 0.93 (0.78-1.11) 
1Adjusted for age, race, smoking energy, family history of MI, physical activity, anti-hypertensive 
medication use, and intakes of alcohol, trans fat, yogurt, and milk 
2Diet not updated upon report of CABG, angina, or high cholesterol  
Table A.20 Higher cheese intake with a high DASH diet score is associated 
with a lower risk of stroke in women 
NHS 
    Multivariable No Diet Update 
Cheese, DASH score P-yrs 
Stroke 
Cases 
I /100K 
p-yrs HR1 95% CI HR2 95% CI 
            
<0.25/d, <22 220019 492 224 1.00 - 1.00 - 
<0.25/d, ≥22 150093 337 225 0.94 (0.81-1.09) 0.91 (0.79-1.06) 
0.25-4/d, <22 236774 506 214 0.91 (0.80-1.04) 0.91 (0.80-1.03) 
0.25-4/d, ≥22 156106 350 224 0.89 (0.89-1.03) 0.86 (0.74-1.00) 
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  1685          
HPFS 
    Multivariable No Diet Update 
Cheese, DASH score P-yrs 
Stroke 
Cases 
I /100K 
p-yrs HR1 95% CI HR2 95% CI 
            
<0.25/d, <22 47705 102 214 1.00 - 1.00 - 
<0.25/d, ≥22 39982 103 258 1.03 (0.77-1.37) 0.94 (0.70-1.27) 
0.25-4/d, <22 73802 199 270 1.29 (1.01-1.66) 1.26 (0.98-1.61) 
0.25-4/d, ≥22 47914 119 248 1.03 (0.78-1.37) 0.98 (0.74-1.29) 
1Adjusted for age, race, smoking energy, family history of MI, physical activity, anti-hypertensive 
medication use, and intakes of alcohol, yogurt, milk, and trans fat 
2Diet not updated upon report of CABG, angina, or high cholesterol  
 
Table A.21 Higher total dairy intake is linked with a lower CHD risk in men 
 
 NHS     
    Multivariable No Diet Update 
Dairy Intake P-yrs 
CHD 
Cases 
I /100K 
p-yrs HR1 95% CI HR2 95% CI 
<0.5/d 112150 317 283 1.00 - 1.00 - 
0.5-<1/d 167949 419 249 0.92 (0.79-1.06) 0.91 (0.79-1.06) 
1-<2/d 194899 677 230 0.87 (0.75-1.00) 0.88 (0.76-1.01) 
2-<6/d 188010 533 284 1.08 (0.92-1.27) 1.07 (0.91-1.26) 
P for linear trend3    0.0454 0.0517 
Per one serving/day     1.06 (1.00-1.13) 1.06 (1.00-1.13) 
 HPFS     
    Multivariable No Diet Update 
Dairy Intake P-yrs 
CHD 
Cases 
I /100K 
p-yrs HR1 95% CI HR2 95% CI 
<0.5/d 31973 183 569 1.00 - 1.00 - 
0.5-<1/d 51640 305 591 1.02 (0.84-1.22) 1.05 (0.87-1.28) 
1-<2/d 79213 505 638 1.05 (0.88-1.25) 1.11 (0.93-1.33) 
2-<6/d 46309 275 594 0.87 (0.71-1.07) 0.92 (0.75-1.14) 
P for linear trend3    0.0679 0.1653 
Per one serving/day     0.94 (0.87-1.00) 0.95 (0.89-1.02) 
1Adjusted for age, race, smoking, energy, family history of MI, physical activity, BMI, anti-
hypertensive medication use, and intakes of alcohol, trans fat, and fiber 
2Diet was not updated upon report of CABG, angina, or high cholesterol    
3Linear trend across total dairy intake categories was quantified with a Wald test for linear trend 
by assigning the median value to each category and modeling it as a continuous variable 
  186
 
Table A.22 Total dairy intake is inversely associated with risk of stroke in 
women 
 NHS     
    Multivariable No Diet Update 
Dairy Intake P-yrs 
Stroke 
Cases 
I /100K 
p-yrs HR1 95% CI HR2 95% CI 
<0.5/d 112153 256 228 1.00 - 1.00 - 
0.5-<1/d 167938 382 227 0.94 (0.80-1.10) 0.92 (0.78-1.08) 
1-<2/d 294855 642 218 0.90 (0.77-1.05) 0.88 (0.75-1.03) 
2-<6/d 188047 405 215 0.88 (0.74-1.05) 0.86 (0.72-1.03) 
P for linear trend3    0.2106 0.1485 
Per one serving/day     0.96 (0.90-1.02) 0.95 (0.89-1.02) 
 HPFS     
    Multivariable No Diet Update 
Dairy Intake P-yrs 
Stroke 
Cases 
I /100K 
p-yrs HR1 95% CI HR2 95% CI 
<0.5/d 32020 81 253 1.00 - 1.00 - 
0.5-<1/d 51717 129 249 0.96 (0.72-1.27) 0.93 (0.70-1.24) 
1-<2/d 79317 190 240 0.88 (0.67-1.15) 0.89 (0.67-1.17) 
2-<6/d 46349 123 265 0.93 (0.68-1.26) 0.94 (0.69-1.29) 
P for linear trend3    0.7054 0.9080 
Per one serving/day     0.98 (0.88-1.09) 0.99 (0.89-1.11) 
1Adjusted for age, race, smoking, energy, family history of MI, physical activity, BMI, anti-
hypertensive medication use, and intakes of alcohol, trans fat, and fiber 
2Diet was not updated upon report of CABG, angina, or high cholesterol    
3Linear trend across total dairy intake categories was quantified with a Wald test for linear trend 
by assigning the median value to each category and modeling it as a continuous variable 
 
Table A.23 Higher total dairy intake combined with a high DASH diet score is 
associated with a lower risk of CHD in women and men 
 NHS     
    Multivariable No Diet Update 
Dairy, DASH score P-yrs 
CHD 
Cases 
I /100K 
p-yrs HR1 95% CI HR2 95% CI 
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<1/d, <22 184691 482 261 1.00 - 1.00 - 
<1/d, ≥22 95408 254 266 0.96 (0.82-1.12) 0.93 (0.79-1.09) 
1-<6/d, <22 272119 705 259 1.01 (0.89-1.14) 1.02 (0.90-1.15) 
1-<6/d, ≥22 210790 505 240 0.88 (0.77-1.01) 0.87 (0.75-1.00) 
            
 HPFS     
    Multivariable No Diet Update 
Dairy, DASH score P-yrs 
CHD 
Cases 
I /100K 
p-yrs HR1 95% CI HR2 95% CI 
            
<1/d, <22 51092 301 589 1.00 - 1.00 - 
<1/d, ≥22 32521 186 572 0.86 (0.71-1.05) 0.85 (0.70-1.03) 
1-<6/d, <22 70266 441 628 0.99 (0.85-1.16) 1.02 (0.88-1.19) 
1-<6/d, ≥22 55256 339 614 0.87 (0.73-1.03) 0.88 (0.74-1.05) 
1Adjusted for age, race, smoking energy, family history of MI, physical activity, anti-hypertensive 
medication use, and intakes of alcohol, and trans fat 
2Diet not updated upon report of CABG, angina, or high cholesterol  
Table A.24 Higher total dairy intake combined with a high DASH diet score is 
linked with a lower risk of stroke in women and men 
 NHS     
    Multivariable No Diet Update 
Dairy, DASH score P-yrs 
Stroke 
Cases 
I /100K 
py HR1 95% CI HR2 95% CI 
            
<1/d, <22 184688 419 227 1.00 - 1.00 - 
<1/d, ≥22 95402 219 230 0.94 (0.79-1.12) 0.93 (0.78-1.10) 
1-<6/d, <22 272105 579 213 0.92 (0.81-1.05) 0.92 (0.81-1.05) 
1-<6/d, ≥22 210797 468 222 0.88 (0.76-1.02) 0.85 (0.73-0.98) 
            
 HPFS     
    Multivariable No Diet Update 
Dairy, DASH score P-yrs 
Stroke 
Cases 
I /100K 
py HR1 95% CI HR2 95% CI 
            
<1/d, <22 51169 119 233 1.00 - 1.00 - 
<1/d, ≥22 32568 91 279 0.97 (0.73-1.30) 0.90 (0.66-1.21) 
1-<6/d, <22 70338 182 259 1.01 (0.79-1.29) 1.01 (0.79-1.29) 
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1-<6/d, ≥22 55329 131 237 0.78 (0.59-1.03) 0.77 (0.58-1.01) 
1Adjusted for age, race, smoking energy, family history of MI, physical activity, anti-hypertensive 
medication use, and intakes of alcohol, and trans fat 
2Diet not updated upon report of CABG, angina, or high cholesterol  
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